

**OREGON BOARD OF PHARMACY 2017-19
GOVERNOR’S BUDGET**

TABLE OF CONTENTS

		<u>Page</u>
	<u>INTRODUCTORY INFORMATION</u>	
	Table of Contents	i-ii
	Certification (107BF01).....	iii
A:	<u>LEGISLATIVE ACTION</u>	
	2015-17 Budget Report and Measure Summary – 78th Legislative Assembly, 2015 Regular Session.....	1
	Summary of Emergency Board Action – May 2016.....	7
B:	<u>AGENCY SUMMARY</u>	
	Agency Summary Narrative.....	12
	• Budget Summary Graphics.....	12
	• Mission Statement and Statutory Authority.....	13
	• Agency 2 year Strategic Plan.....	16
	• Program Descriptions.....	26
	• Environmental Factors.....	30
	• Initiatives and Accomplishments.....	33
	• Criteria for 2017-19 Budget Development.....	36
	• Major Information Technology Project.....	38
	• 10% Reduction Option.....	38
	• Reduction Options (ORBITS Narrative, 107BF17).....	39
	Summary of 2017-19 Biennium Budget (BDV104).....	41
	ORBITS Agency wide Program Unit Summary (BPR010).....	47
	Program Prioritization for 2017-19 (107BF23)	48
	2015-2017 Organizational Chart	49
C:	<u>REVENUES</u>	
	Revenue Forecast Narrative/Graphics	50
	Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (107BF07).....	52
	ORBITS Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (BPR012).....	54

<i>D:</i>	<u><i>PROGRAM UNITS</i></u>	
	Organization Chart 2017-2019.....	56
	Program Unit Executive Summary.....	57
	Program Unit Narrative.....	57
	Program Funding Request.....	58
	Program Justification and Link to 10 Year Outcomes.....	60
	Program Performance & Graphics.....	61
	Essential Packages	66
	Policy Package 100 MyLicense Business Upgrade.....	68
	Policy Package 101 Academic & Regulatory Fellowship.....	71
	Policy Package 102 Board Member Per Diem.....	73
	ORBITS Essential and Policy Package Fiscal Impact Summary (BPR013).....	74
	PICS Package Fiscal Impact Report	85
	Detail of Lottery Funds, Other Funds, and Federal Funds Revenue (107BF07).....	86
<i>E:</i>	<u><i>SPECIAL REPORTS</i></u>	
	Annual Performance Progress Report.....	88
	Affirmative Action Report.....	97
	Bi-lingual Information (graphic).....	98
	Ethnic Breakdown (graphic).....	99
	Oregon Board of Pharmacy Outreach & Presentations 2015.....	100
	Oregon State Board of Pharmacy Newsletters (Nov 2015, November 2016).....	101
	Summary Cross Reference Listing and Packages (BSU003A).....	109
	Policy Package List by Priority (BSU-004A).....	110
	Budget Support – Detail Revenues and Expenditures BDV103A.....	111
	Version/Column Comparison Report Detail (Base Budget by SCR) ANA100A	125
	Package Comparison Report Detail ANA101A	147
	PICS Summary List by Package by Summary (PPDPLBUDCL).....	148
	PICS Summary List by Package by Agency (PPDPLAGYCL).....	151
	PICS Detail Listing by Summary XREF Agency (PPDPLWSBUD).....	153
	PICS Package Fiscal Impact Report	156

CERTIFICATION

I hereby certify that the accompanying summary and detailed statements are true and correct to the best of my knowledge and belief and that the accuracy of all numerical information has been verified.

Oregon Board of Pharmacy

800 NE Oregon St., Suite 150, Portland, OR 97213

AGENCY NAME

AGENCY ADDRESS



Board President

SIGNATURE

TITLE


Notice: Requests of agencies headed by a board or commission must be approved by official action of those bodies and signed by the board or commission chairperson.

The requests of other agencies must be approved and signed by the agency director or administrator.

Agency Request

Governor's Budget

Legislatively Adopted



BUDGET REPORT AND MEASURE SUMMARY

CARRIER: Rep. Komp

Joint Committee On Ways and Means

Action: Do Pass.

Action Date: 05/08/15

Vote:

House

Yeas: 12 - Buckley, Gomberg, Huffman, Komp, McLane, Nathanson, Rayfield, Read, Smith, Whisnant, Whitsett, Williamson

Senate

Yeas: 12 - Burdick, Devlin, Girod, Hansell, Johnson, Monroe, Roblan, Shields, Steiner Hayward, Thomsen, Whitsett, Winters

Prepared By: Clair Clark, Department of Administrative Services

Reviewed By: Kim To, Legislative Fiscal Office

Agency: Board of Pharmacy

Biennium: 2015-17

Budget Summary*

	2013-15 Legislatively Approved Budget ⁽¹⁾	2015-17 Current Service Level	2015-17 Committee Recommendation	Committee Change from 2013-15 Leg. Approved	
				\$ Change	% Change
Other Funds Limited	\$ 5,957,609	\$ 6,164,443	\$ 6,892,573	\$ 934,964	15.7%
Total	\$ 5,957,609	\$ 6,164,443	\$ 6,892,573	\$ 934,964	15.7%

Position Summary

Authorized Positions	19	19	20	1
Full-time Equivalent (FTE) positions	19.00	19.00	20.00	1.00

⁽¹⁾ Includes adjustments through December 2014

* Excludes Capital Construction expenditures

Revenue Summary

The Oregon Board of Pharmacy receives revenue from fees charged to licensees, civil penalties and a small number of administrative “user” fees. With the adoption of the Subcommittee’s recommendation, the agency’s estimated 2015-17 ending fund balance is \$2,706,092, or the equivalent of approximately 9.4 months of operating expenses.

The Subcommittee approved the following recommendations:

- Package 801, Revenue Reduction, reduces \$806,548 Other Funds revenue to provide for the transition to biennial licensure for Pharmacists and Certified Pharmacy Technicians at a reduced rate. The reduced fee rate for Pharmacist renewal licenses will be \$120 and for Certified Pharmacy Technicians the reduced renewal license fee rate will be \$175. Transitioning to biennial licensure will allow the Board to reduce its large ending balance and achieve workload efficiencies by adjusting the renewal cycle to alternate years.

Summary of Education Subcommittee Action

The Board of Pharmacy promotes, preserves, and protects the health, safety and welfare of Oregon citizens through the control and regulation of the practice of pharmacy. The Board regulates the quality and distribution of drugs through outlets involved in the manufacture, production, sale and distribution of prescription drugs, over-the-counter drugs, controlled substance and devices and other materials as may be used in the diagnosis, cure, mitigation, prevention and treatment of injury, illness and disease.

The Subcommittee recommended a budget for the Board of Pharmacy of \$6,892,573 Other Funds and 20.00 full-time equivalent positions. This is a 15.7 percent increase from the 2013-15 Legislatively Approved Budget.

The Subcommittee approved the following recommendations:

- Package 100, Personnel Management, provides \$363,604 Other Funds expenditure limitation to fund: (1) a pay line exception approved by the Department of Administrative Services and, (2) establish one full-time Program Analyst 1 position (1.00 FTE) in the Licensing Division as recommended in a 2012 operational review.
- Package 101, Business Improvement Database Upgrade, provides \$316,756 Other Funds expenditure limitation, of which \$275,000 is a one-time cost, to fund the replacement of the Board's System Automation (SA) License 2000 software. This package will be funded using one-time revenues from a civil penalty of over \$500,000 collected by the Board.
- Package 102, IT Professional Services, provides \$25,000 Other Funds expenditure limitation for costs associated with an increase in Professional Liability Insurance.
- Package 103, Paperless Records Retention Part 2, provides \$22,770 Other Funds expenditure limitation to fund the continuation of the Board's Paperless Records Retention project that began in the 2013-15 biennium. This increase will fund usage-based fees charged by the Secretary of State's Archives Division for the use of the Oregon Records Management Solution.

Summary of Performance Measure Action

See attached Legislatively Adopted 2015-17 Key Performance Measures form.

DETAIL OF JOINT COMMITTEE ON WAYS AND MEANS ACTION

SB 5530-A

Board of Pharmacy
Clair Clark -- 503-378-3117

DESCRIPTION	GENERAL FUND	LOTTERY FUNDS	OTHER FUNDS		FEDERAL FUNDS		TOTAL ALL FUNDS	POS	FTE
			LIMITED	NONLIMITED	LIMITED	NONLIMITED			
2013-15 Legislatively Approved Budget at Dec 2014 *	\$ -	\$ -	\$ 5,957,609	\$ -	\$ -	\$ -	5,957,609	19	19.00
2015-17 Current Service Level (CSL)*	\$ -	\$ -	\$ 6,164,443	\$ -	\$ -	\$ -	6,164,443	19	19.00
<u>SUBCOMMITTEE ADJUSTMENTS (from CSL)</u>									
SCR 001 - Board of Pharmacy									
Package 100: Personnel Management									
Personal Services	\$ -	\$ -	\$ 274,664	\$ -	\$ -	\$ -	274,664	1	1.00
Services and Supplies	\$ -	\$ -	\$ 88,940	\$ -	\$ -	\$ -	88,940		
Package 101: Business Improv. Database Upgrade									
Services and Supplies	\$ -	\$ -	\$ 45,679	\$ -	\$ -	\$ -	45,679		
Capital Outlay	\$ -	\$ -	\$ 271,077	\$ -	\$ -	\$ -	271,077		
Package 102: IT Professional Services									
Services and Supplies	\$ -	\$ -	\$ 25,000	\$ -	\$ -	\$ -	25,000		
Package 103: Paperless Record Retention Part 2									
Services and Supplies	\$ -	\$ -	\$ 22,770	\$ -	\$ -	\$ -	22,770		
TOTAL ADJUSTMENTS	\$ -	\$ -	\$ 728,130	\$ -	\$ -	\$ -	728,130	1	1.00
SUBCOMMITTEE RECOMMENDATION *	\$ -	\$ -	\$ 6,892,573	\$ -	\$ -	\$ -	6,892,573	20	20.00
% Change from 2013-15 Leg Approved Budget	0.0%	0.0%	15.7%	0.0%	0.0%	0.0%	15.7%		
% Change from 2015-17 Current Service Level	0.0%	0.0%	11.8%	0.0%	0.0%	0.0%	11.8%		

*Excludes Capital Construction Expenditures

Legislatively Approved 2015-2017 Key Performance Measures

Agency: PHARMACY, BOARD OF

Mission: The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs.

Legislatively Proposed KPMs	Customer Service Category	Agency Request	Most Current Result	Target 2016	Target 2017
1 - Percent of inspected pharmacies that are in compliance annually.		Approved KPM	83.00	75.00	75.00
2 - Percent of audited pharmacists who complete continuing education on time.		Approved KPM	95.00	100.00	100.00
3 - Percent of pharmacies inspected annually.		Approved KPM	100.00	100.00	100.00
4 - Average number of days to complete an investigation from complaint to board presentation.		Approved KPM	97.00	100.00	100.00
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Accuracy	Approved KPM	92.00	85.00	85.00
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Availability of Information	Approved KPM	88.00	85.00	85.00
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Expertise	Approved KPM	95.00	85.00	85.00
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Helpfulness	Approved KPM	93.00	85.00	85.00
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Overall	Approved KPM	93.00	85.00	85.00

Agency: PHARMACY, BOARD OF

Mission: The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs.

Legislatively Proposed KPMs	Customer Service Category	Agency Request	Most Current Result	Target 2016	Target 2017
5 - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.	Timeliness	Approved KPM	90.00	85.00	85.00
6 - Board Best Practices - Percent of total best practices met by the Board.		Approved KPM	100.00	100.00	100.00

LFO Recommendation:

Recommend approval of KPM and targets as presented.

Sub-Committee Action:

Approved LFO recommendation.

Legislative Fiscal Office

900 Court St. NE, Rm. H-178
Salem, OR 97301
503-986-1828



Ken Rocco
Legislative Fiscal Officer

Daron Hill
Deputy Legislative Fiscal Officer

Summary of Emergency Board Action May 2016

The Legislative Emergency Board met on May 25, 2016 and considered an agenda of 62 items. The Emergency Board approved allocations from the general purpose Emergency Fund in response to eight separate requests, totaling \$2.6 million. Another four requests were allocated funds from special purpose appropriations made to the Emergency Board that totaled \$11.5 million. Additional details on these allocations are described below. After the Emergency Board actions, the balance in the general purpose Emergency Fund is \$29.6 million. An additional \$51.8 million remains in various special purpose appropriations, including \$40 million for caseload costs or other unbudgeted expenses of the Oregon Health Authority and the Department of Human Services. Unused special purpose appropriations become available for any lawful use by the Emergency Board on December 1, 2016.

The agenda included 17 items that requested additional 2015-17 biennium authority to spend Lottery Funds, Other Funds, and Federal Funds. The Emergency Board approved expenditure limitation increases of approximately \$95,628 Lottery Funds, \$55 million Other Funds (including \$27.6 million for the Department of Transportation) and \$4.8 million Federal Funds (including \$2.5 million for the Department of Justice). The Emergency Board also authorized the establishment of 64 positions (33.1 FTE) and the extension of six currently existing positions through the end of the biennium (4.29 FTE).

The agenda also included 15 agency reports which the Emergency Board acknowledged receiving. The Emergency Board heard 22 requests for the submission of federal grant applications (13 of which were on a consent agenda). The Emergency Board also deferred taking action on two requests for allocations from the Emergency Fund.

The following is a summary of significant Emergency Board actions taken at the May 2016 meeting:

EDUCATION

- Acknowledged receipt of a report by the Department of Education on the implementation of the mixed delivery preschool program.
- Allocated \$273,062 from the Emergency Fund to the Department of Education for grants to school districts to improve internet connectivity and access.
- Acknowledged receipt of reports by the Higher Education Coordinating Commission on 2016-17 academic year University tuition and mandatory fee increases for resident undergraduates and on the distribution of funding for Community College academic counselors.
- Approved the submission of a federal grant application by the Department of Education for

child care related implementation research and evaluation planning.

HUMAN SERVICES

- Acknowledged receipt of a report by the Department of Human Services on program sustainability options and actions.
- Acknowledged receipt of reports by the Oregon Health Authority on the Oregon Health Plan 1115 waiver renewal for 2017-22 and on the Medicaid Management Information System and related systems and interfaces.
- Approved the submission of federal grant applications by the Department of Human Services for the enhancement of adult protective services and for enhancing the state's system for

providing information on and access to long term services and supports.

- Approved the submission of federal grant applications by the Oregon Health Authority for epidemiology and laboratory capacity for infectious diseases, chronic disease and oral health, emerging infections, and prescription drug and opioid addiction/overdose prevention.
- Increased the Other Funds expenditure limitation for the Board of Nursing by \$244,452 for the establishment of two permanent positions (1.58 FTE) and the reclassification of six other positions to address workload increases.

PUBLIC SAFETY and JUDICIAL BRANCH

- Acknowledged receipt of a report by the Department of Corrections on female and male population trends and system bed capacity.
- Allocated \$3 million from a special purpose appropriation made to the Emergency Board to the Department of Corrections to continue activating minimum security prison beds at the Deer Ridge Correctional Institution, authorized the establishment of 33 positions (18.64 FTE), and indicated that remaining unfunded prison capacity needs would be addressed at a future Emergency Board meeting this interim or during the 2017 session.
- Allocated \$1 million from the Emergency Fund to the Department of Corrections and increased the agency's Other Funds expenditure limitation by \$100,000 to begin preparing the Oregon State Penitentiary-Minimum to house women offenders in the 2015-17 biennium.
- Acknowledged receipt of a report by the Department of Justice on the Child Support Enforcement Automated System (CSEAS) and increased the Federal Funds expenditure limitation by \$2,538,107 for the project to cover expenditures through October 2016.
- Increased the Other Funds expenditure limitation for the Department of Public Safety Standards and Training by \$100,000 for additional training of 911 tele-communicators and by \$337,000 for crisis intervention training for first responders.
- Approved the submission of a federal grant application by the Department of State Police for a grant in the amount of \$9.4 million to replace the CrimeVue criminal history database and messaging system.
- Allocated \$2 million from a special purpose

appropriation made to the Emergency Board for state and local government costs associated with the takeover of the Malheur National Wildlife Refuge in Harney County, allocated \$73,053 from the Emergency Fund for the same purpose, and increased the Other Funds expenditure limitation for the Department of State Police by \$874,188 in order for the agency to receive reimbursement for its costs. The allocations were made to the Department of Administrative Services for distribution to eligible state and local government units.

- Allocated \$170,000 from the Emergency Fund to the Military Department for roof repairs at the Forest Grove and Kliever-Portland armories and directed the agency to use \$500,000 of one-time General Fund savings available in the current budget to match the federal funding to complete the roof repairs.
- Increased the Other Funds expenditure limitation for the Military Department by \$256,000 and the Federal Funds expenditure limitation for the Military Department by \$518,000 for the Oregon Youth Challenge Program.
- Increased the Federal Funds expenditure limitation for the Military Department by \$270,000 for the STARBASE Program.
- Approved the submission of federal grant applications by the Criminal Justice Commission for the Justice Reinvestment program and by the Department of State Police for SAFE kit inventory, tracking, and reporting.
- Acknowledged receipt of a report by the Commission on Judicial Fitness and Disability on compensation plan changes.
- Deferred taking action on a request by the Public Defense Services Commission to fund proposed salary increases.

NATURAL RESOURCES

- Allocated \$5,000 from the Emergency Fund for the Columbia River Gorge Commission to match the 2015-17 budget provided by the State of Washington for Commission operations as required by interstate compact.
- Acknowledged receipt of a report by the Department of Geology and Mineral Industries on the progress of the tactical IT remediation plan, allocated \$554,808 from the Emergency Fund for the plan, authorized the establishment of two positions (1.00 FTE), and increased the Other

Funds expenditure limitation for the Department by \$64,754 for the Mined Land Reclamation and Regulation program.

- Allocated \$225,000 from the Emergency Fund for the Department of Environmental Quality to acquire metals and particulate monitoring equipment.
- Allocated \$2,176,549 from a special purpose appropriation made to the Emergency Board for fire severity resources to the Department of Forestry for the purchase of catastrophic fire insurance for the 2016 fire season.
- Allocated \$250,000 from the Emergency Fund for the Department of Forestry to augment and add to existing resources for the treatment of Sudden Oak Death.
- Increased the Other Funds expenditure limitation for the Parks and Recreation Department by \$615,500 for grants received from the Marine Board.
- Increased the Federal Funds expenditure limitation for the Parks and Recreation Department by \$29,214 to correct a technical error in personal services from the 2016 session.
- Approved the submission of a federal grant application by the Parks and Recreation Department for purchase of land by the Southern Oregon Land Conservancy for habitat conservation.
- Approved the submission of federal grant applications by the Department of Fish and Wildlife for the acquisition of a conservation easement on 1,751 acres near Ashland, by the Department of Environmental Quality for pollution prevention, and by the Department of Agriculture for Food Safety Modernization Act implementation.

ECONOMIC and COMMUNITY DEVELOPMENT

- Acknowledged receipt of a report by the Oregon Business Development Department and the Higher Education Coordinating Commission on a business plan for the American Manufacturing Innovation District, increased the Other Funds expenditure limitation for the Oregon Business Development Department by \$2,499,999 for the project, increased the Other Funds Capital Construction expenditure limitation for the Higher Education Coordinating Commission by \$4,999,999 for the project, and increased the Other Funds expenditure limitation for the Higher

Education Coordinating Commission by \$70,000 for the development of the Oregon Manufacturing Innovation Center.

- Approved the submission of a federal grant application by the Oregon Department of Business Development for the State Trade Expansion Program and authorized the agency to submit future grants for the same program under certain specified conditions.
- Approved the submission of two federal grant applications by the Housing and Community Services Department totaling \$94.5 million under the Hardest Hit program to assist Oregonians at risk of experiencing mortgage foreclosure.
- Approved the submission of a federal grant application by the Employment Department to support expansion and diversification of registered apprenticeship.

TRANSPORTATION

- Increased the Other Funds expenditure limitation for the Department of Transportation by \$16,966,375 for the Maintenance and Emergency Relief programs and by \$10,732,666 for the Local Government program for costs associated with repairing highways due to 2015-16 winter storm damage.
- Approved the submission of a federal grant application by the Department of Transportation in the amount of \$75.7 million under the federal FASTLANE program for three interstate highway projects.
- Approved the submission of federal grant applications by the Department of Transportation for bus facilities, positive train control, railroad best practices, utility solutions, and bridge and tunnel testing.

CONSUMER and BUSINESS SERVICES

- Acknowledged receipt of a report by the Department of Consumer and Business Services on the Oregon Health Insurance Marketplace program and increased the Other Funds expenditure limitation for the Department by \$558,617 to correct a double counted reduction from the 2016 session.

ADMINISTRATION


- Acknowledged receipt of a report by the Office of the Governor on its organizational structure and Key Performance Measures.

- Increased the Other Funds expenditure limitation for the Department of Administrative Services, Chief Human Resources Office by \$6,520,731; authorized the establishment of 22 limited duration positions (9.17 FTE) and the extension of six existing limited duration positions through the end of the current biennium (4.29 FTE); and adjusted state agency budgets by allocating \$4,292,256 from a special purpose appropriation made to the Emergency Board for Department of Administrative Services' assessment increases, increased the Lottery Funds expenditure limitation of state agencies by \$95,628, the Other Funds expenditure limitations by \$3,357,479, and the Federal Funds expenditure limitations by \$1,489,374 for assessment increases related to continuation of the Human Resources Information System project and other adjustments related to previously approved Department IT reorganization effects.
- Established an Other Funds Capital Construction expenditure limitation in the amount of \$2,336,040 for the Department of Administrative Services for a roof replacement at the Department of Environmental Quality and Public Health laboratory and established an Other Funds Capital Construction expenditure limitation in the amount of \$4,000,000 for the Department of Administrative Services for tenant improvements at the 550 Building.

- Acknowledged receipt of a report by the Department of Administrative Services on compensation plan changes.
- Acknowledged receipt of a report by the Department of Administrative Services on uniform rent rates for the 2017-19 biennium and to recommend to the next Legislative Assembly that agency budgets include sufficient spending authority to cover the rent costs as required by ORS 276.390.
- Increased the Other Funds expenditure limitation for the Department of Revenue by \$379,481, authorized the establishment of five permanent positions (2.71 FTE), and authorized the movement of an existing manager position from limited duration to permanent status for the recreational marijuana tax cash management program.
- Deferred taking action on a request by the Department of Revenue to allocate funds from the Emergency Fund for the Property Valuation System.
- Acknowledged receipt of a report by the Department of Revenue on GenTax data availability for research purposes.

10


Emergency Fund Balance Summary		
	Agency Requests	Emergency Board Action
General Purpose Emergency Fund		
Appropriation (after 2016 Session adjustments)	32,000,000	32,000,000
Allocations to date		
Unallocated Balance	32,000,000	32,000,000
# May 2016 Requests - General Purpose		
2 Public Defense Services Commission - Proposed Salary Increases	(541,014)	0
6 Department of Education - School Fiber Optic Broadband	(500,000)	(273,062)
25 Military Department - Armory Roof Repair	(670,000)	(170,000)
28 Oregon State Police - Malheur National Wildlife Refuge Occupation Costs (see SPA Section below)	(2,487,914)	(73,053)
31 Department of Corrections - Deer Ridge Correctional Institution Male Capacity (see SPA Section below)	(6,899,109)	0
32 Department of Corrections - Oregon State Penitentiary Minimum Women Capacity	(10,569,266)	(1,000,000)
38 Columbia River Gorge Commission - Operational Expense Washington Match	(5,000)	(5,000)
40 Department of Geology and Mineral Industries - Information Technology Remediation Plan	(713,907)	(554,808)
43 Department of Environmental Quality - Air Toxics Monitoring	(225,000)	(225,000)
44 Department of Forestry - Catastrophic Wildfire Insurance Policy (see SPA Section below)	(2,176,549)	0
46 Department of Forestry - Sudden Oak Death Eradication	(250,000)	(250,000)
65 Department of Revenue - Property Valuation System Project	(1,500,000)	0
Total Requests - General Purpose	(26,537,759)	(2,550,923)
General Purpose Unallocated Balance after 05/2016	5,462,241	29,449,077
Special Purpose Appropriations - Agency Specific (after 2016 Session actions)		
Allocations/Transfers to Date	63,255,445	63,255,445
Unallocated Balance	63,255,445	63,255,445
# May 2016 Requests - Special Purpose Appropriations - Agency Specific		
28 Oregon State Police - Malheur National Wildlife Refuge Occupation Costs (see above)	0	(2,000,000)
31 Department of Corrections - Deer Ridge Correctional Institution Male Capacity (see above)	0	(3,000,000)
44 Department of Forestry - Catastrophic Wildfire Insurance Policy (see above)	0	(2,176,549)
61 Department of Administrative Services - Rates/Assessment Adjustments	(4,292,784)	(4,292,256)
Total Requests - Special Purpose - Agency Specific	(4,292,784)	(11,468,805)
Special Purpose - Agency Specific - Unallocated Balance after 05/2016	58,962,661	51,786,640



BUDGET NARRATIVE – 17-19

Program Description AGENCY SUMMARY NARRATIVE


2015-2017 Program Allocation



- Operations & Admin 23.42% (Includes fingerprinting \$221,248 pass-thru) *
- Board Member Activities 2.38%
- Licensing 25.33%
- Compliance 42.23%
- Health Professionals Service Program (HPSP) 2.57%
- Capital Outlay (IT - Database Upgrade) 4.06%

*InterAgency Activities – Payment for PMP & WDC of \$349,445 are reflected in revenue as a pass through.


2017-2019 Program Allocation



- Operations & Admin 27.9% (Includes fingerprinting \$229,434 pass-thru) *
- Board Member Activities 2.3%
- Licensing 18.4%
- Compliance 44.3%
- Health Professionals Service Program (HPSP) 2.4%
- MyLicense (IT Upgrade) 4.6%


*InterAgency Activities – Payment for PMP & WDC of \$409,357 are reflected in revenue as a pass through.

2015-2017 Expenditures by Type \$6,856,245



- Personnel 67.02%
- Travel 1.85%
- Data Processing & Telecommunications 5.42%
- Prof. Services/Hearings Panel 1.70%
- Agency Program Related S & S (Fingerprinting) 3.23% *PASS THRU
- IT Expendable Property .59%
- IT Professional Services 1.14%
- Publicity & Publications .61%
- Office Expenses/Supplies (Includes Storage Fees & Postage) 1.74%
- Attorney General 4.58%
- State Government Service Charges 1.06%
- Facilities & Rent 3.17%
- Employee Training .71%
- Expendable Property .15%
- OHA Health Professional's Service Program 2.58%
- Other Special Payments .17%
- Other Services & Supplies 4.26%
- Medical Services & Supplies .02%

2017-2019 Expenditures by Type \$7,530,291




- Personnel 66.41%
- Travel 1.73%
- Data Processing & Telecommunications 5.25%
- Prof. Services/Hearings Panel 2.87%
- Agency Program Related S & S (Fingerprinting) 3.02% *PASS THRU
- IT Expendable Property .58%
- IT Professional Services 1.07%
- Publicity & Publications .57%
- Office Expenses/Supplies (Includes Storage Fees & Postage) 1.63%
- Attorney General 4.68%
- State Government Service Charges 1.77%
- Facilities & Rent 3.06%
- Employee Training .69%
- Expendable Property .14%
- Health Professional's Service Program 2.42%
- Other Special Payments .16%
- Other Services & Supplies 3.93%
- Medical Services & Supplies .01%

BUDGET NARRATIVE – 17-19

Mission Statement and Statutory Authority

Oregon Board of Pharmacy Funding Limitation 15-17 LAB



■ Other Funds
\$6,856,245

Oregon Board of Pharmacy Funding Limitation 17-19 ARB



■ Other Funds
\$7,530,291

Mission: The mission of the Oregon Board of Pharmacy is to promote, preserve and protect the public health safety and welfare by establishing high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of pharmaceutical products.

Statutory Authority: The authority and responsibilities of the Board of Pharmacy are contained in Chapter 689 of the Oregon Revised Statutes (The Oregon Pharmacy Act) and Chapter 475 (Uniform Controlled Substances Act).

ORS 689.005 - 995	Pharmacists; Drug Outlets; Drug Sales
ORS 475.005 - 999	Controlled Substances; Illegal Drug Cleanup; Paraphernalia; Precursors
OAR 855 Divisions 001 – 110	Board of Pharmacy Administrative Rules

Statement of Purpose: The practice of pharmacy in the State of Oregon is declared a professional practice affecting the public health, safety and welfare and is subject to regulation and control in the public interest. It is further declared to be a matter of public interest and concern that the practice of pharmacy, as defined in ORS Chapter 689, merit and receive the confidence of the public and that only qualified persons be permitted to engage in the practice of pharmacy in the State of Oregon.

The purpose of the Board of Pharmacy under chapter 689 is to promote, preserve, and protect the public health, safety and welfare by and through:

BUDGET NARRATIVE – 17-19

1. Control and regulation of the practice of pharmacy.
2. Regulation of all entities involved in the commerce, manufacture, production, sale and distribution of:
 - a. legend (*prescription*) drugs
 - b. over-the-counter (*nonprescription*) drugs
 - c. controlled substances (*drugs with abuse or addiction potential*)
 - d. devices and other materials as may be used in the diagnosis and treatment of injury, illness and disease that is required under federal or state law to be prescribed by a practitioner and dispensed by a pharmacist.

“Drug” means: [ORS 689.005 (11)]

- (a) Articles recognized as drugs in the official United States Pharmacopoeia, official National Formulary, official Homeopathic Pharmacopoeia, other drug compendium or any supplement to any of them;
- (b) Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in a human or other animal;
- (c) Articles, other than food, intended to affect the structure or any function of the body of humans or other animals; and
- (d) Articles intended for use as a component of any articles specified in paragraph (a), (b) or (c) of this subsection.

“Practice of Pharmacy” means: [ORS 689.005 (31)]

- (a) The interpretation and evaluation of prescription orders;
- (b) The compounding, dispensing and labeling of drugs and devices, except labeling by a manufacturer, packer or distributor of nonprescription drugs and commercially packaged legend drugs and devices;
- (c) The prescribing and administering of vaccines and immunizations and the providing of patient care services pursuant to ORS 689.645;
- (d) The administering of drugs and devices to the extent permitted under ORS 689.655;
- (e) The participation in drug selection and drug utilization reviews;
- (f) The proper and safe storage of drugs and devices and the maintenance of proper records therefor;
- (g) The responsibility for advising, where necessary or where regulated, of therapeutic values, content, hazards and use of drugs and devices;
- (h) The monitoring of therapeutic response or adverse effect to drug therapy;
- (i) The optimizing of drug therapy through the practice of clinical pharmacy;
- (j) Patient care services, including medication therapy management and comprehensive medication review;
- (k) The offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of pharmacy; and
- (L) The prescribing and dispensing of hormonal contraceptive patches and self-administered oral hormonal contraceptives pursuant to ORS 689.683.

BUDGET NARRATIVE – 17-19

“Drug Outlet” means: [ORS 689.005(13)]

Any pharmacy, nursing home, shelter home, convalescent home, extended care facility, drug abuse treatment center, penal institution, hospital, family planning clinic, student health center, retail store, wholesaler, manufacturer, mail-order vendor or other establishment with facilities located within or out of this state that is engaged in dispensing, delivery or distribution of drugs within this state.

Registration of drug outlets; rules [ORS 689.305]

- (1) All drug outlets shall annually register with the State Board of Pharmacy.
- (2)(a) Each drug outlet shall apply for a certificate of registration in one or more of the following classifications:
 - (A) Retail drug outlet.
 - (B) Institutional drug outlet.
 - (C) Manufacturing drug outlet.
 - (D) Wholesale drug outlet.
 - (E) Nonprescription drug outlet.
- (b) No individual who is employed by a corporation which is registered under any classification listed in paragraph (a) of this subsection need register under the provisions of this section.
- (3) The board shall establish by rule under the powers granted to it under ORS 689.155 and 689.205 the criteria which each drug outlet must meet to qualify for registration in each classification designated in subsection (2)(a) of this section. The board may issue various types of certificates of registration with varying restrictions to the designated outlets where the board deems it necessary by reason of the type of drug outlet requesting a certificate.
- (4) It shall be lawful for a drug outlet registered under this section to sell and distribute nonprescription drugs. Drug outlets engaging in the sale and distribution of such items shall not be deemed to be improperly engaged in the practice of pharmacy. [1979 c.777 §30; 1993 c.571 §8]

This includes the following categories of drug outlets as of 1/01/17:

Charitable Pharmacy	13	Non-Prescript Drug Outlet-A	2406
Consulting / Drugless Pharmacy	13	Non-Prescript Drug Outlet-B	106
Institutional Drug Outlet	152	Med Device/Equip/Gases-C	497
Retail Drug Outlet	1343	Non-Prescript Drug Outlet-E	1
Supervising Physician Dispensing Outlet	33	Precursor	15
Home Dialysis Drug Outlet	5	Prophylactic/Contraceptive	14
Hospital Drug Room	27	Drug Distribution Agent	225
Remote Distribution Facility	4	Manufacturer	958
Correctional Facility	57	Wholesaler - Nonprescription	129
Community Health Clinic (formally known as County Health/Family Planning Clinics	148	Wholesaler with Prescription	441

BUDGET NARRATIVE – 17-19

Wholesaler – Class III	136	Controlled Substance	1969
Animal Euthanasia	25	TOTAL:	8697

Agency two-year Strategic Plan

The Agency is tied to the Governor’s Safety primary outcome area. The Agency has identified three long-term strategic goals consistent with its mission statement that will provide direction for ongoing activities and resource allocation. These three goals are tied to the agency Key Performance Measures. They are:

1. Protect Oregon consumers by regulating the practice of pharmacy and the commerce of drugs from manufacturer to the end user;
2. Provide Excellent Customer Service; and,
3. Conduct business in a manner that supports a positive environment for the pharmacy and pharmaceutical industries.

The Board of Pharmacy has an annual Strategic Planning Session where Board members review and establish priorities. In November 2016, the Board updated its Strategic Plan Outcomes that fit into the overarching Strategic Goals and Objectives developed in 2014, which are: Licensees’ operating excellence: “At the top of their license,” “No adverse impact on patient safety due to the workplace environment,” and “An adequate and safe drug supply for the State or Oregon.” Please see the following pages for the updated 2016 Strategic Planning Desired Outcomes.

BUDGET NARRATIVE – 17-19

Oregon Board of Pharmacy 2016 Strategic Planning – Retreat Outcomes

Issue	Desired Outcomes	Needed to Accomplish	Next Steps	By Whom	By when
How We Do Business	Clarify: (1) how to treat applicants who have marijuana related charges on their record and (2) how to deal with unsworn falsifications on license applications (e.g. failing to report an arrest that happened twenty years ago)?		<ul style="list-style-type: none"> • Staff will edit guidelines relating to marijuana possession so that marijuana possession cases will be treated similarly to alcohol impairment cases. • Staff's authority to review applications and submit cases will be placed on the "grid". • The "A-B-C" components will be reviewed at least annually at June Business Meeting. 	<p>Staff</p> <p>Marc Watt & Gary Miner</p> <p>Board</p>	<p>August 2016 DONE!!</p> <p>6/2017</p>

BUDGET NARRATIVE – 17-19

Oregon Board of Pharmacy 2016 Strategic Planning – Retreat Outcomes

Issue	Desired Outcomes	Needed to Accomplish	Next Steps	By Whom	By when
Board Process	To improve the board’s process by developing a consistent form of consensus building. As topics are concluded, define who is doing what and by when.		<ul style="list-style-type: none"> The President and Executive Director will co-facilitate meetings, using the 1-5 consensus tool whenever possible; The Vice President will assist by clarifying action items and polling the group for consensus. 	The President, Executive Director, & the Vice President of the Board.	February 2016 meeting & onward. Implemented 4/2016, the Board is working with this tool and other strategies.
Division 45 Rewrite (Drug Shortage Strategy)	A strategy is in place to insure critical drug shortages are avoided	Education and awareness	<ul style="list-style-type: none"> Discuss at December meeting whether to keep this issue on strategic plan Work with FDA to insure ability to use compounders for shortage drugs. Obtain a root-cause analysis of drug shortage causes. Open Division 045. Establish and implement strategy. 	Fiona/Gary	Q2 -2014 – “office use” compounding still being negotiated. Q4 – 2014 – still needed? Q4- 2014- delayed due to FDA complexities Q1 – 2015 – 2017 dates to be adj.
Workplace Environment	A valid framework from which to take workplace safety actions that meet the intent of patient safety	Continue to test temperature of stakeholders/licensees Share results of	<ul style="list-style-type: none"> Discuss at December 2016 meeting whether to keep this issue on strategic plan 	Staff	Ongoing

BUDGET NARRATIVE – 17-19

Oregon Board of Pharmacy 2016 Strategic Planning – Retreat Outcomes

Issue	Desired Outcomes	Needed to Accomplish	Next Steps	By Whom	By when
		7/2016 survey with the Board.	<ul style="list-style-type: none"> Draft and adopt administrative rules. 		
Legislative Concepts	1) Review housekeeping related issues and submit those this year; 2) Select three to five policy concepts and have a workgroup focus on these topics with a recommendation submitted by April 15, 2018.		<ul style="list-style-type: none"> The board will identify topics if necessary for the 2019 Session. 	The Board	October 2017 for final review at February 2018 meeting.
Preventing Medication Errors	To improve the reporting of medication errors through anonymous data collection based on (1) the type of error and (2) the position of the person who committed the error. The goal of this effort is to improve pharmacy practices in Oregon—not to find errors in order to penalize practitioners.	Deeper dive to get information in order to reduce medication errors and actionable ways to improve it.	<ul style="list-style-type: none"> Marc and Ken will meet with OPSC staff members between now and April to discuss creating an Oregon specific reporting forum and report back to the Board. Talk with other state re: approaches they use and report back to OBOP. 	Marc Watt & Ken Wells	November 2017 Retreat
Interns/Preceptors	To determine whether the laws and rules of the	Break into smaller component and get	<ul style="list-style-type: none"> Draft letter to gauge level of 	Fiona Karbowicz &	?

BUDGET NARRATIVE – 17-19

Oregon Board of Pharmacy 2016 Strategic Planning – Retreat Outcomes

Issue	Desired Outcomes	Needed to Accomplish	Next Steps	By Whom	By when
	intern-preceptor dynamic should be updated and to remind the field of the importance of this relationship for professional development.	input from school systems, students and pharmacists.	<p>interest/engagement beyond the school based preceptor/intern program.</p> <ul style="list-style-type: none"> • Explore reestablishing a board letter to be sent to all designated preceptors 	<p>Laura Elvers Roberto Linares</p> <p>Roberto Linares</p>	
Technician Rules, Education and Evolution	Examine the duties of pharmacy technicians as outlined in the statute and discuss whether their roles/duties should be further clarified / defined.	Continue discussion on the expanding role of technicians and whether a second license/delegation agreement is needed.	<ul style="list-style-type: none"> • Draft a list of what a tier-two technician cannot do. • Draft a template for a delegation agreement. 	Oregon Board of Pharmacy Staff	April 2017 Meeting (change in technician rules is 12-18 month process)
Medication Reconciliation/History	<p>(1) Send a clear message to pharmacists and technicians about the Board's expectations in Medication Reconciliation.</p> <p>(2) Move toward enhanced training for pharmacies in hospital settings.</p> <p>(3) Develop a "Best Practices" article to be distributed in the OPOB and pharmacy newsletters, which cites rules and</p>	Review this in conjunction with technician issues.	<ul style="list-style-type: none"> • Staff will draft a clarification article on "Best Practices" in the February 2018 newsletter 	Oregon Board of Pharmacy Staff	After Rule adoption in 12/2017. <u>Feb</u> 2018 newsletter article on best practices.

BUDGET NARRATIVE – 17-19

Oregon Board of Pharmacy 2016 Strategic Planning – Retreat Outcomes

Issue	Desired Outcomes	Needed to Accomplish	Next Steps	By Whom	By when
	statutes. (4) A rule needs to be created about Medication Reconciliation.				
Opioid/ Drug Take Back	Develop a strategy to further reduce opioid epidemic	Staff take part in statewide discussions & provide information to the board on that communication	<ul style="list-style-type: none"> • Begin to define a role for BOP • Communicate important role pharmacists have in helping identify/report misuse 	Oregon Board of Pharmacy Staff & Board	Ongoing

Agency Process Improvement Efforts

The Agency regularly reviews processes for improvement, to streamline and the Management Team tracks performance measurement for Licensing and Compliance, as well as other administrative responsibilities. Four of the most significant improvements implemented towards continuous improvement are:

IPad's for Board Meetings and Compliance Inspections

The Board previously reported about implemented I-Pads for Board Members, Compliance Pharmacy Inspectors and Management Staff that actively participate in board meetings. This past year, the Agency was selected for an FBI Security Audit. Among the recommendations were a few criteria the agency was able to implement immediately to add increased security measures that satisfied the FBI Audit.

BUDGET NARRATIVE – 17-19

Biennial Licensure

The Board is currently in the process of finalizing the shift to biennial license renewal for all individuals and this is proving to be a positive streamlining effort from a licensure, compliance, continuing education, and revenue timing perspective; this also directly ties to improve workflow and customer service. The Board received a very positive response during the pharmacist transition in 2015 and the pharmacy technicians are transitioning in the summer of 2016. This change moves the Board's two largest renewal cycles to the same expiration date in alternate years and should free up time for staff to improve process and workload management of the growing number of incoming new applications and other added/changing responsibilities.

Electronic Records Retention

The other major improvement implemented during in the last two years was the Board's move to online records retention through the State's Enterprise solution, the Oregon Records Management Solution (ORMS) established with the Secretary of State's Archives Division. The Agency utilized policy package funds to scan all active licensing records and current compliance materials eliminating over 34 filing cabinets of paper records. Staff now, actively scans new and renewing licensing records, as well as all completed compliance materials for electronic storage in ORMS. These records are in an electronic format that meets the state's records retention and destruction guidelines. We are now working to move the other agency operational records to the paperless environment; that will be an ongoing project.

Licensing Department Supervisor

The 2015-17 budget included a new supervisory position for the Licensing Department. This position is in place and an overall review of licensing applications, processes and procedures is in progress to identify areas where efficiency, effective communication and customer service can be achieved. More in-depth cross training efforts has already occurred which has increased efficiency due to the ability to share workloads in high volume application or renewal times.

Additional Program Objectives

As noted previously, the Board has identified goals, objectives and priority outcomes for the next two years; however, the Board continues to regularly do the following to achieve the overall mission, goals, objectives and priorities of the Agency.

Assess and monitor the competency levels of pharmacists through testing, peer review, and improved continuing education:

Evaluating continued competence of licensees beyond initial licensure is a difficult and controversial endeavor. The Oregon Board of Pharmacy participates as an active member with the National Association of Boards of Pharmacy (NABP) to provide a nationally standardized pharmacist licensure exam for candidates who have met approved minimum entry level education, training and competency standards. The Board of Pharmacy staff maintains and updates annually a large pool of questions used with the computerized national Multi-State Pharmacy Jurisprudence Exam (MPJE) and the North American Pharmacy Licensure Exam (NAPLEX). A candidate for licensure as a pharmacist must take and pass both the NAPLEX exam, and the MPJE for the state or states in which he or she desires to become licensed. A

BUDGET NARRATIVE – 17-19

pharmacist wishing to reciprocate (transfer) his or her license from another state to practice in Oregon, and who has taken and passed the NAPLEX exam, must take and pass the MPJE for Oregon. A pharmacist educated in another country wishing to transfer his or her license to Oregon, or any other U. S. state, must take and pass the Foreign Pharmacy Graduate Equivalency Examination (FPGEE) to obtain a Foreign Pharmacy Graduate Equivalency Certificate (FPGEC). The Board's NABP membership and participation has been an important aspect of the Board of Pharmacy's efforts to maintain high professional standards. In the absence of NABP membership and active participation, the Board of Pharmacy would be held responsible for and bear the cost of developing, maintaining, administering and defending its own examination process for the entry level licensing and continued competency of pharmacists in Oregon at a significantly increased expense. The long-term financial savings directly attributable to the Board's active participation and membership in NABP is substantial.

Review and evaluate the frequency of on-site inspections of the various drug outlets:

Board of Pharmacy inspectors evaluate hospital, charitable, consulting, and community pharmacies, supervising physician dispensing outlets, drug manufacturers and wholesalers, correctional facilities, county health and family planning clinics and other drug outlets for compliance with federal and state laws and rules. The Board has developed a pharmacy self-inspection form for each of these outlet types which enable the outlet's pharmacist-in-charge to assess compliance before an on-site inspection is made. The form is reviewed and updated annually by Board of Pharmacy staff to reflect current priorities and is provided to each pharmacy at the beginning of each year for completion. This has been received by pharmacists as a valuable educational tool and has helped the inspectors and the pharmacists-in-charge in bringing pharmacies into voluntary compliance without need of warning notices or other corrective or disciplinary measures. Oregon was the first state and continues to be one of the few states to vigorously encourage voluntary compliance by the use of the pharmacy self-inspection form. Additionally, Board of Pharmacy inspectors are available to answer questions from pharmacists, interns, pharmacy technicians, other healthcare professionals, and the general public.

The Oregon Pharmacy Practice Act requires the Board to perform on sight inspections at regular intervals. The Board has traditionally interpreted this as meaning annually. All retail and hospital and institutional pharmacies are inspected annually. As time allows and necessity dictates, Inspectors also inspect Manufacturers and Wholesalers within the state. In Oregon "Voluntary Compliance" is the heart of the regulatory process which enables the pharmacy and pharmaceutical industries and pharmacy profession to provide quality products and services to consumers without intrusive presence or intervention by the Board's investigators. The "sentinel effect", the uncertainty of when the inspector might appear on sight, provided by these unannounced on-site inspections of pharmacies serves to facilitate the needed voluntary compliance. Inspections also serve as an educational opportunity to share new information and answer questions an outlet may need more information about. Compliance staff reports current inspection statistics to the Board at each scheduled Board meeting.

Because of widely reported concerns of counterfeit or tainted drugs and general concerns about the integrity and security of the nation's drug distribution system, the Board feels it is also necessary to perform on sight inspections of the pharmaceutical wholesaler and manufacturing drug outlets on a periodic basis. In addition, for nonresident wholesale drug outlets that distribute prescription drugs into Oregon, the Board requires confirmation of a recent inspection. Inspection reports from other Boards of Pharmacy or the Food and Drug Administration (FDA)

BUDGET NARRATIVE – 17-19

are reviewed and proper bonding requirements are verified annually. The Board also works with the National Association of Boards of Pharmacy to annually verify if its resident and nonresident wholesale drug outlets are Verified Accredited Wholesaler Distributors (VAWD). To further ensure public safety the Board requires that all disciplinary action be reported with initial and annual renewal applications. Any disciplinary action is thoroughly reviewed prior to issuing a registration.

Administrative rules for the licensing of pharmaceutical manufacturers, wholesale drug distributors and drug distribution agents are continuously reviewed and updated to provide the most appropriate oversight of these outlets. In November 2013, the Drug Quality and Security Act (DQSA) was signed into federal law. Title I is called the Compounding Quality Act and Title II is the Drug Supply Chain Security Act (DSCSA). The Board continues to work with the Food and Drug Administration and other stakeholders to ensure its rules support the DQSA. A national system is established to enable verification of the legitimacy of the drug product identifier, eventually down to the package (or patient/end user) level. Detection and notification of illegitimate products in the drug supply chain will be enhanced, and more efficient recalls of drug products will be facilitated. Updated rules help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful and to improve detection and removal of potentially dangerous drugs from the drug supply chain to protect consumers.

In 2013, the Board updated its manufacturer rules relating to compounding. The purpose of this update was to ensure that nonresident compounders shipping non-patient specific products into Oregon register with the Board as a manufacturer. Note that in order to qualify for a manufacturer registration, registration with the Food and Drug Administration is required as a licensure prerequisite. This requirement provided the Board with an additional safety control over nonresident compounders and deterrent for illegitimate nonresident compounders to apply for licensure.

In 2015, the Board adopted amendments to its drug distribution agents, wholesale distributors, and manufacturer drug outlet rules as a result of the 2013 Federal Drug Supply Chain Security Act (DSCSA). Oregon continues to be a leader as it was the first state to update its administrative rules in response to the DQSA and the Board's registration processes and rules are effective tools that help to protect the drug supply by ensuring that the Board has adequate oversight over companies doing business with or in Oregon on behalf of its citizens.

Because of the complexity of the drug distribution process through manufacturers and wholesalers, staff devotes considerable time answering multifaceted questions and responding to high-level inquiries from licensees, legal teams, and various other stakeholders. Over the past several years, one full time licensing representative has been assigned exclusively to wholesalers and manufacturers, as they require a high level of detail and comprehension. A licensing representative and a manager review every wholesaler and manufacturer application. This requires a significant amount of the Agency's staff time. However, it is necessary in order to ensure protection of the state's drug supply. It should be noted that although compliance cases involving wholesalers have decreased significantly due to the work done on the administrative rules over the years, when compliance cases do occur they are costly and extremely time and labor intensive.

BUDGET NARRATIVE – 17-19

Focus on the investigation of consumer complaints and allegations of diversion and other drug distribution violations:

The Board's Compliance staff investigates all consumer complaints as required by Oregon law. Some complaints are minor and require minimal investigation or involve issues over which the Board has no jurisdiction. The majority of complaints require full and comprehensive investigations involving complex and evolving issues of professional practice and intrastate, interstate and international drug distribution. Each investigation results in a report to the full Board for deliberation and possible action, and a response to the complainant regarding the disposition of the case. Increasingly, these investigations are consuming greater amounts of agency resources including investigator time, administrative involvement, settlement negotiations and legal advice from the Attorney General's office.

Work closely with the Medical, Nursing, Dental, Optometry, Veterinary and Naturopathic Boards and Associations as well as Local State and Federal Law Enforcement Agencies, the Colleges of Pharmacy at Oregon State University and Pacific University in an ongoing effort to eliminate the diversion of drugs from legitimate distribution channels to illegal and harmful recreational use.

Controlled substance prescription drug diversion, deliberately or through carelessness, incompetence or indifference, continues to be a challenge for the professions of medicine, nursing, dentistry and pharmacy. The risk of addiction and drug diversion by pharmacists and pharmacy technicians, with their necessary ongoing access to controlled substance inventories, is a constant concern for the Board of Pharmacy. Audits of controlled substance purchases and distribution are done by the agency's compliance staff in hospital and community pharmacies if there have been unexplained shortages. When a pharmacist or pharmacy technician is discovered illegally diverting or using prescription controlled substances, the Board has a range of disciplinary options including suspension or revocation of the individual's license.

2016 HB 4016 legislation modifies the organizational structure of the Health Professionals Services Program (HPSP) that was established within the Oregon Health Authority (OHA) in 2010 for licensees who have been diagnosed with alcohol or substance abuse or a mental disorder. This change removes OHA and allows the health professional licensing boards to establish or contract with to establish an impaired health professional program by the creation of an Impaired Health Professional Work Group that consists of individuals from the participant health boards. The Oregon Medical Board will provide staff support to the work group and facilitate contracting as required. This program allows the Board to refer an individual licensee for treatment in lieu of or in addition to disciplinary action. While this program is still very expensive to operate, with this legislative change, the health professional licensing boards expect to see an overall reduction in the cost of administering the HPSP program, which is a direct cost to each of the agencies that have participated since inception.

The health professions regulatory boards, including nursing, medicine, dentistry, veterinary medicine and other Health Professional Regulatory Boards (HPRB's) meet at regular intervals to discuss issues of mutual interest and explore ways to develop and incorporate efficiencies by reducing duplication of resources and taking advantage of opportunities for collaboration. This group has developed an orientation packet for new legislators to help them understand the HPRB's. The group also meets regularly with the Governor's Staff and invited representatives from the Department of Administrative Services (DAS), other public and private entities, and works with various legislators on issues affecting the agencies and public health.

BUDGET NARRATIVE – 17-19

Maintain staffing levels and resources necessary to accomplish the long term plan and to provide timely and informative presentations on pharmacy and drug law to pharmacists, pharmacy students, consumer groups and other health care providers and students and meet other stakeholder demands;

Agency staff regularly respond to requests from a variety of stakeholder organizations, including colleges, professional associations, consumer organizations and other groups to speak on topics related to pharmacy and drug law at meetings, conferences, workshops and classes. These activities are encouraged by the individuals and associations representing the Board's licensees. These requests are evaluated regularly and we participate to the fullest extent possible. This agency needs not only to be prepared to respond to requests, but should also be able to take a pro-active posture in reaching out to its stakeholders including individuals, and appropriate consumer, health care provider and business organizations. As the Agency's workload and responsibilities continue to evolve, so must the Agency's staffing and resource level. The Board benefits from these outreach activities by improving our relationships with our licensees, as well as achieving higher compliance without having to resort to disciplinary measures.

Work closely with appropriate state and federal agencies to develop policies and guidelines for the use of electronic signatures and coding to facilitate the use of electronic technologies in prescribing and dispensing drugs and devices;

These policies and guidelines must facilitate the use of appropriate technology and protect the integrity of electronic data by providing a means of positively identifying the prescriber and the dispenser electronically. They must also address the broader issue of privacy by protecting the confidentiality of and preventing unauthorized access to an individual's confidential medical and pharmacy records. The confidentiality requirements of the Health Insurance Portability and Accountability Act (HIPAA) must be included in the overall development of electronic technologies applied to prescribing and dispensing. Proposals for the use of electronic technologies in the practice of pharmacy and the distribution of drugs are currently before the Board, challenging the existing regulations. Regulations need to be updated to facilitate emerging technologies. Board members and staff have participated in activities with NABP, Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) and the state Health Professional Regulatory Boards (HPRB's) to facilitate the transition from hand written prescriptions to prescriptions that can be electronically generated and transmitted from the practitioner to the pharmacy. Ongoing development and maintenance of procedures and regulations will be necessary as professional practice standards evolve with the electronic technology. Electronic prescribing is rapidly becoming more prevalent with the added ability to transmit controlled substance prescriptions electronically. It is expected to improve recordkeeping, reduce the opportunity for diversion, and reduce dispensing errors due to illegible handwritten prescriptions. The Agency has encouraged the move to e-prescribing at every opportunity and has sought to amend statutes and rules to further facilitate this evolution; laws are now in effect to authorize the ability for practitioners to electronically transmit prescriptions for Schedule II controlled substance in nonemergency situations.

Agency Programs

The Oregon Board of Pharmacy is made up of five practicing pharmacist members, two public members and two pharmacy technicians who are not pharmacists and 20 full or part time positions. The Board is budgeted and accounted as a single program. The staff is internally

BUDGET NARRATIVE – 17-19

organized into three distinct sections including Licensing, Compliance and Operations/Administration. The agency additionally tracks expenditures separately for Board Member Activities and Interagency Activities.

The *Licensing section* is made up of 6 positions which includes the newly established Licensing Program Supervisor position that was legislatively approved 2015, that handles all details related to licensing and examinations including applications, renewals, production and mailing of more than 27,030 certificates of registration and licensure and frequent communication with licensees and applicants that represent 32 different categories of licensure for individuals and drug outlets. Examinations include the North American Pharmacy Licensure Examination (NAPLEX), the Multi-state Pharmacy Jurisprudence Examination (MPJE), the Foreign Pharmacy Graduate Equivalency Examination (FPGEE), and the Test of English as a Foreign Language (TOEFL iBT). The Board requires national fingerprint based FIB background checks for all new applicants for pharmacist, pharmacy technician, certified pharmacy technicians and pharmacy intern licensure. The Licensing and Background Check Specialist staff also performs annual criminal background checks with established Policies and Procedures using the Oregon Law Enforcement Data System (LEDS). Staff regularly visits the pharmacy schools in Oregon to meet and talk to the incoming students about professional responsibilities and licensing and to talk to the soon to be graduating students about procedures and requirements for licensure as a pharmacist.

The *Compliance section*, made up of eight positions, which includes six pharmacists and two administrative staff and is responsible for all on-site inspections of pharmacies and drug outlets, all investigations of consumer complaints, reports of possible drug diversion and other suspected violations, administrative details of proposed and ordered disciplinary action and monitoring all licensees who have been placed on probation through the disciplinary process. Compliance staff is also responsible for interpretation and review of pharmacy laws and rules and provision of information to and consultation with all stakeholders on pharmacy and drug laws upon request.

The *Operations/Administration section* includes six positions that is a combination of operations and administrative functions. It includes the Executive Director, Administrative Director, Pharmacist Consultant, Project Manager, Office Manager, and Management Secretary/Background Check Specialist. The Executive Director is responsible for the overall operation of the Agency, which includes, supervision of the Operations, Licensing and Compliance sections and the performance of all staff, the interpretation and implementation of Board policy, oversight of all public and media relations, active participation with the National Association of Boards of Pharmacy (NABP), the American Council of Pharmaceutical Education (ACPE), and the state and federal regulatory bodies including the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) and the development and maintenance of the network of stake holder relationships.

The Executive Director directly supervises the Administrative Director, the Compliance Director, Pharmacist Consultant, and the Project Manager and answers to the President of the Board. The Administrative Director supervises and oversees the daily operations of the agency and supervises the Office Manager and Management Secretary. This position also encompasses a variety of other administrative functions including, coordination of board meeting activities, agenda development, budget preparation, accounting, contracts, and coordinates various

BUDGET NARRATIVE – 17-19

activities with the Department of Administrative Services. The Compliance Director directly supervises the Compliance section activities and staff. The Pharmacist Consultant position is specifically responsible for conducting research and managing projects that require pharmacist expertise. The position also assists the Executive Director with media requests and legislative activities to name a few. The Project Manager position provides essential support in researching issues and managing projects for the Agency. The Office Manager is responsible for general office management, including database and network administration, accounts payable/receivable, facilities management, purchasing etc. Staff in this section is involved in conducting policy research, writing reports and recommendations, and coordinating committees and task forces as required by the Board.

“*Board Member Activities*” includes capturing all activities related to board members’ compensation, travel, lodging and other expenses and all activities related to holding board meetings.

“*Interagency Activities*” includes pass through payments to Oregon State Police for fingerprint for criminal background checks for all new licensees, Workforce Data Collection fees for data analysis to the Oregon Health Authority (OHA), Prescription Drug Monitoring Program fees to OHA and the Health Professional’s Services Program costs for impaired professionals.

The following list reflects additional ongoing operational tasks that are required of the Agency.

Regulating the Practice of Pharmacy & Distribution of Drugs in the Public Interest Ongoing Operational Tasks

Office/Agency Management

- Operate office efficiently consistent with DAS administrative requirements for state agencies
- Develop & maintain efficient internal information and data management systems
- Perform all aspects of the budget process, including preparation, monitoring, accounting and reporting
- Develop & maintain appropriate operational structure for efficient administration of Board meetings, timely implementation of Board policies and effective achievement of goals identified by the Board

Licensing & Examinations

- Verify qualifications and provide licenses to all qualified applicants in a timely manner
- Develop and maintain a large pool of exam questions for the NAPLEX and MPJE national licensure examinations
- Conduct criminal background checks on all new licensees and annual renewing licensees

Investigations

- Investigate all consumer complaints fully in a timely manner

BUDGET NARRATIVE – 17-19

- Investigate all allegations of drug abuse or diversion by licensees in a timely manner
- Provide complete and timely reports to the Board
- Collaborate with federal, state and local law enforcement agencies when appropriate

On Site Inspections

- Inspect Pharmacies annually, other Drug Outlets as resources permit
- Monitor outcomes, identify trends, report, educate and discipline when necessary

Information and Assistance

- Answer questions & provide information requested by stakeholders in a timely manner
- Produce quarterly OBOP/NABP Newsletter and OBOP Internet website

Pharmacy Profession

- Monitor state and national trends in pharmacy & pharmaceutical industries, and professional practice
- Monitor state and federal drug laws and rules affecting the pharmacy & pharmaceutical industries, and professional practice
- Maintain and update Oregon administrative rules and laws related to pharmacy practice and drug distribution
- Develop and maintain collaborative working relationships with pharmacy professional associations
- Develop and maintain appropriate entry level education and continuing competency policies for pharmacists and pharmacy technicians as required by law

Other Stake Holders

- Develop and maintain collaborative working relationships with consumers & consumer groups, industry stakeholders, and other health care professional associations, pharmacy students and faculty, state agencies and the legislature

Oregon Legislature

- Monitor for Legislative measures affecting the agency or the prescribing, dispensing or distribution of drugs
- Draft legislative measures and provide oral and written testimony as necessary
- Actively participate with legislators, legislative committees, and task forces when appropriate

Outreach

- Communicate safety practices to consumers and collaborate with other agencies when appropriate
- Provide appropriate education to pharmacists, inters and pharmacy technicians, 26 outreach activities/presentations were conducted in 2015, please see the Special Reports tab, [page 100](#) for a detailed list.

BUDGET NARRATIVE – 17-19

- Communicate laws to non-English speaking citizens when needed
- Boards of pharmacy, unlike other health regulatory boards, are required to interface and interact with many other state and federal regulatory agencies. These include, on the federal level, the U.S. Food and Drug Administration (FDA), with federal authority over prescription and non-prescription drugs and devices and the U.S. Drug Enforcement Administration (DEA), with federal authority over narcotics and other controlled substances. These also include, at the state level, the Health Professional Regulatory Boards (HPRB's) for every discipline with the authority to prescribe, dispense, administer or possess drugs and devices including physicians, nurses, nurse practitioners, dentists, veterinarian, optometrists, physician assistants, and naturopathic physicians.
- Boards of pharmacy also uniquely differ from other health regulatory boards in that boards of pharmacy not only regulate the licensed professional individual, but they also regulate the commerce of all drugs from manufacturer to end user for the quality and distribution of products and services by registering the various types of drug outlets. These are locations at which the licensed health professional practices his or her profession, and the locations at which un-licensed employees manufacture and distribute drugs and devices. It is the drug outlet, not the individual pharmacist or employee that has the authority to possess prescription and non-prescription drug inventory for distribution. This creates a dual role that involves a variety of unique circumstances with which pharmacy boards must be concerned and which are not shared by the other health regulatory boards. The impact of this multi-disciplinary and dual role is compounded by the fact that these individuals and drug outlets exist not only within Oregon, but also outside of Oregon in all U.S. states and jurisdictions where drug outlets are involved in distributing drugs into Oregon or are planning to do so. These out of state pharmacies, wholesalers and manufacturers must be licensed by the Oregon Board of Pharmacy to do business in the state.
- The Oregon Board of Pharmacy, pursuant to ORS Chapter 475, regulates the narcotics and other controlled substances and investigates complaints and allegations of prescription controlled substance diversion. Some states have established separate bureaus of narcotics and dangerous drugs which assume authority over the investigation and enforcement activities involving controlled substances. Oregon is not one of these.

Environmental Factors

1. Because changes in the focus of pharmacy practice and technological advances are being incorporated into systems of drug distribution, the Board is being required to rewrite many of its major administrative rules. Rules relating to continuing professional education, the licensing and supervision of pharmacy technicians, the licensing and operation of pharmaceutical wholesalers, manufacturers and drug distribution agents and the operation of pharmacies serving long term care facilities are in the process of being reviewed and updated.
2. While U.S. drug supplies are generally considered safe, incidents of counterfeit and diverted or stolen drugs have been increasing. Counterfeiters are becoming more sophisticated in their technologies and methods of remaining undetected while introducing adulterated and

BUDGET NARRATIVE – 17-19

counterfeit drugs into the US system. Prescription controlled substances are increasingly becoming targets of theft from pharmacies and pharmaceutical distributors. The country's drug supply is under unprecedented attack from a variety of increasingly sophisticated threats. Although counterfeiting and prescription drug theft was once a rare event, we are seeing increasing numbers of pharmacy and pharmaceutical wholesaler robberies and large supplies of counterfeit versions of finished drugs being manufactured and distributed by well-funded and elaborately organized networks.

There are several reasons for the increase. There is generally a higher recognition and demand for prescription drugs, as more drugs are developed to treat more diseases. Drugs are getting more expensive, so consumers may be more willing to turn to nontraditional sources and criminals are more willing to assume risk for higher returns. Prescription controlled substances are replacing traditional "street drugs" such as marijuana, cocaine, methamphetamine and heroin. New technologies make it easier for criminals to make counterfeit drugs, and now that drugs are being sold over the Internet, without face-to-face contact between buyer and seller, it's more difficult for consumers to know if the source is legitimate.

Some prescription drugs follow a long path, through wholesalers and re-packagers, before reaching the pharmacy shelf. Some unscrupulous individuals have been able to sneak counterfeit drugs into the system of wholesale distribution. When pharmaceutical wholesalers or re-packagers get their drug products from sources other than original manufactures, opportunities for introducing inexpensive counterfeit products into the system unbeknownst to the legitimate wholesaler are opened up. Once outside the "regular distribution system" and into the "gray market system" the drugs are no longer protected by the regulatory safeguards for packaging and storage. Drug counterfeiting has become a very lucrative, and in some cases a very systematically coordinated and organized crime. Adding to this, the Internet and the advent of "on-line" drug distribution schemes have created a dynamic that goes far beyond the Agency's ability and authority. Increasingly, the Agency has been required to devote significant resources in its efforts to regulate websites involved in legal distribution, as well as illegal distribution of adulterated and counterfeit drugs.

Prescription Opioid abuse and deaths are at an all time high in Oregon and across the country. The Oregon Public Health Division created a new Oregon Prescribing Guidelines Task Force, which has adopted the *CDC Guidelines for Prescribing Opioids for Chronic Pain* as the foundation for opioid prescribing in Oregon. The Task Force is actively engaged in furthering discussions at the state, regional and organizational levels to implement consistent application of the guidelines. The Oregon Prescription Drug Monitoring Program (PDMP) continues to evolve and expand access to the program for other users within the healthcare system and use has increased to be a more effective tool for prescribers in Oregon to identify fraudulent activity and over prescribing. The Board continues to advocate for PDMP use within the pharmacy community.

The Board maintains a list serve for community pharmacists and health system pharmacy's staff to share reliable information from pharmacies or from law enforcement of organized prescription forgery rings or confirmation from a prescriber that the prescribers DEA number or prescription blanks have been compromised. The Board alerts its pharmacists through its list serve usually within 24 hours of the

BUDGET NARRATIVE – 17-19

occurrence. These alerts have been a valuable tool for the timely sharing fraudulent activity information and have resulted in arrests and increased awareness of prescription fraud.

3. In addition to increasing numbers of licensees the Agency's workload continues to be driven primarily by an increase in the complexity of consumer complaints, and to the growing complexity as well as number of investigations and requests for information. This has led to an increase in the amount staff time required to adequately address and attend to stake holder issues. The consumer of pharmaceutical supplies and services is becoming more informed (or misinformed) and thus, is demanding or needing a higher level of service and a greater amount of information. The drugs and devices available to consumers through pharmacies and other drug outlets are becoming more sophisticated and more potent, have the potential for more serious adverse effects and are being used to treat more conditions and more critical conditions. More pharmacies than ever before are owned and operated by corporations, many of whom are large, publicly held national and multinational companies with complex business and financial structures, with heavily staffed legal departments and government relations teams. Pharmaceutical researchers and manufacturers are becoming more involved in direct to consumer advertising and promotion of prescription drugs and devices. This is resulting in an increase in consumer awareness, but an increase in consumer confusion, as well as an increase in demand for pharmaceutical products, information and services. Medicaid, managed care companies and pharmacy benefit management companies (PBM's), in their zeal to reduce costs, are inadvertently contributing to a disruptive environment by placing barriers, restrictions and requirements on access to and reimbursement for pharmacy services, drugs and devices.
4. As the state's population increases in age and number, the use of prescription and non prescription drugs continues to increase. This increase in demand for prescription drugs and services is stressing the industries abilities to meet consumer's expectations.
5. As pharmacists' professional activities assume increased responsibility in areas of direct patient care, such as prescribing contraception, medication therapy management (MTM) under Medicare, disease state management programs and protocols, collaborative drug therapy management (CDTM), immunizations and clinical laboratory health screen testing, pharmacy technicians are being trained, certified and licensed to perform many of the mechanical tasks of preparing and packaging medications, and other production functions that were previously performed by pharmacists. Pharmacists have become trained and are much more focused on patient care and drug therapy management while pharmacy technicians are focusing on production activities under training and supervision of the pharmacist. This has required an extensive revision of the pharmacy practice rules which are currently being reviewed and updated regularly.
6. Agency staff is being asked to contribute increasing time and resources to participate in a variety of new and ongoing activities with other state agencies. Increased activity at the state level regarding preparation for natural disasters, public health emergencies and bio-terrorism events has required agency staff participation. Other areas include review of immunization protocols, Recreational Marijuana Advisory Committee, opioid abuse, and drug take back. Increased activity at the state level to develop mechanisms for assessing quality and systems for effectively reporting to appropriate entities such as the Oregon Patient Safety Commission, has required Agency staff participation. Other issues such as emergency and business continuity planning, ethnic diversity, language and cultural competence, health care workforce

BUDGET NARRATIVE – 17-19

shortages, the Health Professional’s Services Program, Prescription Drug Monitoring Program, and the OHA’s Workforce Data Collection and Opioid Workgroups are requiring agency staff participation.

Agency staff worked closely with law enforcement agencies and researchers from the Oregon State University College of Pharmacy to ban the sale of synthetic cannabis and dangerous stimulants such as substituted cathinones known as bath salts. The Board adopted rules to amend Controlled Substance Schedule One to include synthetic cannabinoids and cathinone-type derivatives that are subject to abuse, and have no legitimate medical purpose. Instead of scheduling only known cathinone-type drugs the Board scheduled derivatives of cathinone and methcathinone, as well as all cannabinoid receptor agonists that are not FDA approved drugs. The Oregon State Police Forensics Laboratory later requested the Board update these rules to capture additional derivatives of these synthetic drugs that continue to be developed and abused. Most recently, the Forensics Laboratory requested the Board consider adding substituted-fentanyl compounds to the Schedule I Controlled Substance list in Oregon. Seven deaths in Oregon identify fentanyl-related compounds as the contributing factor. Fentanyl is about 100 times more potent than morphine as an analgesic. The potency of the substituted fentanyls are not yet known, but are opening the door for overdoses. The Board is also working with the Forensics Lab. on other synthetic opioid analgesic drugs like U-47700 and W-18 that have been in the news recently to research the possibility of adding them to the Schedule I Controlled Substance list.

- 7. A number of calls, contacts and requests being diverted and directed to the Board of Pharmacy that would otherwise more appropriately be directed to Oregon State Pharmacist Association (OSPA) continue. The Board does not function as or in lieu of a professional association. In the absence of a visible and active professional association, the Board will continue to carefully determine appropriate responses to the various requests for attention to pharmacy related issues. This does impact staff work load and flow, but it is important that Board resources and activities remain focused on representing the interest of public health and safety and not the interest of the pharmacy profession or the pharmaceutical industry.

Strategic Initiatives & Accomplishments

The Agency has identified a number of strategic initiatives that will support the intermediate outcome targets or objectives of the Board’s strategic and business plans. The Board will:

Implement Legislation on Contraceptive Therapy

With the passage of HB 2879, which was signed into law in July of 2015, Oregon became the first state in the country to advance the ability of pharmacists to prescribe and dispense contraceptives. The legislative intent is to provide a woman timely access to contraceptive care, by developing procedures for the pharmacist prescribing of certain hormonal contraceptive patches and self-administered oral hormonal contraceptives. The Board was required to adopt rules to establish these procedures in consultation with the Oregon Medical Board, the Oregon State Board of Nursing and the Oregon Health Authority, as well as consider the guidelines established by the American Congress of Obstetricians and Gynecologists (ACOG). Temporary rules were passed in November of 2015 and operative when the legislation took effect

BUDGET NARRATIVE – 17-19

on January 1, 2016. A permanent rule making committee convened in March of 2016 and the Board adopted the permanent rules at their April 2016 Board meeting.

Board staff worked with Oregon State University (OSU) on the development and implementation of the brand new online training program for Comprehensive Contraceptive Education and Training for the Prescribing Pharmacist at the Board's request with the Consultative Committee. A program specific to address pharmacist prescribing contraceptives did not exist anywhere in the country and OSU is currently the only ACPE (American Council for Pharmacy Education) accredited Continuing Education provider in the state to create and provide this resource in a timely manner. It was the Board's goal to ensure that a quality training program was established within the short time-frame required to allow for the January 1, 2016 operational date and OSU was able to assist. As of December 2016, 957 pharmacists have completed the training program.

To educate pharmacists the Board has established a "Standard Procedures Algorithm for Pharmacist Prescribing of Contraceptives". This document provides consistent care to all Oregonian women; it includes defined parameters of safety; is streamlined and straightforward and is a process based on: ACOG statements related to safety and access, a Consultative Committee that was established with representatives from those agencies mentioned previously and subject matter experts and clinicians and assisted by directives from the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and Family Health International (FHI360). A "Toolkit" of resources is available on the Board's website including: "The Standard Procedures Algorithm for Oregon RPH Prescribing of Contraceptives", the "Hormonal Contraceptive Self-Screening Questionnaire" and the "Summary Chart of US Medical Eligibility Criteria for Contraceptive Use" documents are meant to be used together.

Work toward reducing the number of dispensing errors, or mis-filled prescriptions.

The Board is aggressively addressing ways to improve patient safety and reduce medication errors. One of the tools implemented by the Board is its prescription identification label, or "PIL" rule. It is intended to help the patient at home, long after the dispensing, to positively identify tablets and capsules. Oregon was the first and remains one of the few states requiring the PIL. The Board also adopted a position statement on *Medication Error Reduction called Optimizing Patient Safety and Reducing Medication Errors in Oregon*. This topic continues to be a top priority of the Board.

Explore ways to better assess and appropriately respond to the public and other stake holder interests in a timely manner.

It is in the interest of the public health, safety and welfare that consumers have reasonably convenient access to pharmacy services provided by qualified and competent pharmacists and reasonable trust that the pharmaceutical products are safe and effective. It is the role of the Board of Pharmacy to regulate the industry and the professional practice of pharmacy in the public interest, as well as to eliminate or, at least, to not introduce unreasonable or unnecessary regulatory barriers to the public's access to pharmaceutical products and services.

BUDGET NARRATIVE – 17-19

In April 2012 the Board adopted rules to allow hospitals to implement Technician Checking Validation Programs (TCVP) to allow the redirection of a pharmacist from a distributive role to a patient oriented role. There are now eight hospitals have received the Board's approval to implement TCVP systems. The Board requires each hospital to report back after one year of implementation and the Board is receiving good feedback on their progress and ways to improve the rule requirements that were unidentified at the time of rulemaking.

Develop high standards in pharmacy practice by working more closely with the Oregon State University and Pacific University Colleges of Pharmacy to facilitate the transition of pharmacists to drug therapy managers and drug counseling specialists to function in a manner more consistent with their education and training.

By working closely with physicians and other health care professionals, pharmacists can focus primarily on the health and quality of life of the patient. Pharmacists are required, by both federal and state law, to provide information to patients on drugs, to keep complete pharmacy records on every patient, and to review those records for therapeutic duplication, drug interactions, side effects, appropriate dosing, allergies, etc. They are also expected to advise prescribers on what drugs and dosages are available and to provide other information to help determine which might be the preferred drug product, dose or dosage form for a particular patient. Patient counseling, drug therapy management and patient monitoring and follow up are a part of the 'therapeutic outcome' approach to pharmacy practice. The end results are better drug therapy outcomes, a more involved and knowledgeable patient and better overall health care for the population. To this end, the Board will continue to encourage appropriate collaborative drug therapy management relationships, and disease state management programs. Pharmacists also have an increased responsibility to administer immunizations and improve immunization rates for the Oregon population.

In July of 2013 the Agency re-conducted an opinion survey first done in 2011, which surveyed pharmacists regarding workplace conditions related to professional practice and patient safety. The results of the survey have been published on the Agency's website:

http://www.oregon.gov/pharmacy/Imports/OBOP-Pharmacy_Working_Conditions_Survey_Results11.13.pdf. The Agency utilized the results of the survey to determine whether its drug outlet conduct rules were effective and which remaining issues still need to be addressed. However, survey results clearly identify there is still room for improvement. Recently, Board Staff have again been hearing increased concerns and complaints about this issue and the Board reissued the survey to obtain current opinion on this topic in July 2016. Upon a limited initial review, it is sounding like the problem is growing worse again.

Find ways to increase the public's awareness of the Board of Pharmacy and understanding of services provided by pharmacists: Direct contact and outreach with consumer advocacy groups, written publications and electronic communications through the Board of Pharmacy's website are being used to help consumers understand what to expect from their pharmacist or pharmacy, and how and when to report problems they might have experienced or concerns they may have.

The Agency continues to work with NABP to promote and develop content for the AWARe website <http://www.awarx.org/> which provides information for consumers on counterfeit medications, prescription drug abuse and medication safety issues. The Board's website links to a [Red Flag video](#) that helps pharmacists identify signs of drug seeking behavior, drug diversion and prescription forgeries.

BUDGET NARRATIVE – 17-19

Pharmacists play a critical role in limiting inappropriate entry of controlled substances into the population. This video can also be accessed from our home page, www.oregon.gov/pharmacy.

Accomplishments: Key accomplishments over the last few years include:

- Completed temporary and subsequently permanent rule making on pharmacist contraceptive prescribing which implemented 2015 HB 2879 and had official trainings developed and coordinated with key stakeholders prior to the effective date of the law. This allowed trainings to begin immediately and pharmacists trained when the law became operative January 1, 2016.
- Implementation of rules for biennial licensure for pharmacist and pharmacy technicians completed.
- Converted paper licensing & recent compliance files to electronic records. Online records retention through the State's Enterprise solution, the Oregon Records Management Solution (ORMS).
- Active cross-training & succession planning - ongoing

Criteria for 2017-2019 Budget Development

The following goals have been identified by the Board to be used as a basis to develop this budget proposal. From these general goals, and with these goals in mind, all agency activities and allocation of resources are determined. Agency staff continues to ensure that Agency direction remains consistent with the Agency's mission statement. The short and long term goals of the agency all tie directly to the mission of public safety.

Goal 1. Protect Oregon Consumers by regulating the practice of pharmacy and the distribution of drugs

Goal 2. Provide Excellent Customer Service

Goal 3. Conduct business in a manner that supports a positive environment for the pharmacy industry

Annual Performance Progress Report (APPR)

The Board has the following legislatively approved Key Performance Measures:

- Percent of inspected pharmacies that are in compliance annually
- Percent of audited pharmacists who complete continuing education on time
- Percent of pharmacies inspected annually
- Average number of days required to complete an investigation from complaint to board presentation

BUDGET NARRATIVE – 17-19

- Percent of customers rating their satisfaction with the agency’s customer services as “good” or “excellent”
- Board Best Practices – Percent of total best practices met by the Board

See the Special Reports tab for a copy of the 2016 Annual Performance Progress Report, which reflects a combination of 2015 and 2016 data available at the time of publishing in September 2016 on page 85.

BUDGET NARRATIVE – 17-19

Major Information Technology Projects/Initiatives

The 2015-17 Legislatively Approved Budget included Policy Package #101 to upgrade the Agency’s Licensing and Compliance database and enhance online e-government opportunities for applicants and licensees, as well as upgrade the online Licensee Look Up & Verification system. This project has been renamed the “MyLicense Office Upgrade”. Staff is working closely with the Office of the Chief Information Officer to finalize project and procurement requirements. In the 2017-19 Agency Request Budget is an updated Policy Package #100 that carries over funding in the event that the project is not completed prior to 6/30/2016. The Board has worked closely with the current vendor to identify the estimated cost of this project. The Governor’s Budget proposal includes \$351,989 for this project and is described in detail in Policy Package 100 under the Program Unit tab. These upgrades will allow the Agency to leverage new technology and therefore expand the database with current technology that is more flexible and customizable. Implementation will facilitate the application and renewal processes for both the applicant and the Agency staff. Applicants will be able to apply for new licenses online rather than by paper and this supports the Board’s business plan to move towards a more paperless office that is currently being implemented. This upgrade will also be beneficial to the public with an upgrade to the License Verification system. Complete information can be found in the Program Unit section under Policy Package 100.

10% REDUCTION OPTION

As a small other funded agency, it is difficult to identify where significant reductions can be made. A 10% reduction for our 17-19 current service level is \$716,348. To make this kind of reduction and because Personal Services comprises approximately 70% of the overall budget, the only meaningful option is to reduce staff. Individual line items under Office Expenses have been reviewed in close detail and minimal reductions can be identified unless the Board cancels or reduces some of the State Government Service Charge options or reductions are implemented that may affect having enough resources for printing and postage which are essential. This all presents other challenging options for example; we could eliminate the Shared Client Services budget and accounting services and bring that work in- house. However, we do not have the expertise in-house to handle the work and would need to add a staff member with the appropriate qualifications.

Reluctantly, the Board proposes to eliminate one full time Operations & Policy Analysts 2, one full time Pharmacist Inspector/Investigator, reduce one full time Office Specialist 2 to 0.50 FTE and one full time Executive Support Specialist 2 to 0.50 FTE. The Board has worked very hard to identify staffing and expenditures to meet its operational requirements. Eliminating these positions will hamper the Board’s ability to do business, achieve its statutory public safety obligations and mission, especially in the face of additional Board and stakeholder initiatives. Duties assigned to these positions would have to be absorbed and result in significant delays and potential harm to the public if complaints are not investigated and licenses are not issued in a timely manner.

Fund Type: Other Funds

ACTIVITY OR PROGRAM	DESCRIBE REDUCTION	AMOUNT AND FUND TYPE	RANK AND JUSTIFICATION
(WHICH PROGRAM OR ACTIVITY WILL NOT BE UNDERTAKEN)	(DESCRIBE THE EFFECTS OF THIS REDUCTION. INCLUDE POSITIONS AND FTE IN 2017-19 AND 2019-21)	(GF, LF, OF, FF. IDENTIFY REVENUE SOURCE FOR OF, FF)	(RANK THE ACTIVITIES OR PROGRAMS NOT UNDERTAKEN IN ORDER OF LOWEST COST FOR BENEFIT OBTAINED)
1. ELIMINATE ONE FULL TIME OPERATIONS POLICY ANALYST.	This position is responsible for reviewing policy, rules and managing operational projects. Eliminating this position would require restructuring and reassigning duties within the remaining operational staff. The ability to meet operational management needs or deadlines with this staff reduction would be impacted considerably.	201,494 OF	RANK #1
2. REDUCE ONE FULL TIME OFFICE SPECIALIST 2 POSITION TO HALF TIME.	The production of licenses and registrations would be delayed significantly and negatively impact applicants employment opportunities. Eliminating this position would require restructuring and reassigning duties within the remaining licensing staff.	70,154 OF	RANK #2
3. REDUCE ONE FULL TIME EXECUTIVE SUPPORT SPECIALIST 2 POSITION TO PART TIME.	This position functions as the agencies Office Manager. Eliminating this position or even a slight reduction would compromise agency operation significantly as well as hinder the ability of the recently added Licensing Department Supervisor position to fully function within its scope of responsibilities.	72,600 OF	RANK #3
4. ELIMINATE ONE FULL TIME HEALTHCARE INVESTIGATOR/ADVISOR.	Eliminating this position would result in a delay of response to complete complaint investigations and report them to the Board within the statutory mandated 120 days. This would affect the agencies Key Performance Measure (KPM) productivity. In addition, Annual	368,215 OF	RANK #4

	<p>inspections of retail & institutional drug outlets could be delayed and compromised leading to decreased compliance with pharmacy and drug laws and rules which imposes an increased risk to the public. This too would affect our KPM results.</p>		
<p>5. DECREASE VARIOUS SERVICE AND SUPPLIES ACCOUNTS</p>	<p>This would require the agency to make reductions on both general line items like office expenses as well as reduce resources available for essential services like printing and DAS services in addition to categories that are not discretionary to the agency.</p>	<p>\$3,884 OF</p>	

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
2015-17 Leg Adopted Budget	20	20.00	6,856,245	-	-	6,856,245	-	-	-
2015-17 Emergency Boards	-	-	200,825	-	-	200,825	-	-	-
2015-17 Leg Approved Budget	20	20.00	7,057,070	-	-	7,057,070	-	-	-
2017-19 Base Budget Adjustments									
Net Cost of Position Actions									
Administrative Biennialized E-Board, Phase-Out	-	-	210,852	-	-	210,852	-	-	-
Estimated Cost of Merit Increase	-	-	-	-	-	-	-	-	-
Base Debt Service Adjustment	-	-	-	-	-	-	-	-	-
Base Nonlimited Adjustment	-	-	-	-	-	-	-	-	-
Capital Construction	-	-	-	-	-	-	-	-	-
Subtotal 2017-19 Base Budget	20	20.00	7,267,922	-	-	7,267,922	-	-	-
Essential Packages									
010 - Non-PICS Pers Svc/Vacancy Factor									
Non-PICS Personal Service Increase/(Decrease)	-	-	26,074	-	-	26,074	-	-	-
Subtotal	-	-	26,074	-	-	26,074	-	-	-
020 - Phase In / Out Pgm & One-time Cost									
021 - Phase - In	-	-	-	-	-	-	-	-	-
022 - Phase-out Pgm & One-time Costs	-	-	(302,500)	-	-	(302,500)	-	-	-
Subtotal	-	-	(302,500)	-	-	(302,500)	-	-	-
030 - Inflation & Price List Adjustments									
Cost of Goods & Services Increase/(Decrease)	-	-	114,812	-	-	114,812	-	-	-
State Gov't & Services Charges Increase/(Decrease)	-	-	57,170	-	-	57,170	-	-	-
Subtotal	-	-	171,982	-	-	171,982	-	-	-

41

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
040 - Mandated Caseload									
040 - Mandated Caseload	-	-	-	-	-	-	-	-	-
050 - Fundshifts and Revenue Reductions									
050 - Fundshifts	-	-	-	-	-	-	-	-	-
060 - Technical Adjustments									
060 - Technical Adjustments	-	-	-	-	-	-	-	-	-
Subtotal: 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-

42

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Pharmacy, Board Of
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
Subtotal: 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-
070 - Revenue Reductions/Shortfall									
070 - Revenue Shortfalls	-	-	-	-	-	-	-	-	-
Modified 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-
080 - E-Boards									
080 - May 2016 E-Board	-	-	-	-	-	-	-	-	-
Subtotal Emergency Board Packages	-	-	-	-	-	-	-	-	-
Policy Packages									
081 - September 2016 Emergency Board	-	-	-	-	-	-	-	-	-
090 - Analyst Adjustments	-	-	-	-	-	-	-	-	-
091 - Statewide Adjustment DAS Chgs	-	-	(42,912)	-	-	(42,912)	-	-	-
092 - Statewide AG Adjustment	-	-	(23,343)	-	-	(23,343)	-	-	-
100 - MyLicense Business Upgrade	-	-	351,989	-	-	351,989	-	-	-
101 - Academic & Regulatory Fellowship	-	-	69,260	-	-	69,260	-	-	-
102 - Board Member Per Diem	-	-	11,819	-	-	11,819	-	-	-
Subtotal Policy Packages	-	-	366,813	-	-	366,813	-	-	-
Total 2017-19 Governor's Budget	20	20.00	7,530,291	-	-	7,530,291	-	-	-

Percentage Change From 2015-17 Leg Approved Budget	-	-	6.71%	-	-	6.71%	-	-	-
Percentage Change From 2017-19 Current Service Level	-	-	5.12%	-	-	5.12%	-	-	-

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-001-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
2015-17 Leg Adopted Budget	20	20.00	6,856,245	-	-	6,856,245	-	-	-
2015-17 Emergency Boards	-	-	200,825	-	-	200,825	-	-	-
2015-17 Leg Approved Budget	20	20.00	7,057,070	-	-	7,057,070	-	-	-
2017-19 Base Budget Adjustments									
Net Cost of Position Actions									
Administrative Biennialized E-Board, Phase-Out	-	-	210,852	-	-	210,852	-	-	-
Estimated Cost of Merit Increase			-	-	-	-	-	-	-
Base Debt Service Adjustment			-	-	-	-	-	-	-
Base Nonlimited Adjustment			-	-	-	-	-	-	-
Capital Construction			-	-	-	-	-	-	-
Subtotal 2017-19 Base Budget	20	20.00	7,267,922	-	-	7,267,922	-	-	-
Essential Packages									
010 - Non-PICS Pers Svc/Vacancy Factor									
Non-PICS Personal Service Increase/(Decrease)	-	-	26,074	-	-	26,074	-	-	-
Subtotal	-	-	26,074	-	-	26,074	-	-	-
020 - Phase In / Out Pgm & One-time Cost									
021 - Phase - In	-	-	-	-	-	-	-	-	-
022 - Phase-out Pgm & One-time Costs	-	-	(302,500)	-	-	(302,500)	-	-	-
Subtotal	-	-	(302,500)	-	-	(302,500)	-	-	-
030 - Inflation & Price List Adjustments									
Cost of Goods & Services Increase/(Decrease)	-	-	114,812	-	-	114,812	-	-	-
State Gov't & Services Charges Increase/(Decrease)			57,170	-	-	57,170	-	-	-
Subtotal	-	-	171,982	-	-	171,982	-	-	-

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	<i>Positions</i>	<i>Full-Time Equivalent (FTE)</i>	<i>ALL FUNDS</i>	<i>General Fund</i>	<i>Lottery Funds</i>	<i>Other Funds</i>	<i>Federal Funds</i>	<i>Nonlimited Other Funds</i>	<i>Nonlimited Federal Funds</i>
040 - Mandated Caseload									
040 - Mandated Caseload	-	-	-	-	-	-	-	-	-
050 - Fundshifts and Revenue Reductions									
050 - Fundshifts	-	-	-	-	-	-	-	-	-
060 - Technical Adjustments									
060 - Technical Adjustments	-	-	-	-	-	-	-	-	-
Subtotal: 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-

Summary of 2017-19 Biennium Budget

Pharmacy, Board of
Board of Pharmacy
2017-19 Biennium

Governor's Budget
Cross Reference Number: 85500-001-00-00-00000

Description	Positions	Full-Time Equivalent (FTE)	ALL FUNDS	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds
Subtotal: 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-
070 - Revenue Reductions/Shortfall									
070 - Revenue Shortfalls	-	-	-	-	-	-	-	-	-
Modified 2017-19 Current Service Level	20	20.00	7,163,478	-	-	7,163,478	-	-	-
080 - E-Boards									
080 - May 2016 E-Board	-	-	-	-	-	-	-	-	-
Subtotal Emergency Board Packages	-	-	-	-	-	-	-	-	-
Policy Packages									
081 - September 2016 Emergency Board	-	-	-	-	-	-	-	-	-
090 - Analyst Adjustments	-	-	-	-	-	-	-	-	-
091 - Statewide Adjustment DAS Chgs	-	-	(42,912)	-	-	(42,912)	-	-	-
092 - Statewide AG Adjustment	-	-	(23,343)	-	-	(23,343)	-	-	-
100 - MyLicense Business Upgrade	-	-	351,989	-	-	351,989	-	-	-
101 - Academic & Regulatory Fellowship	-	-	69,260	-	-	69,260	-	-	-
102 - Board Member Per Diem	-	-	11,819	-	-	11,819	-	-	-
Subtotal Policy Packages	-	-	366,813	-	-	366,813	-	-	-
Total 2017-19 Governor's Budget	20	20.00	7,530,291	-	-	7,530,291	-	-	-
Percentage Change From 2015-17 Leg Approved Budget	-	-	6.71%	-	-	6.71%	-	-	-
Percentage Change From 2017-19 Current Service Level	-	-	5.12%	-	-	5.12%	-	-	-

46

Pharmacy, Board of


Agency Number: 85500


**Agencywide Program Unit Summary
2017-19 Biennium**

Version: Y - 01 - Governor's Budget

Summary Cross Reference Number	Cross Reference Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
001-00-00-00000	Board of Pharmacy						
	Other Funds	5,599,379	6,856,245	7,057,070	7,596,546	7,530,291	-
TOTAL AGENCY							
	Other Funds	5,599,379	6,856,245	7,057,070	7,596,546	7,530,291	-

BUDGET NARRATIVE – 17-19






BUDGET NARRATIVE – 17-19


REVENUES 17-19

**2015-2017 LAB Estimated Revenues
\$5,325,387**



■ Business Licensing Fees - 92.48%	■ Non-Business Lic & Fees - 1.24%
■ Delinquent Fees & Civil Penalties - 5.07%	■ Interest Income - .66%
■ Miscellaneous Sales - .56%	

**2017-2019 GBB Estimated Revenues
\$5,444,919**



■ Business Licensing Fees - 80.52%	■ Non-Business Lic & Fees - 9.70%
■ Delinquent Fees & Civil Penalties - 8.09%	■ Interest Income - .92%
■ Miscellaneous Sales - .76%	

BOARD REVENUE FORCAST

- Board of Pharmacy revenues are in the Other Fund Category and come from pharmacist, pharmacy technician, pharmacy intern and the various drug outlet license fees and miscellaneous charges. Miscellaneous charges include delinquent license fees, charges for printing and mailing laws and rules, photo copying, civil penalties, re-inspection fees and interest income.
- The projected revenue for the 2017-2019 budget was calculated by taking a predicted number of licensees and registrants and multiplying by the amount of each fee. It also anticipates revenue impact for new and lapsing applicants and for each category. This method assumes projected changes in the numbers of licensees and registrants based upon analysis of factors affecting the state's economy, the profession and the industry. The 2017-19 estimated revenue reflects the rest of the implementation of biennial licensure in a few categories. With the exception of one pass-through fee for the OHA Workforce Data Collection Survey that was reduced from \$5.00 to \$4.00 per biennium effective 1/1/16, the Board's fees remain at the same level and assumptions as the 2015-17 Legislatively Adopted Budget. This is a continued effort to reduce the Agency's ending balance as required by the Legislature and anticipates reevaluating all licensing fees to propose adjusted fees as part of the 2019-21 budget proposal.

2017-19

Agency Request

Governor's Budget

Legislatively Adopted

Budget Page 50 107BF02

BUDGET NARRATIVE – 17-19

The Board has implemented or is in the process of implementing the 2015-17 approved policy packages, which will make a difference in the operational stability of the agency and ending balance. By all standards, the Board has managed its resources well and rolling back fees the past two biennia is a commendable record of accomplishment for any state agency and a clear statement of responsible management of agency resources. The Board proposes to continue the temporary fee reductions in place until an acceptable level of ending balance is achieved.

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Source	Fund	ORBITS Revenue Acct	2013-2015 Actual	2015-17 Legislatively Adopted	2015-17 Estimated	2017-19		
						Agency Request	Governor's	Legislatively Adopted
Animal Euthanasia	4360	0205	2,300	2,100	2,100	2,500	2,600	
Certified Pharmacy Technician	4360	0205	662,396.50	661,900	661,900	325,685	328,759	
Charitable Pharmacy	4360	0205	1,950	1,800	1,800	1,950	1,950	
Consulting/Drugless Pharmacy	4360	0205	2,450	1,750	1,750	3,889	6,572	
Controlled Substance	4360	0205	211,900	194,200	194,200	201,635	200,790	
Community Health Clinic (formally known as County Health Clinic/Family Planning)	4360	0205	21,075	20,400	20,400	12,016	19,735	
Drug Distribution Agents	4360	0205	36,400	16,400	16,400	153,720	166,320	
Hospital Drug Room	4360	0205	12,700	12,700	12,700	4,212	4,212	
Home Dialysis	4360	0205		1,750	1,750	1,750	1,750	
Interns	4360	0205	51,450	45,000	45,000	44,570	51,912	
Manufacturers	4360	0205	794,000	850,400	850,400	769,488	814,752	
Med Device/Equip/Gases-Class C	4360	0205	52,125	41,750	41,750	42,622	48,480	
Non-Prescript – Drug Outlet – Class A	4360	0205	245,095	224,100	224,100	226,646	254,977	
Non-Prescript – Drug Outlet – Class B	4360	0205	12,450	12,600	12,600	10,400	10,500	
Non-Prescript – Drug Outlet – Class D	4360	0205	0.00	0.00	0.00	0.00	0.00	
Pharmacist	4360	0205	1,663,280	777,932	777,932	940,658	997,535	

_____ Agency Request

_____ **X** _____ Governor's Budget

_____ Legislatively Adopted

Budget Page 52

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy Technician	4360	0205	97,650	113,700	113,700	115,331	184,635
Precursor	4360	0205	2,300	1,550	1,550	1,600	1,800
Prophylactic/Contraceptive	4360	0205	1,600	1,650	1,650	1,400	1,829
Remote Dispensing	4360	0205	1,200	1,000	1,000	800	800
Retail/Institutional Drug Outlet	4360	0205	511,725	560,468	560,468	502,705	551,187
Supervising Physician Dispensing Outlet	4360	0205	8,000	8,400	8,400	13,440	13,860
Wholesalers	4360	0205	719,200	681,600	681,600	691,856	616,896
Delinquent Fees	4360	0505	111,635	70,000	70,000	70,000	70,000
Reciprocity	4360	0205	177,700	125,000	125,000	160,000	160,000
NAPLEX/Exams	4360	0205	56,125	43,485	43,485	58,000	58,000
Civil Penalty	4360	0505	915,739.26	200,000	200,000	350,000	350,000
Interest Income	4360	0605	50,077.47	35,000	35,000	48,000	48,000
NSF	4360	0975	840	400	400	700	700
Misc Fees	4360	0975	12,549.81	28,600	28,600	10,000	10,000
Laws & Rules	4360	0975	9,575	7,000	7,000	8,000	8,000
Prescription Drug Monitoring Fee – transfer to OHA	4360	0205	430,290	283,590	283,590	352,747	374,076
Prescription Drug Monitoring Fee – 10% retention	4360	0205	47,810	28,359	28,359	39,194	41,564
Workforce Data Collection – Transfer to OHA	4360	0210	77,340.50	65,855	65,855	56,610	58,752
Fingerprinting Fees – Transfer to OSP depending on volume	4360	0352	233,005	211,248	211,248	228,800	228,800

_____ Agency Request

_____ X Governor's Budget

_____ Legislatively Adopted

Budget Page 53

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy, Board of
2017-19 Biennium

Agency Number: 85500

Cross Reference Number: 85500-000-00-00-00000

<i>Source</i>	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
Other Funds						
Business Lic and Fees	5,881,772	4,924,832	4,924,832	4,179,867	4,431,667	-
Non-business Lic. and Fees	310,346	65,855	65,855	503,410	505,552	-
Fines and Forfeitures	1,024,899	270,000	270,000	420,000	420,000	-
Interest Income	50,077	35,000	35,000	48,000	48,000	-
Other Revenues	56,851	29,700	29,700	39,700	39,700	-
Tsfr To Oregon Health Authority	(488,238)	(349,445)	(349,445)	(409,357)	(409,357)	-
Total Other Funds	\$6,835,707	\$4,975,942	\$4,975,942	\$4,781,620	\$5,035,562	-

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE


Pharmacy, Board of
2017-19 Biennium

Agency Number: 85500

Cross Reference Number: 85500-001-00-00-00000

<i>Source</i>	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
Other Funds						
Business Lic and Fees	5,881,772	4,924,832	4,924,832	4,179,867	4,431,667	-
Non-business Lic. and Fees	310,346	65,855	65,855	503,410	505,552	-
Fines and Forfeitures	1,024,899	270,000	270,000	420,000	420,000	-
Interest Income	50,077	35,000	35,000	48,000	48,000	-
Other Revenues	56,851	29,700	29,700	39,700	39,700	-
Tsfr To Oregon Health Authority	(488,238)	(349,445)	(349,445)	(409,357)	(409,357)	-
Total Other Funds	\$6,835,707	\$4,975,942	\$4,975,942	\$4,781,620	\$5,035,562	-

BUDGET NARRATIVE – 17-19




BUDGET NARRATIVE – 17-19

PROGRAM UNIT NARRATIVE

PROGRAM UNIT EXECUTIVE SUMMARY

10 Year Plan Outcome Areas that are impacted by the program

Primary Outcome Area: Safety
 Secondary Outcome Area: N/A
 Program Contact: Marcus Watt or Karen MacLean, 971-673-0001



The chart above reflects the actual and estimated expenditures and licensee numbers for the Oregon Board of Pharmacy from 2005-2025, including the 2017-19 Governor’s Budget. The business of pharmacy has moved from the corner drug store to the national chain drug store. This is true throughout all aspects of the pharmaceutical industry, and is directly relates to the number of licensees that the Board has grown to have and expects to see in the future. It also includes the current and projected FTE for 2017-2019.

Program Overview

The Oregon Board of Pharmacy (OBOP) under ORS Chapter 689 regulates the practice of pharmacy and the quality, commerce and distribution of drugs within and into the State. The practice of pharmacy in the State of Oregon has been declared by the Oregon Legislature to be a professional practice affecting public health, safety and welfare and is subject to regulation and control in the interest of Oregon Citizens. The Legislature further

BUDGET NARRATIVE – 17-19

declared it to be a matter of public interest and concern that the practice of pharmacy merit and receive the confidence of the citizens of Oregon and that only qualified person are permitted to engage in the practice of pharmacy in the State.

Program Funding Request

- The Board is requesting Other Funds budget limitation of \$7,530,291 for the 2017-19 biennium in the Governor’s Budget. This includes funding for the Current Service Level budget and three Policy Packages.
- Policy Package 100 carries over funding from the 2015-17 MyLicense Office upgrade as a contingency to ensure project implementation is completed. The Agency is in the process of working with the Chief Information Officer and State Procurement Office to ensure the project has appropriate planning, staff and funds. Upon completion, this project will upgrade the Agency’s Licensing and Compliance database and enhances online e-government opportunities for applicants and licensees, as well as upgrades the online Licensee Look Up & Verification system. Policy Package 101 will cost \$351,989.
- Policy Package 101 implements an Academic and Regulatory Fellowship in partnership with Pacific University School of Pharmacy (PUSOP). This Fellowship will be the first of its kind and establishes a one-year program designed to transition the fellow from a general practitioner to a regulatory pharmaceutical specialist and clinical educator. Upon successful completion of the PUSOP-OBOP Fellowship, graduates will be on track to pursue careers in: 1) Regulatory oversight services at a State Board of Pharmacy, and 2) Academic/faculty positions that involve pharmacy practice, the tripartite mission of didactic and experiential teaching responsibilities, scholarship, and school service, as well as preceptor development opportunities. The fellowship gives participants the unique opportunity to experience careers in the areas of government and academia, thereby qualifying graduates to pursue career opportunities in these respective areas. Policy Package 101 will cost \$69,260.
- Policy Package 102 requests to increase limitation for Board members per diem to add resources for the two new pharmacy technician members that were added in 2016 without funding. In addition, in June 2016, the Board reviewed its daily per diem policy and voted to pursue rulemaking pursuant to ORS 689.115(4) to increase the daily per diem from \$30 to \$100. Board Members unanimously agreed that with the growing diversity in the membership on our Board that is not employer supported, the amount of time required to participate in Board meeting activities and the need for retention and diversity of Board members, this was important to address at this time. Policy Package 102 is projected to cost \$11,819 to accommodate the additional members per diem and the rate increase for all members upon permanent rulemaking.
- Estimated costs on the charts incorporated into this Executive Summary assume a standard inflation rate for 2017-19 as 3.7%, 2019-21 as 3.0% and 2021-23 as 3.1% and the personnel costs are increased by 9% each biennia as directed by the Department of Administrative

BUDGET NARRATIVE – 17-19

Services. The estimated number of licensees for the next ten years is based on an average increase for the last 10 years and the estimated number of complaints is based on historical perspective and also assumes a 2% increase consistent with the increase in licensees.

Program Description

The purpose of the Board of Pharmacy under ORS Chapter 689 is to promote, preserve, and protect the health, safety and welfare of Oregon citizens by control and regulation of the practice of pharmacy and the quality and distribution of drugs through outlets involved in the manufacture, production, sale and distribution of legend drugs (*prescription*), over-the-counter drugs (*non-prescription*), controlled substances (*drugs identified by the U.S. Drug Enforcement Administration (DEA) as having abuse or addiction potential*) and devices and other materials as may be used in the diagnosis, cure, mitigation, prevention and treatment of injury, illness and disease.

This is accomplished through:

Examinations: Any individual wishing to practice as a pharmacist in the State must take and pass an entry level competency exam, the North American Pharmacy Licensure Examination (NAPLEX). This exam has been standardized throughout all fifty states. Candidates for licensure in Oregon must also take and pass a pharmacy law exam, the Multistate Pharmacy Jurisprudence Examination (MPJE). These exams are administered by the National Association of Boards of Pharmacy (NABP). The exam questions are written and maintained and updated by OBOP staff and members through annual review of the exam question pool and psychometric analysis of the questions by NABP.

Licensing: Upon verifying that the exams have been taken and passed, the candidate is allowed to submit an application. The application and required documents are vetted through the NABP Disciplinary Clearinghouse and a criminal background check is performed. Licenses are renewable annually. The OBOP has established an electronic online renewal process for licensees. Pharmacy technicians must be licensed in the State and must become nationally certified within one year of their initial Oregon license. Pharmacies, pharmaceutical manufacturers & wholesalers, non-prescription drug outlets, practitioner dispensing outlets and a variety of other drug outlets must also be licensed with the OBOP to do business in the State. Establishments seeking licensure undergo similar scrutiny and vetting of applications and documents for licensure.

Investigations: The OBOP investigates complaints and allegations of violations of the Oregon Pharmacy Act (ORS Chapter 689) and corresponding administrative rules (OAR Chapter 855). The OBOP also investigates allegations of drug diversion, illegal online drug distribution operations or unlicensed pharmacies and local prescription fraud activity.

Information and Education: A receptionist answers questions and routes calls to a designated pharmacist investigator and to one of the licensing representatives who are available to answer questions regarding licensure requirements and processes as well as general questions from the public. OBOP staff also responds to many requests for appearances and presentations to pharmacy professional associations and pharmacy schools regarding pharmacy and drug law and licensing issues.

Agency costs are primarily reflected in staff payroll. Ongoing expenses for “services and supplies” are inherent and tend to not fluctuate significantly. Major cost drivers are described below.

2017-19

Agency Request

Governor’s Budget

Legislatively Adopted

Budget Page 59

107BF02

BUDGET NARRATIVE – 17-19

Staffing is the largest single expenditure since what the agency does involves people working with people.

Instate travel is another cost. The OBOP's authority is statewide, therefore, onsite inspections and investigations occur throughout the State. Board members also reside throughout the State, therefore, wherever meetings are held, some Board members are required to travel. Most meetings are held in Portland.

Administrative initiatives and projects such as budget preparation, document security, business continuity, workforce data collection, disaster planning, various joint rulemaking requirements and cultural competence are some of the many activities that consume an increasing portion of staff time.

Legislative mandates utilize an increasing portion of staff time. Such Legislative mandates include pharmacist prescriptive authority for hormonal contraceptives, charitable pharmacies, expedited partner therapy and Health Professionals Service Program, among many others.

Prescription drug abuse Staff investigates illegal Internet drug distribution, local fraudulent prescription scams and diversion and theft of controlled substances from pharmacies. Many drug related issues such as these are also covered by the news media and requests for information, interviews and statements from Board members and staff are common.

Prescription drug overutilization continues to impact staff work load. Prescription drugs have become ubiquitous and efforts to educate citizens in areas such as medication safety, proper drug disposal and the dangers of polypharmacy are needed more and more. Prescription drugs appear in our medicine cabinets, in the pockets of our sons & daughters and in our schools. Drugs are advertised on television and radio, in newspapers and in magazines, on billboards. The nation's health care delivery system is so rushed that the standard solution to each medical office visit is a "quick fix" prescription.


Program Justification and Link to 10-Year Outcome

Because of the efforts and diligence of the OBOP in administering the Oregon Pharmacy Act and the Oregon Controlled Substances Act, the safety of Oregon's citizens is enhanced and protected. Active participation by Board members and staff with the NABP, DEA and U.S. Food and Drug Administration evokes national best practice standards on behalf of Oregonians.

BUDGET NARRATIVE – 17-19


Program Performance

The following chart reflects the total / estimated number of cases each year, actual / estimated number of Final Orders and the actual / estimated number of Complaints & Investigations conducted by the Board since 2012. The more complex the industry becomes, including from the number of drugs available to increased laws and regulation, demonstrates just a few of the reasons why there is more of a possibility for compliance and complaint related issues. The total number of cases is significantly higher because it includes warning notices that are a result of annual pharmacy inspections. Some of these go on to become cases of non-compliance, where others are resolved in a timely manner. Additionally, every complaint and violation the Board receives requires some level of investigation. Some low level of complaints or issues do not rise the level of Board formal disciplinary action. The complexity of the Board’s oversight makes it difficult to show in a picture the volume of work that is completed by our Compliance Staff for the Board.



BUDGET NARRATIVE – 17-19

The following chart includes a graphic representation of the 31 different categories of licensure and registration covered by the Board, along with the number of licensees represented in each category and the percentage each represents. Each is unique and different and requires all Board staff whether Licensing, Compliance or Administration to understand the different laws & rules associated with each license type.



BUDGET NARRATIVE – 17-19

The Agency Key Performance, Customer Service Measure addresses the question of timeliness of services provided and quality of the services provided. The Agency continues to exceed the targeted goal of 85% with the most recent report at 92% over all for all customer service satisfaction.

If the Board were to divide its total proposed budget by the number of licensees, it could presume that the current cost per service unit would be \$278.41. However, not all licenses are alike, as has been demonstrated throughout this narrative, nor are all the services the Board provides directly attributed to individual licensees. Therefore, it is very difficult to identify an accurate cost per service unit.

Enabling Legislation/Program Authorization

The OBOP was established and received its authority and responsibility through a mandate of the Oregon Legislature, ORS Chapter 689 the Oregon Pharmacy Act. The OBOP received further authority and responsibility through ORS Chapter 475 the Oregon Controlled Substances Act. The Board does not have any Legislative Concepts proposed for consideration.

Funding Streams

The OBOP is entirely other funded and receives revenue by fees charged to licensees, civil penalties and a handful of administrative “user” fees. No lottery or general funds are allotted to the OBOP.

Significant Proposed Program Changes from 2015-17

Significant changes from the 2015-17 budget modify the Current Service Level by adding one legislatively approved position to current staff, upgrading the Agency database systems, continuing the paperless records retention project and adding resources for IT Professional Services. See further explanation under “Program Funding Request” above and a detailed description of the Policy Packages included after this section.

The Oregon Board of Pharmacy is currently made up of five members who are practicing pharmacists, two pharmacy technicians, two members of the public and 20 full or part time positions. The Board is budgeted and accounted as a single program. The staff is internally organized into three distinct sections including Licensing, Compliance and Operations/Administration. The agency additionally tracks expenditures separately for Board Member Activities and Interagency Activities.

The *Licensing section* is made up of 6 positions which includes the newly established Licensing Program Supervisor position that was legislatively approved 2015, that handles all details related to licensing and examinations including applications, renewals, production and mailing of more than 27,030 certificates of registration and licensure and frequent communication with licensees and applicants that represent 32 different categories of licensure for individuals and drug outlets. Examinations include the North American Pharmacy Licensure Examination (NAPLEX), the Multi-state Pharmacy Jurisprudence Examination (MPJE), the Foreign Pharmacy Graduate Equivalency Examination (FPGEE), and the Test of English as a Foreign Language (TOEFL iBT). The Board requires national fingerprint based FBI criminal background checks for all new applicants for

2017-19

Agency Request

Governor’s Budget

Legislatively Adopted

Budget Page 63 107BF02

BUDGET NARRATIVE – 17-19

pharmacist, pharmacy technician, certified pharmacy technicians and pharmacy intern licensure. The Licensing and Background Check Specialist staff also performs annual criminal background checks with established policies and procedures using the Oregon Law Enforcement Data System (LEDS). Staff regularly visits the pharmacy schools in Oregon to meet and talk to the incoming students about professional responsibilities and licensing and to talk to the soon to be graduating students about procedures and requirements for licensure as a pharmacist.

The *Compliance section*, made up of eight positions, which includes six pharmacists and two administrative staff and is responsible for all on-site inspections of pharmacies and drug outlets, all investigations of consumer complaints, reports of possible drug diversion and other suspected violations, administrative details of proposed and ordered disciplinary action and monitoring all licensees who have been placed on probation through the disciplinary process. Compliance staff is also responsible for interpretation and review of pharmacy laws and rules and provision of information to and consultation with all stakeholders on pharmacy and drug laws upon request.

The *Operations/Administration section* includes six positions that is a combination of operations and administrative functions. It includes the Executive Director, Administrative Director, Pharmacist Consultant, Project Manager, Office Manager, and Management Secretary/Background Check Specialist. The Executive Director is responsible for the overall operation of the Agency, which includes, supervision of the Operations, Licensing and Compliance sections and the performance of all staff, the interpretation and implementation of Board policy, oversight of all public and media relations, active participation with the National Association of Boards of Pharmacy (NABP), the American Council of Pharmaceutical Education (ACPE), and the state and federal regulatory bodies including the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) and the development and maintenance of the network of stakeholder relationships.

The Executive Director directly supervises the Administrative Director, the Compliance Director, Pharmacist Consultant, and the Project Manager and answers to the President of the Board. The Administrative Director supervises and oversees the daily operations of the agency and supervises the Office Manager and Management Secretary. This position also encompasses a variety of other administrative functions including, coordination of board meeting activities, agenda development, budget preparation, accounting, contracts, and coordinates various activities with the Department of Administrative Services. The Compliance Director directly supervises the Compliance section activities and staff. The Pharmacist Consultant position is specifically responsible for conducting research and managing projects that require pharmacist expertise. The position also assists the Executive Director with media requests and legislative activities to name a few. The Project Manager position provides essential support in researching issues and managing projects for the Agency. The Office Manager is responsible for general office management, including database and network administration, accounts payable/receivable, facilities management, purchasing etc. Staff in this section is involved in conducting policy research, writing reports and recommendations, and coordinating committees and task forces as required by the Board.

“*Board Member Activities*” includes capturing all activities related to board members’ compensation, travel, lodging and other expenses and all activities related to holding board meetings.

BUDGET NARRATIVE – 17-19

“*Interagency Activities*” includes pass-through payments to Oregon State Police for fingerprint for criminal background checks for all new licensees, Workforce Data Collection fees for data analysis to the Oregon Health Authority (OHA), Prescription Drug Monitoring Program fees to OHA and the Health Professional’s Services Program costs for impaired professionals.

From 1990 to 2010, the Board’s operation included a recovery program for chemically dependent licensees (PRN) as authorized by ORS 689.342-348. The 2009 Legislature established a statewide impaired health professionals program, which repealed 689.342-348 and eliminated the Board’s authority to maintain its PRN program. This statewide program allows the Board to refer an individual licensee for treatment in lieu of or in addition to disciplinary action. Preparation for and transition into the program has been more costly than expected. 2016 HB 4016, effective July 1, 2017, changes ORS 676.190 and authorizes the health professional regulatory boards to establish or contract for an impaired health professional program. The new program will replace the OHA Health Professionals’ Services Program (HPSP). The health profession regulatory boards have partnered to contract a service provider and continue to work together to ensure a seamless transition for current program participants. The Boards are committed to ensuring participant monitoring is uninterrupted while keeping patient safety paramount.

Through a Technical Adjustment for the 2017-19 budget, the Board of Pharmacy has reallocated funds previously paid to the OHA for this program to Agency Services and Supplies – Professional Services in the amount of \$184,152 for the 2017-19 budget. Using current projected figure provided by OHA for the cost of the program to the Agency for 2016-17 is \$88,781 per year or about \$5222 per participant per year for 17 people. This is a fee paid by the Agency for the ability to participate in the program. Individual participants pay for their own program expenses such as lab toxicology tests. There are a number of licensees who do not meet the Board’s criteria for referral into the HPSP program. These individuals have been placed on probation and the Board’s staff monitors their compliance with the conditions of probation. This is a workload challenge for the existing Board staff.

The Board’s participation in the HPSP program is optional. The Board is currently participating in the HPSP and plans to annually review its decision to participate.

The Agency’s operating revenue is “other funds” and is derived from annual license and registration fees collected during the year from the following: animal euthanasia, certified pharmacy technicians, correctional facility & hospital drug rooms, county health clinics, pharmaceutical manufacturers and wholesalers, nonprescription drug distributors, pharmacies, pharmacists, pharmacy interns, pharmacy technicians, precursor substance distributors, prophylactic/contraceptive manufacturers, delinquent fees, examination fees, out of state pharmacist license reciprocity, and miscellaneous service charges. Details on who pays, number of payees, and the rates are on form 107BF07 in this binder. There are no new fees that were established during 2015-17.

Pharmacy – 85500

ESSENTIAL PACKAGES

010 Non-PICS Psnl Svc / Vacancy Factor

Package Description

This essential package includes an overall increase of \$26,074 for non-PICS personal services such as inflation for All Other Differentials, Temporary Appointments and most significantly, \$15,772 for the Pension Bond Contribution.

022 Phase Outs & One-time Cost Eliminations

Package Description

This essential package removes one-time funds in the amount of (\$302,500) that were added in the 2015-17 Legislatively Adopted Budget for the **Business Improvement Database Upgrade** Policy Package 101. Additional resources for 2017-19 are noted in Policy Package 100 as a contingency plan in the event that this project which is now called MyLicense Office Upgrade is not completed.

030 Inflation & Price List Adjustments

Package Description -

This essential package incorporates the cost of goods and services and state government service charge changes to the 2017-19 budget. These numbers are incorporated in package 031 Standard Inflation.

031 Standard Inflation & Price List Adjustments

Package Description -

This essential package consists of increases for an additional \$164,174 for overall inflation for the Price List for the cost of goods and services. The bulk of the adjustments and increases can be found in the following areas:

- State Government Service Charge Assessments / Other Services & Supplies have been re-organized by the Department of Administrative Services (DAS) in a variety of different budget fund categories for 42 various services and assessments, as well as a change in rate setting for all areas which resulted in significant increases as noted below:
 - State Government Service Charges \$57,170, this is a 74.13% increase
 - Shared Payroll and Financial Client Services \$32,415, this is an 24.02% increase
 - DAS EHRS PPDB assessment \$ 727, this is a 10.06% increase
 - Attorney General Charges \$41,265, this is a 13.14% increase

- Other significant Standard Inflation is associated with: Attorney General, Facilities Rental & Taxes and general Other Services and Supplies.

032 Above Standard Inflation

Package Description

This essential package adds an additional \$7,808 for “above standard inflation” to cover for the increased 2017-19 estimated State Government Service Charges identified by DAS.

060 Technical Adjustments

Package Description

This package includes an \$184,152 adjustment approved by the agency’s Department of Administrative Services (DAS), Chief Financial Office Analyst. Resources were reallocated from Special Payments to OHA to the Board of Pharmacy Professional Services budget object to establish funds for this category to accommodate 2016 HB 4016 move to the health boards.

091 Statewide Adjustment DAS Charges

Package Description

This essential package reduces DAS statewide charges by \$42,912.

092 Statewide Attorney General Adjustment

Package Description

This essential package reduces Attorney General statewide charges by \$23,343.

Pharmacy – 85500 Policy Packages

Policy Package

100 My License Business Upgrade

Package Description

Purpose:

The purpose of this package is to carry over funding for a 2015-17 Legislatively Approved upgrade for the Agency's Licensing and Compliance database and enhance online e-government opportunities for applicants and licensees, as well as upgrade the online Licensee Look Up & Verification system.

How Achieved:

- Policy Package 100 carries over funding from the 2015-17 MyLicense Office upgrade as a contingency to ensure project implementation is completed. The Agency is in the process of working with the Chief Information Officer (CIO) and State Procurement Office to ensure the project has appropriate planning, staff and funds. Upon completion, this project will upgrade the Agency's Licensing and Compliance database and enhances online e-government opportunities for applicants and licensees, as well as upgrades the online Licensee Look Up & Verification system. Policy Package 101 will cost \$351,989.

In November 2003, the Board implemented the System Automation (SA) License 2000 (L2k) software, an off the shelf product. We have maintained the software since then and added various hybrid systems to allow for greater flexibility to allow for online license renewals and online licensee look up and verification. However, System Automation is no longer making improvements to the License 2000 software. Instead, they have shifted their development to a more advanced web-based platform called MyLicense Office (MLO) that would provide us with options for expansion and configuration. MLO uses the same back office database as L2k, however, the user interface is much more customizable and user friendly. MLO is one part of a suite of products SA offers.

This package also considers adding SA's MyLicense e-Gov and MyLicense Verification, two additional suites that we are interested in leveraging off MLO. These would replace the hybrid systems that have been developed and require adjustments annually to connect into our database because they are external to our database.

The proposal is to finish implementation, MyLicense Office, MyLicense e-Gov and MyLicense Verification during the course of 2017-19. The agency would be able to centralize online licensing services. As mentioned previously, we currently have a hybrid system where our IT Consultant "builds" or uniquely programs each of our online renewals, connects securely to US Bank's payment system and the Oregon Health Authority's Workforce Data Collection survey as needed for specific licensing categories. He has also created a "connector" to take the online renewal data securely from the renewal and back into L2k. MyLicense e-Gov would remove the need to maintain three different pieces in order to facilitate a license renewal. It will incorporate a safe and secure environment for payments. It would also expand our licensee's opportunities to change their address or employer online themselves, and as incorporated into this proposal, establish the ability to implement online license applications and the ability to receive electronic documents. Applicants would be able to track their own licensure

and renewal process and see what else is outstanding for licensure or renewal. Receiving documents electronically is a growing expectation for many, including recently passed Oregon legislation regarding healthcare professional credentialing. This also complements the work that we are currently doing to scan all of our licensing and compliance files and move towards paperless recordkeeping, which was a 2013-15 legislatively, approved policy package. Finally, we would also implement My License Verification, which is a public facing application that would replace our current hybrid for Online Licensee Look up, and it would all be contained within the same system. Last, SA also has I-Phone and android apps to access the Board's verification information from almost anywhere.

Implementing this upgrade of Suite options is a natural progression for the Board of Pharmacy. It builds on our existing database without totally replacing the existing database. Establishing this provides for more customizable options for the Licensing Team the opportunity to enhance our ability to provide greater customer service to our licensees, applicants and the public. In addition, SA has upgraded the Enforcement portion of the database, which should assist our Compliance Team with much needed customizable improvements.

Some combination of these products is currently in use in 21 states; this includes 11 Boards of Pharmacy.

The package includes resources to implement the software upgrade and the required training, which would be a one-time professional services cost. It also includes a new additional required annual maintenance fees for MyLicense eGov. This is added to the current annual maintenance fees that are currently established within the Agency budget limitation. The current annual maintenance fees are \$13,282. Adding the new fees for My License eGov will increase this expenditure by \$6,480, which is a total of \$19,761 annually, and a biennial rate of \$39,522 for maintenance fees, \$12,960 of additional new resources will be required and are included in this policy package. This 2017-19 package also adds agency IT staff and project management resources that were not factored in during 2015-17 at the recommendation of the CIO Strategic Technology Officer.

Staffing & Revenue Impact:

The expected impact on staffing is related to project management that will be handled by the current Administrative Director, Licensing Department Supervisor who serves as the Database Administrator and the IT Consultant as required. The Database Administrator and assigned back-ups will receive MLO and eGov System Administrator Training. There will be user training for agency staff once the migration is complete.

This package is projected to cost \$351,989, of that; \$272,042 is a onetime expenditure that is for IT Professional Services. \$34,565 is budgeted for employee training; \$29,700 for project management resources or IT expendable property. \$15,682 is budgeted for data processing (maintenance fees) which will be an ongoing increased expense. Note the Board received a unique one-time civil penalty in July 2014, which will more than cover the expenses associated with this policy package. This will allow us to upgrade our systems with no additional cost to our licensees.

The Agency is in the process of obtaining project authorization through the DAS Chief Information Office and initiating this procurement with the assistance of DAS Procurement and will need to have the contract evaluated by the Department of Justice as required by the DAS Procurement Administrative rules.

The Agency has entered this project into the OSCIO Stage Gate Review process.

The Board has the resources to implement this package in full through Other Funds resources within the existing Ending Balance.

Quantifying Results:

With this upgrade that allows for greater customization, the Agency will be able to improve services to our Licensees, Stakeholders and the public. We would also have an increased ability to respond to information gathering requests or the need for new fields of data collection within our database that are asked for regularly. This policy package does not correspond specifically to a Key Performance Measure, however it does relate to internal performance measures, which are currently difficult capture. Without this upgrade, the Board will continue to need to maintain external hybrid systems and we would not be able to offer the option for online applications, the ability to collect information electronically, check license application status, the ability for licensees to update their address and employer themselves without building more unique and complex hybrid systems etc. We expect that with these enhancements, we expect to see greater efficiencies in our processing and client interactions.

Revenue Source: The revenue source is Other Funds.

Pharmacy - 85500

Policy Package

101 Shared Academic & Regulatory Fellowship Program for Post-Graduate Learners

Package Description

Purpose:

The purpose of this package is to establish funding to pay for an ongoing, shared academic & regulatory fellowship program for post-graduate learners. This program would be coordinated through a contract with Pacific University School of Pharmacy. This package includes resources to help cover half of the expenses associated with this program.

There is an insufficient pipeline of appropriately educated professionals who can teach and practice Social and Administrative Sciences (i.e. legal and regulatory affairs) in academic pharmacy or work in a state regulatory agency. There are no known programs combining training in academia with experience in state regulatory affairs. There are currently only three post-graduate programs in the US, which provide training in federal regulatory affairs and drug development, with or without academic training (FDA/Purdue University; UNC Chapel Hill/GlaxoSmithKline; VCU/American College of Clinical Pharmacy). These programs focus on regulation at drug manufacturers, rather than this proposed program that focuses on the State and public interface.

Policy Package 101 implements an Academic and Regulatory Fellowship in partnership with Pacific University School of Pharmacy (PUSOP). This Fellowship will be the first of its kind and establishes a one-year program designed to transition the fellow from a general practitioner to a regulatory pharmaceutical specialist and clinical educator. Upon successful completion of the PUSOP-OBOP Fellowship, graduates will be on track to pursue careers in: 1) Regulatory oversight services at a State Board of Pharmacy, and 2) Academic/faculty positions that involve pharmacy practice, the tripartite mission of didactic and experiential teaching responsibilities, scholarship, and school service, as well as preceptor development opportunities. The fellowship gives participants the unique opportunity to experience careers in the areas of government and academia, thereby qualifying graduates to pursue career opportunities in these respective areas. Policy Package 101 will cost \$69,260 and if successful, this will be a reoccurring budget item with associated inflation costs.

How Achieved:

- 1) Engagement in the delivery of Social and Administrative Sciences material to pharmacy students and providing CE to preceptors/pharmacists
- 2) Engagement in the Oregon BOP regulatory discussions and meetings
- 3) Engagement in Scholarly activities (research)

Staffing Impact and Revenue Source:

Other Funds request: \$69,260

Fellow funding: \$34,630 annually / \$69,260 biennium

Total Other Funds Request \$69,260 – ongoing expenditure for Professional Services budget object

This Fellow will work for Pacific University and spend approximately half their time with the Board of Pharmacy learning about government and agency related activities.

Quantifying Results

Should funding not be secured for this package, this program will not be initiated. The State’s academic pharmacy programs will continue have a shortage of qualified, experienced Social and Administrative Sciences professors or a pool of future, trained regulators that might be interested in state service.

Revenue Source:

The revenue source is Other Funds.

Pharmacy - 85500
Policy Package
102 Increase Board Member Per-diem

Package Description

Purpose:

The purpose of this package is to fund two new pharmacy technician member positions and increase the compensation of the volunteer members of the Board which will improve Board performance through increased recruitment, retention and Board diversity. Vacancies on the Board can slow or even prevent the Board from performing its regulatory duties. Increasing the per diem will give greater opportunities for individuals to serve on the Board from broader socio-economic statuses. In June 2016, the Board reviewed its daily per diem policy and voted to pursue rulemaking pursuant to ORS 689.115(4) to increase the daily per diem from \$30 to \$100. Board Members unanimously agreed that it was important to address the growing diversity in the membership on our Board, which is not always employer supported, as well as the amount of time required to participate in Board meetings and activities. The need for retention measures of Board members is important to address at this time. Policy Package 102 is projected to cost \$11,819 to accommodate the additional members per diem and the rate increase for all members upon permanent rulemaking.

How Achieved:

If funding is approve, the Board would initiate rulemaking as required by ORS 689.115(4) to raise the per-diem from \$30 to \$100.

Staffing Impact and Revenue Source:

Staffing: There will be no direct impact on agency staffing or workload.

Total Other Funds Request \$11,819.

Quantifying Results

Should funding not be secured for this package, the per-diem amount will remain at its current level and the Board may experience a lack of representative and engaged volunteer Board members with the consequent harm to the public mission of the Agency.

Revenue Source:

The revenue source is Other Funds.

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 010 - Non-PICS Psnl Svc / Vacancy Factor

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Personal Services							
Temporary Appointments	-	-	900	-	-	-	900
Overtime Payments	-	-	-	-	-	-	-
All Other Differential	-	-	6,546	-	-	-	6,546
Public Employees' Retire Cont	-	-	1,250	-	-	-	1,250
Pension Obligation Bond	-	-	15,772	-	-	-	15,772
Social Security Taxes	-	-	570	-	-	-	570
Unemployment Assessments	-	-	-	-	-	-	-
Mass Transit Tax	-	-	1,036	-	-	-	1,036
Total Personal Services	-	-	\$26,074	-	-	-	\$26,074
Total Expenditures							
Total Expenditures	-	-	26,074	-	-	-	26,074
Total Expenditures	-	-	\$26,074	-	-	-	\$26,074
Ending Balance							
Ending Balance	-	-	(26,074)	-	-	-	(26,074)
Total Ending Balance	-	-	(\$26,074)	-	-	-	(\$26,074)

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 022 - Phase-out Pgm & One-time Costs

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

Description	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Employee Training	-	-	(31,423)	-	-	-	(31,423)
Total Services & Supplies	-	-	(\$31,423)	-	-	-	(\$31,423)
Capital Outlay							
Data Processing Software	-	-	(271,077)	-	-	-	(271,077)
Total Capital Outlay	-	-	(\$271,077)	-	-	-	(\$271,077)
Total Expenditures							
Total Expenditures	-	-	(302,500)	-	-	-	(302,500)
Total Expenditures	-	-	(\$302,500)	-	-	-	(\$302,500)
Ending Balance							
Ending Balance	-	-	302,500	-	-	-	302,500
Total Ending Balance	-	-	\$302,500	-	-	-	\$302,500

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 031 - Standard Inflation

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Instate Travel	-	-	3,946	-	-	-	3,946
Out of State Travel	-	-	739	-	-	-	739
Employee Training	-	-	634	-	-	-	634
Office Expenses	-	-	4,420	-	-	-	4,420
Telecommunications	-	-	1,345	-	-	-	1,345
State Gov. Service Charges	-	-	57,170	-	-	-	57,170
Data Processing	-	-	2,074	-	-	-	2,074
Publicity and Publications	-	-	1,391	-	-	-	1,391
Professional Services	-	-	4,785	-	-	-	4,785
IT Professional Services	-	-	3,202	-	-	-	3,202
Attorney General	-	-	41,265	-	-	-	41,265
Employee Recruitment and Develop	-	-	7	-	-	-	7
Dues and Subscriptions	-	-	164	-	-	-	164
Facilities Rental and Taxes	-	-	15,015	-	-	-	15,015
Facilities Maintenance	-	-	2	-	-	-	2
Medical Services and Supplies	-	-	40	-	-	-	40
Agency Program Related S and S	-	-	8,186	-	-	-	8,186
Other Services and Supplies	-	-	10,654	-	-	-	10,654
Expendable Prop 250 - 5000	-	-	375	-	-	-	375
IT Expendable Property	-	-	1,491	-	-	-	1,491
Total Services & Supplies	-	-	\$156,905	-	-	-	\$156,905

Capital Outlay

Data Processing Software	-	-	-	-	-	-	-
--------------------------	---	---	---	---	---	---	---

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 031 - Standard Inflation

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Capital Outlay							
Data Processing Hardware	-	-	296	-	-	-	296
Total Capital Outlay	-	-	\$296	-	-	-	\$296
Special Payments							
Other Special Payments	-	-	428	-	-	-	428
Spc Pmt to Oregon Health Authority	-	-	6,545	-	-	-	6,545
Total Special Payments	-	-	\$6,973	-	-	-	\$6,973
Total Expenditures							
Total Expenditures	-	-	164,174	-	-	-	164,174
Total Expenditures	-	-	\$164,174	-	-	-	\$164,174
Ending Balance							
Ending Balance	-	-	(164,174)	-	-	-	(164,174)
Total Ending Balance	-	-	(\$164,174)	-	-	-	(\$164,174)

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 032 - Above Standard Inflation

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Telecommunications	-	-	7,100	-	-	-	7,100
Total Services & Supplies	-	-	\$7,100	-	-	-	\$7,100
Special Payments							
Spc Pmt to Oregon Health Authority	-	-	708	-	-	-	708
Total Special Payments	-	-	\$708	-	-	-	\$708
Total Expenditures							
Total Expenditures	-	-	7,808	-	-	-	7,808
Total Expenditures	-	-	\$7,808	-	-	-	\$7,808
Ending Balance							
Ending Balance	-	-	(7,808)	-	-	-	(7,808)
Total Ending Balance	-	-	(\$7,808)	-	-	-	(\$7,808)

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 060 - Technical Adjustments

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Professional Services	-	-	184,152	-	-	-	184,152
Total Services & Supplies	-	-	\$184,152	-	-	-	\$184,152
Special Payments							
Spc Pmt to Oregon Health Authority	-	-	(184,152)	-	-	-	(184,152)
Total Special Payments	-	-	(\$184,152)	-	-	-	(\$184,152)
Total Expenditures							
Total Expenditures	-	-	-	-	-	-	-
Total Expenditures	-	-	-	-	-	-	-
Ending Balance							
Ending Balance	-	-	-	-	-	-	-
Total Ending Balance	-	-	-	-	-	-	-

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 091 - Statewide Adjustment DAS Chgs

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Office Expenses	-	-	(924)	-	-	-	(924)
Telecommunications	-	-	(6,685)	-	-	-	(6,685)
State Gov. Service Charges	-	-	(8,789)	-	-	-	(8,789)
Data Processing	-	-	(514)	-	-	-	(514)
Facilities Rental and Taxes	-	-	(13,102)	-	-	-	(13,102)
Other Services and Supplies	-	-	(12,898)	-	-	-	(12,898)
Total Services & Supplies	-	-	(\$42,912)	-	-	-	(\$42,912)
Total Expenditures							
Total Expenditures	-	-	(42,912)	-	-	-	(42,912)
Total Expenditures	-	-	(\$42,912)	-	-	-	(\$42,912)
Ending Balance							
Ending Balance	-	-	42,912	-	-	-	42,912
Total Ending Balance	-	-	\$42,912	-	-	-	\$42,912

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 092 - Statewide AG Adjustment

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Attorney General	-	-	(23,343)	-	-	-	(23,343)
Total Services & Supplies	-	-	(\$23,343)	-	-	-	(\$23,343)
Total Expenditures							
Total Expenditures	-	-	(23,343)	-	-	-	(23,343)
Total Expenditures	-	-	(\$23,343)	-	-	-	(\$23,343)
Ending Balance							
Ending Balance	-	-	23,343	-	-	-	23,343
Total Ending Balance	-	-	\$23,343	-	-	-	\$23,343

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 100 - MyLicense Business Upgrade

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Employee Training	-	-	34,565	-	-	-	34,565
Data Processing	-	-	15,682	-	-	-	15,682
Professional Services	-	-	27,500	-	-	-	27,500
IT Professional Services	-	-	272,042	-	-	-	272,042
IT Expendable Property	-	-	2,200	-	-	-	2,200
Total Services & Supplies	-	-	\$351,989	-	-	-	\$351,989
Total Expenditures							
Total Expenditures	-	-	351,989	-	-	-	351,989
Total Expenditures	-	-	\$351,989	-	-	-	\$351,989
Ending Balance							
Ending Balance	-	-	(351,989)	-	-	-	(351,989)
Total Ending Balance	-	-	(\$351,989)	-	-	-	(\$351,989)

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 101 - Academic & Regulatory Fellowship

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Services & Supplies							
Professional Services	-	-	69,260	-	-	-	69,260
Total Services & Supplies	-	-	\$69,260	-	-	-	\$69,260
Total Expenditures							
Total Expenditures	-	-	69,260	-	-	-	69,260
Total Expenditures	-	-	\$69,260	-	-	-	\$69,260
Ending Balance							
Ending Balance	-	-	(69,260)	-	-	-	(69,260)
Total Ending Balance	-	-	(\$69,260)	-	-	-	(\$69,260)

ESSENTIAL AND POLICY PACKAGE FISCAL IMPACT SUMMARY

Pharmacy, Board of
Pkg: 102 - Board Member Per Diem

Cross Reference Name: Board of Pharmacy
Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	General Fund	Lottery Funds	Other Funds	Federal Funds	Nonlimited Other Funds	Nonlimited Federal Funds	All Funds
Personal Services							
Class/Unclass Sal. and Per Diem	-	-	10,980	-	-	-	10,980
Social Security Taxes	-	-	839	-	-	-	839
Total Personal Services	-	-	\$11,819	-	-	-	\$11,819
Total Expenditures							
Total Expenditures	-	-	11,819	-	-	-	11,819
Total Expenditures	-	-	\$11,819	-	-	-	\$11,819
Ending Balance							
Ending Balance	-	-	(11,819)	-	-	-	(11,819)
Total Ending Balance	-	-	(\$11,819)	-	-	-	(\$11,819)

PACKAGE: 102 - Board Member Per Diem

POSITION NUMBER	CLASS	COMP	CLASS NAME	POS CNT	FTE	MOS	STEP	RATE	GF SAL/OPE	OF SAL/OPE	FF SAL/OPE	LF SAL/OPE	AF SAL/OPE
0004401	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004401	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004402	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004402	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004403	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004403	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004404	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004404	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004405	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004405	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004406	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,060-234-			3,060-234-
0004406	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004407	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,060-234-			3,060-234-
0004407	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004408	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283
0004413	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700283			3,700283

TOTAL PICS SALARY

10,980

85

10,980

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Source	Fund	ORBITS Revenue Acct	2013-2015 Actual	2015-17 Legislatively Adopted	2015-17 Estimated	2017-19		
						Agency Request	Governor's	Legislatively Adopted
Animal Euthanasia	4360	0205	2,300	2,100	2,100	2,500	2,600	
Certified Pharmacy Technician	4360	0205	662,396.50	661,900	661,900	325,685	328,759	
Charitable Pharmacy	4360	0205	1,950	1,800	1,800	1,950	1,950	
Consulting/Drugless Pharmacy	4360	0205	2,450	1,750	1,750	3,889	6,572	
Controlled Substance	4360	0205	211,900	194,200	194,200	201,635	200,790	
Community Health Clinic (formally known as County Health Clinic/Family Planning)	4360	0205	21,075	20,400	20,400	12,016	19,735	
Drug Distribution Agents	4360	0205	36,400	16,400	16,400	153,720	166,320	
Hospital Drug Room	4360	0205	12,700	12,700	12,700	4,212	4,212	
Home Dialysis	4360	0205		1,750	1,750	1,750	1,750	
Interns	4360	0205	51,450	45,000	45,000	44,570	51,912	
Manufacturers	4360	0205	794,000	850,400	850,400	769,488	814,752	
Med Device/Equip/Gases-Class C	4360	0205	52,125	41,750	41,750	42,622	48,480	
Non-Prescript – Drug Outlet – Class A	4360	0205	245,095	224,100	224,100	226,646	254,977	
Non-Prescript – Drug Outlet – Class B	4360	0205	12,450	12,600	12,600	10,400	10,500	
Non-Prescript – Drug Outlet – Class D	4360	0205	0.00	0.00	0.00	0.00	0.00	
Pharmacist	4360	0205	1,663,280	777,932	777,932	940,658	997,535	

_____ Agency Request

 X Governor's Budget

_____ Legislatively Adopted

Budget Page 86

DETAIL OF LOTTERY FUNDS, OTHER FUNDS, AND FEDERAL FUNDS REVENUE

Pharmacy Technician	4360	0205	97,650	113,700	113,700	115,331	184,635
Precursor	4360	0205	2,300	1,550	1,550	1,600	1,800
Prophylactic/Contraceptive	4360	0205	1,600	1,650	1,650	1,400	1,829
Remote Dispensing	4360	0205	1,200	1,000	1,000	800	800
Retail/Institutional Drug Outlet	4360	0205	511,725	560,468	560,468	502,705	551,187
Supervising Physician Dispensing Outlet	4360	0205	8,000	8,400	8,400	13,440	13,860
Wholesalers	4360	0205	719,200	681,600	681,600	691,856	616,896
Delinquent Fees	4360	0505	111,635	70,000	70,000	70,000	70,000
Reciprocity	4360	0205	177,700	125,000	125,000	160,000	160,000
NAPLEX/Exams	4360	0205	56,125	43,485	43,485	58,000	58,000
Civil Penalty	4360	0505	915,739.26	200,000	200,000	350,000	350,000
Interest Income	4360	0605	50,077.47	35,000	35,000	48,000	48,000
NSF	4360	0975	840	400	400	700	700
Misc Fees	4360	0975	12,549.81	28,600	28,600	10,000	10,000
Laws & Rules	4360	0975	9,575	7,000	7,000	8,000	8,000
Prescription Drug Monitoring Fee – transfer to OHA	4360	0205	430,290	283,590	283,590	352,747	374,076
Prescription Drug Monitoring Fee – 10% retention	4360	0205	47,810	28,359	28,359	39,194	41,564
Workforce Data Collection – Transfer to OHA	4360	0210	77,340.50	65,855	65,855	56,610	58,752
Fingerprinting Fees – Transfer to OSP depending on volume	4360	0352	233,005	211,248	211,248	228,800	228,800

_____ Agency Request

 X Governor's Budget

_____ Legislatively Adopted

Budget Page 87

Pharmacy, Board of


Annual Performance Progress Report

Reporting Year 2016

Published: 10/7/2016 5:58:54 PM


KPM # Approved Key Performance Measures (KPMs)

1	Percent of inspected pharmacies that are in compliance annually. -
2	Percent of audited pharmacists who complete continuing education on time. -
3	Percent of pharmacies inspected annually. -
4	Average number of days to complete an investigation from complaint to board presentation. -
5	CUSTOMER SERVICE- Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.
6	Board Best Practices - Percent of total best practices met by the Board.



	Green	Yellow	Red
	= Target to -5%	= Target -6% to -15%	= Target > -15%
Summary Stats:	83.33%	0%	16.67%

KPM #1 Percent of inspected pharmacies that are in compliance annually. -
 Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Percentage of Pharmacies that are in compliance annually.					
Actual	80%	82%	83%	85%	79%
Target	75%	75%	75%	75%	75%

How Are We Doing


This performance measure indicated that the number of inspected pharmacies that were in compliance in 2015 slightly decreased to 79%. This KPM is directly about the pharmacy's compliance with laws and rules.

Factors Affecting Results

The Compliance staff is available to respond to questions and counsel on best practices leading to compliance. Annually updated Pharmacy Self Inspection Forms provide pharmacists with information and references to issues the Board feels are important and reflect new rules which are effective tools that help lead to compliance.

Complete staffing in the Compliance Department assists with a greater ability to serve the pharmacy community and the public. We did have a retirement during 2015 that left us short-handed in Compliance for the last quarter of the year, however it didn't necessarily impact the compliance of pharmacies.

KPM #2 Percent of audited pharmacists who complete continuing education on time. -
 Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Percentage of audited pharmacists who complete continuing education on time.					
Actual	96%	95%	95%	97%	0%
Target	100%	100%	100%	100%	100%

How Are We Doing


For calendar year 2016, there is no data to report as the Board has shifted to a biennial renewal for pharmacists to occur in each odd numbered year. That said, however, in the past our Board has reported for the prior calendar year. In 2015, compliance for this measure determined 38 of the 552 audited were not in compliance. Statistics reflect that fewer individuals were audited in 2015 than 2014 as a result of a slight decline in the number of pharmacists licensed in Oregon. In 2015, 552 pharmacists were audited while in 2014, 583 pharmacists were audited. Note that the data assumes 10% of pharmacists are audited annually. The Board continues to emphasize the importance of keeping up with continuing education by providing Pharmacist-in-Charge training classes and participating in various professional meetings. Staff also provides presentations on pharmacy and drug law at various professional association meetings. The Board's Compliance Director regularly reviews applications for continuing education programs to be offered in Oregon for approval. The Compliance staff periodically audits these programs to ensure that the content is appropriate for pharmacist and pharmacy technician continuing education.

Factors Affecting Results

A decreased availability of live continuing education programs in rural areas is a barrier to achieving the required number of continuing education hours. The availability of some continuing education programs on the internet and in pharmacy journals or periodicals, provides an alternative to attending live continuing education programs. Out-of-state pharmacists often have different continuing education requirements and time frames in their resident state. Therefore, they may miss the required audit period for the state of Oregon.

KPM #3

Percent of pharmacies inspected annually. -
Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Percent of pharmacies inspected annually					
Actual	100%	100%	100%	100%	100%
Target	95%	95%	95%	95%	95%

How Are We Doing

As of October 1, 2016, Board staff have completed 68% of inspections. The goal is to achieve 100 percent by the end of this calendar year.


In 2015, which is the primary data used for this years report, 100% of all pharmacies located in Oregon were inspected. In addition, Board Compliance staff were able to inspect some other outlet types. Performance for this measure varies depending on the Board's workload and direction to focus on inspection for other types of outlets that the Board licenses.

Factors Affecting Results

Having a fully staffed Compliance department where each member is trained makes a positive difference in the Board's ability to satisfy this requirement. We are in good shape for 2016 so far.

QR

KPM #4 Average number of days to complete an investigation from complaint to board presentation. -
 Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Number of days to process complete investigation from complaint to Board presentation.					
Actual	106	71	97	107	98
Target	75	75	100	100	100

How Are We Doing


In 2015, the Board had 271 complaints with an average number of days to complete and report to the Board being 98 days. Board staff diligently investigate complaints and report cases to the Board as quickly as possible. 98 days is an improvement over last years report of 107 days. Both years are still under the statutory requirement of 120 days.

Factors Affecting Results

The results for this KPM are challenging at times. Sometimes there is a delay due to the timing of the Board's meetings approximately every other month, other times it's the challenge of getting information from licensees or drug outlets in time to meet the board meeting deadlines for cases.

KPM #5 CUSTOMER SERVICE - Percent of Customers Rating Their Satisfaction With the Agency's Customer Service as "Good" or "Excellent" : Overall Customer Service, Timeliness, Accuracy, Helpfulness, Expertise, and Availability of Information.

Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Timeliness					
Actual	85%	90%	86%	90%	90%
Target	85%	85%	85%	85%	85%
Expertise					
Actual	91%	95%	94%	96%	94%
Target	85%	85%	85%	85%	85%
Accuracy					
Actual	90%	92%	91%	94%	93%
Target	85%	85%	85%	85%	85%
Helpfulness					
Actual	88%	93%	92%	92%	92%
Target	85%	85%	85%	85%	85%
Overall					
Actual	91%	93%	93%	93%	93%
Target	85%	85%	85%	85%	85%
Availability of Information					
Actual	87%	88%	94%	87%	90%
Target	85%	85%	85%	85%	85%

How Are We Doing

94

The numbers reflected above are for the calendar year 2015. The Board will be adjusting it's reporting to fit within the new KPM system. All areas of reporting continue to exceed the established targets. Overall, we saw a 1.49% increase from our 2014 results in 2015. We are continuing to focus on customer service and are continually striving to provide excellent service in a timely manner in all departments of our agency.


Factors Affecting Results

2015 was a year of significant rule changes, which made it a challenging year, because many of the rules affected the initial licensing and renewal of several different license types. Amendments in OAR 855 Division 025 made the Pharmacy Technician license expire the second June 30th from the date of issue, not to exceed more than two years. Division 019 amendments moved the Pharmacists license to a two year biennial license, expiring in the odd numbered years. Corresponding changes were also made for Preceptor and Pharmacist continuing education requirements since they tie to the Pharmacist renewal cycle. Other amendments include establishing new definitions and requirements in Divisions 060 Manufacturer, 062 Drug Distribution Agent and 065 Wholesaler rules to incorporate terms and categories affected by changes made by the Food and Drug Administration (FDA) that were also incorporated into the Board's rules.

KPM #6

Board Best Practices - Percent of total best practices met by the Board.

Data Collection Period: Jan 01 - Dec 31



Report Year	2012	2013	2014	2015	2016
Is the Board following Best Practices?					
Actual	100%	100%	100%	100%	99%
Target	100%	100%	100%	100%	100%

How Are We Doing

The Board completed the Best Practices Self-Assessment questionnaire at it's June 2016 Annual Meeting. Overall, Board Members scored close to 100% on all of the 15 Best Practices Criteria. New members lacked experience to know about some of the best practices and staff will work to orient them on some of the activities during their first year. Staff regularly works to provide individual members with additional information upon request.

Factors Affecting Results

Our Board increased in size earlier this year from seven to nine members, the two newest members haven't experienced a full year of activities to know answers to some of the questions, so they left them blank. One individual also highlighted issues around the availability and timing of proposed budget information. Overall, the Board continues to do very well with the Board Best Practices.

BUDGET NARRATIVE – 17-19

AFFIRMATIVE ACTION

The Board of Pharmacy affirms and supports the Governor's Affirmative Action Plan and is dedicated to creating a work environment which will attract and retain employees who represent the broadest possible spectrum of society including women, minorities, and the disabled.

The Board of Pharmacy will not tolerate discrimination or harassment on the basis of race, color, sex, sexual orientation, marital status, religion, national origin, age, mental or physical disability, or any reason prohibited by state or federal statute.


The Board and its management further adopts and affirms the Governor's beliefs that the state has a commitment to the right of all persons to work and advance on the basis of merit, ability, and potential.

The nine members of the Board of Pharmacy are appointed by the Governor and confirmed by the Senate to four-year terms. The Board grew from seven to nine members in 2016. Effective February 17, 2016, five members are licensed pharmacists, two members are pharmacy technicians and two members are representatives of the public.

The agency has had 5 staff position changes, which includes one new position and two retirements during the last two years. Our Board and staff are comprised of a diverse group of individuals. Two members of our staff now represent the Asian and Hispanic/Latino cultures. Of the nine board members, 7 women, and 2 are men and one represents the Hispanic/Latino culture. As staff vacancies occur, our recruitment efforts will continue to seek candidates that bring diversity to our staff and Board..


BUDGET NARRATIVE – 17-19

Board of Pharmacy - 2016 Bi-lingual Information - Active Licensees



BUDGET NARRATIVE – 17-19

Board of Pharmacy - 2016 Ethnic Breakdown of Active Licensees



OREGON BOARD OF PHARMACY OUTREACH AND PRESENTATIONS - 2015

Student Outreach

Pacific University School of Pharmacy (PU)
Oregon State University College of Pharmacy (OSU)

- February 9 PU - P1 class, Hillsboro
 - Laura & Fiona
- March 4 OSU P1 class, Corvallis
 - Katie & Bri
- April 27 PU P2 Law & Licensure class, Hillsboro
 - Fiona, Michael and Cheryl
- May 8 OSU Law Review P3 class, Corvallis
 - Inspectors
- May 12 PU Pharmacist in Charge (PIC) P3 class, Hillsboro
 - Fiona, Laura & Gary
- May 15 OSU PIC training P4 class, Corvallis
 - Fiona, Katie & Gary
- November 16 PU Law Informational
 - Fiona

Pharmacist In Charge (PIC) Classes (in office - Portland)

- Feb 19 Fiona and Gary
- March 25 Bri & Michele
- April 15 Fiona & Laura (Cheryl)
- May 14 Michele & Bri
- June 16 Fiona & Cheryl
- August 20 Staff
- September 7 Staff
- November 16 Staff
- December 7 Staff

Associations/Outreach

- February 21 OSPA Lane County CE
 - Fiona, Christine & Penny: law update
 - Ken: patient safety
- April 1 PSOP Law Review
 - Fiona & Bri (Laura)
- April 4 OSHP Technician Law Update
 - Fiona & Laura
- April 18-19 OSHP Salishan booth
 - Marc & Gary
- April 25 OSPA Procrastinator's Seminar
 - Bri, Laura & Marc
- April 28 OSPA/OSHP Southern OR Chapter, Regulatory Update Medford
 - Fiona & Bri
- April 29 Linn Benton Law Review
 - Katie & Roberto
- May 8 Health Futures Law Update, Eugene
 - Gary & Katie (Cheryl)
- October 10-11 OSPA law review
 - Marc, Fiona & Heather
- November 17 FDA presentation
 - Fiona

100



Oregon State Board of Pharmacy

Published to promote compliance of pharmacy and drug law

800 NE Oregon St, Suite 150 • Portland, OR 97232

No. 555 Proper Storage of Drugs and Vaccines

By Kevin Smith, 2016 PharmD Candidate

Proper drug storage is a vital component of patient safety, and our patients certainly expect pharmacists to be the drug experts, mindful at all times of delivering safe drugs. With the adoption of OAR 855-041-1036, which takes effect January 1, 2016, Oregon rules now address proper drug storage for all temperature environments in the pharmacy. This rule creates mandates for the proper storage of drugs in general, cold storage and monitoring, and vaccine drug storage. So what do these rules mean to you? To most people, it will mean that this is the perfect time to reevaluate your current refrigerator and thermometer setup.

All drugs must be stored in appropriate temperature, light, humidity, ventilation, and space according to the manufacturer's published guidelines. Compounding and compounded products must be stored in accordance with United States Pharmacopeia guidelines. Once medications become outdated, adulterated, misbranded, or suspect, a pharmacy must quarantine the drugs to another physical location in the pharmacy where they will not be dispensed.

Regarding cold storage and monitoring temperatures, a refrigerator must maintain temperatures between 2° and 8°C (36° to 46°F). Freezers must remain between -25° and -10°C (-13° to 14°F). The pharmacy must place an accurate and calibrated thermometer in the center of the refrigerator. Meat thermometers are no longer compliant because they cannot be calibrated and cannot be connected to a continuous temperature monitoring system. Finally, refrigerators must be used for drug storage only. The rules state that **no food or drink** is to be kept in refrigerators used for drug storage.

A refrigerator is only as good as the temperature monitoring system inside. With the implementation of this rule, temperatures are to be measured continuously and documented either manually twice daily to include minimum, maximum, and current temperatures, or with an automated system capable of creating a producible history of temperature readings (automated data logging). In order to document that these system checks occur and the personnel are trained, a pharmacy must create and adhere to a monitoring plan. This plan must include, but is not limited to, documentation of training, records of maintaining calibration, maintaining temperature records for a minimum of three years, a written emergency plan, and a plan for routine maintenance of refrigeration equipment.

If you are a pharmacy that also carries vaccines, you will need to adhere to further cold storage specifications. In addition to

the previously stated cold storage guidelines, vaccines must be stored in temperature-stable areas (away from walls, the floor, the ceiling, or vents). The refrigerator must have a calibrated, centrally placed buffered probe thermometer. The buffered probe thermometer gives a better idea of the true temperatures of the vaccines, and the temperature will not immediately fluctuate when the door is opened, which could be a problem when using an alarm system. Additionally, each freezer and refrigerator compartment must have its own exterior door and independent thermostat control. While certain professional grade undercounter refrigerators may be used, traditional dorm-style refrigerators are no longer compliant.

How often do you have to monitor temperatures if you have vaccines? Buffered probe thermometers must be connected to a continuous temperature monitor and provide for automated data logging. Documentation of the temperature of each active storage unit must be logged at least twice daily and data must be downloaded weekly. Additionally, the system is to be validated four times per year (quarterly).

Do you have more questions about the new rules or are unsure where to start with research on a new system? The Oregon Immunization Program and the Oregon Health Authority (OHA) have published their 2015 Oregon VFC Refrigerator & Freezer Guide as well as the 2015 Oregon VFC Thermometer Guide. The guides are great resources on proper vaccine storage, and are available on the OHA website. The Oregon State Board of Pharmacy used those guides as an outline for creating these rules. However, the Vaccines for Children (VFC) program requirements go beyond the Board's regulations, and therefore not everything in the VFC guides is directly applicable. Another great resource is the Vaccine Storage and Handling Toolkit, released by the Centers for Disease Control and Prevention at www.cdc.gov/vaccines/recs/storage/toolkit/default.htm.

No. 556: Pharmacist Prescribing of Birth Control

As you have likely learned by now, 2015 House Bill 2879 passed in Oregon and will allow a pharmacist to prescribe and dispense certain forms of birth control. The purpose put forth by Representative Knute Buehler, who is also a physician, is to provide timely access to care. This law makes Oregon among the first in the country to allow for pharmacist prescribing. In fact, the "go live" date for implementation is January 1, 2016. The following information contains some of the specifics outlined in the bill, as well as points on the timeline toward implementation.

continued on page 4



FDA Issues Warning About Name Confusion for Brintellix and Brilinta

Due to similar brand names, there have been incidents where the antidepressant Brintellix® (vortioxetine) and the anti-blood clotting medication Brilinta® (ticagrelor) have been confused, resulting in prescribing and dispensing errors, warns Food and Drug Administration (FDA). The agency notes that no reports indicate that a patient has ingested the wrong medication; however, reports of prescribing and dispensing errors continue. FDA recommends that health care providers include the generic name of the medication in addition to the brand name, as well as the indication for use when prescribing these medications. Patients are advised to check their prescriptions to ensure that the correct medication was dispensed. More information is available in an FDA safety alert at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm456569.htm.

Seven Persistent Safety Gaffes in Community/Ambulatory Settings That Need to Be Resolved!

 This column was prepared by the Institute for Safe Medication Practices (ISMP). ISMP is an independent nonprofit agency and federally certified patient safety organization that analyzes medication errors, near misses, and potentially hazardous conditions as reported by pharmacists and other practitioners. ISMP then makes appropriate contacts with companies and regulators, gathers expert opinion about prevention measures, and publishes its recommendations. To read about the risk reduction strategies that you can put into practice today, subscribe to ISMP Medication Safety Alert!® Community/Ambulatory Care Edition by visiting www.ismp.org. ISMP provides legal protection and confidentiality for submitted patient safety data and error reports. Help others by reporting actual and potential medication errors to the ISMP National Medication Errors Reporting Program Report online at www.ismp.org. Email: ismpinfo@ismp.org.

This is part two of a three-part series on seven persistent safety gaffes of 2014.

3) Vaccine Errors: Repetitive Errors Reported in the Last Decade

How often do DTaP (diphtheria and tetanus toxoids, and acellular pertussis) and Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine mix-ups need to occur before regulatory action is taken to prevent confusion? Whatever the number, we can say that health care providers have probably met that threshold! Yet, vaccine errors like this continue to occur at an alarming rate (based on those reported to ISMP alone). Vaccine mix-ups occur often because of age-dependent formulations of the same vaccine, similar vaccine abbreviations, similar vaccine containers and labels, and storage near each other. Confusion between the diluent and vaccine has led to administration of the diluent alone or use of the wrong diluent. With an unfortunate rise in parents choosing not to vaccinate their children or themselves, health care providers cannot continue to make errors when

vaccinating those who choose to be immunized; the impact on both individual and community immunity may be far-reaching.

4) Wrong Patient Errors: Not Opening the Bag at the Point of Sale

Community pharmacies are vulnerable to dispensing correctly filled prescriptions to the wrong patient at the point of sale, a risk that is well substantiated in the literature. This error is not influenced by the attributes of a specific medication; thus, dispensing any prescription medication to the wrong patient at the point of sale carries a similar level of risk. Based on an ISMP study, the error happens frequently at an estimated rate of 1.22 per 1,000 prescriptions. Among approximately 56,000 community pharmacies in the United States, this error rate suggests that 332,755 prescriptions will be dispensed to the wrong patient each month, or about six every month per pharmacy. One of the most effective ways to prevent this error is to open the bag of filled prescriptions at the point of sale to verify that the medications are for the correct patient. According to the ISMP study, this simple step reduces the risk of error by 56%, yet few pharmacies follow this practice.

5) Disrespectful Behavior: A History of Tolerance in Health Care

Bullying, incivility, and other forms of disrespectful behavior are still rampant in health care and allowed to exist. Health care providers tolerate the behavior, remain silent, or make excuses in an attempt to minimize the profound devastation that disrespectful behavior causes. An ISMP survey conducted in 2003 clearly demonstrated the scope of disrespectful behavior among many levels of interdisciplinary staff, and an ISMP survey conducted a decade later demonstrates little progress. Disrespect diminishes a person's ability to think clearly, make sound judgments, speak up regarding questions, or avoid at-risk behaviors. Disrespectful behaviors also underlie a resistance to collaborate with others, follow procedures that promote safe practices, or implement new safety practices. While a culture of disrespect is harmful on many levels, its effect on patient safety makes it a matter of national urgency.

FDA Advises Caution Against Codeine for Treating Colds in Young Patients

FDA is evaluating the safety of using medicines containing codeine to treat patients under 18 years old for coughs and colds because of the possibility of severe side effects. Codeine, an opioid, may cause slowed or difficult breathing in children, especially for those who already suffer from breathing problems, the agency notes. FDA recommends that health care providers use caution when prescribing or recommending codeine for patients under 18 years old, and that parents and caregivers be alert for signs of shallow or noisy breathing, confusion, or unusual sleepiness. FDA is also considering a European Medicines Agency recommendation made in April to not give children under 12 codeine for coughs and colds, and to not use codeine for patients 12 to 18 years old who have asthma or other chronic breathing problems. More information is provided in an FDA safety alert available at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm453379.htm.

1001

Compliance News to a particular state or jurisdiction should not be assumed as representing the law of such state or jurisdiction.)



National Association of
Boards of Pharmacy
FOUNDATION

Daytrana Patch May Cause Permanent Skin Color Changes, FDA Warns

In June 2015, FDA warned health care providers and consumers that Daytrana®, a methylphenidate transdermal system prescribed for treating attention deficit hyperactivity disorder, may cause permanent loss of skin color in the affected area. FDA has added a new warning to the drug label to describe this skin condition, known as chemical leukoderma. Chemical leukoderma is a skin condition that causes the skin to lose color as a result of repeated exposure to specific chemical compounds, according to an FDA safety alert. The condition is not physically harmful, but it is disfiguring.

FDA advises patients and caregivers to watch for new areas of lighter skin, especially under the drug patch, and to immediately report any changes to their health care providers. Patients should not stop using the Daytrana patch without consulting a health care provider. FDA also recommends that providers for patients who experience these skin color changes consider alternative treatments. More details are included in the FDA safety alert available at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm452595.htm.

FDA Expands NSAID Warning Labels Regarding Risks of Heart Attack, Stroke

The labels of certain non-steroidal anti-inflammatory drugs (NSAIDs) will soon contain more detailed information about the risk that the drugs may contribute to heart attack and stroke, reports FDA. Such warnings have been on prescription and over-the-counter NSAIDs since 2005, but the new requirements take into account new data showing that the risk of heart attack and stroke occurs even during the first few weeks of taking an NSAID. People who have cardiovascular and other heart problems are at even greater risk of adverse effects. An FDA alert available at www.fda.gov/ForConsumers/ConsumerUpdates/ucm453610.htm provides more details.

Baxter International, Inc, Recalls Three Lots of IV Solutions Due to Particulate Matter

In July 2015, Baxter International, Inc, voluntarily recalled two lots of intravenous (IV) solutions distributed to hospitals and other health offices because of the presence of particulate matter identified as an insect. The problem was identified before patient administration and no adverse health effects have been reported. The recall affects 0.9% sodium chloride injection, USP 50 mL and 100 mL, lot numbers P319921 and P327635, which were distributed to US customers between October 7, 2014, and July 14, 2015. Additional information is available in an FDA press release at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm455421.htm.

Baxter also voluntarily recalled one lot of IV solution to the hospital/user level because of the potential for leaking containers, particulate matter, and missing port protectors. This recall affects 0.9% sodium chloride injection, USP (AUTO-C) with lot number C964601 (National Drug Code 0338-0049-03; expiration date: April 30, 2016). This recalled lot was distributed to

customers and distributors nationwide between January 22, 2015, and February 12, 2015. Leaking containers, particulate matter, and missing port protectors could result in contamination of the solution and, if not detected, could lead to a bloodstream infection or other serious adverse health consequences, explains FDA. The agency notes further that “injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver. There is also the possibility of allergic reactions, local irritation and inflammation in tissues and organs.” More information about this recall is available in an FDA safety alert at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm456793.htm.

FDA Warns Against Unapproved Prescription Ear Drops

FDA has ordered the manufacturers of certain prescription ear drops to stop making and distributing the products because they are not FDA-approved. The product labels do not disclose that they lack FDA approval, and health care providers may not be aware of the unapproved status, notes FDA. The agency took action against unapproved prescription otic drug products containing these ingredients:

- ◆ benzocaine;
- ◆ benzocaine and antipyrine;
- ◆ benzocaine, antipyrine, and zinc acetate;
- ◆ benzocaine, chloroxylenol, and hydrocortisone;
- ◆ chloroxylenol and pramoxine; and
- ◆ chloroxylenol, pramoxine, and hydrocortisone.

These drugs are frequently given to relieve ear swelling and pain in young children, and FDA took this action to protect patients from the risks of taking unapproved drugs with no proven safety or effectiveness information. Further, such drugs may be contaminated or manufactured incorrectly, notes the agency. More information is provided in an FDA news release available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453348.htm.

Acino Products in New Jersey Ordered to Stop Selling Rectacort-HC and GRx HiCort 25

Under the direction of FDA, a federal judge for the District of New Jersey has ordered Acino Products, LLC, of Hamilton, NJ, to stop selling and destroy certain unapproved and misbranded prescription drugs in its possession.

According to FDA, Acino has marketed unapproved hydrocortisone acetate 25 mg suppositories, under the brand names Rectacort-HC and GRx HiCort 25, for treatment of medical conditions including inflamed hemorrhoids, chronic ulcerative colitis, and other inflammatory conditions. The drugs have not been FDA-approved and also fail to carry adequate directions for use on their labels. Acino continued to market and sell the products despite several warnings from FDA investigators. The FDA news release is available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453466.htm.

103

National Association of Boards of Pharmacy Foundation
1600 Feehanville Drive
Mount Prospect, IL 60056

OREGON STATE BOARD OF PHARMACY

Presorted Standard
U.S. Postage
PAID
Chicago, Illinois
Permit No. 5744

401

continued from page 1

A group of stakeholders, including subject matter experts and representatives from the OHA, Oregon Medical Board, and the Oregon State Board of Nursing, is currently adding the finishing touches to the algorithm and risk assessment questionnaire that pharmacists will use. The Accreditation Council for Pharmacy Education online training program is currently under construction, and is on target to be available in early November.

There are three components that a pharmacist must adhere to for participation: 1) Complete a Board-approved training program, 2) Use a patient self-screening risk assessment questionnaire and adhere to a standard procedural algorithm for each evaluation, and 3) Follow the pharmacy's policies and procedures that will be written pursuant to the rules.

Some specifics for you to know: The law allows pharmacists to prescribe oral and patch dosage forms, but it does not provide for implants, vaginal rings, or IUDs. Eligible patients are women 18 years of age and older, or those under 18 years of age with evidence of a previous prescription from a primary or women's health care clinician. Pharmacists **will not** be allowed to: require that patients schedule appointments, prescribe beyond three years following the initial prescription without the patient having evidence of a clinical visit, prescribe against the algorithm, or prescribe to self or family members.

For additional details, please visit the Board's website or contact the Board's consultant pharmacist at fiona.karbowicz@state.or.us.

No. 557: Compliance Corner – Policy Notes and Reminders

Regarding pseudoephedrine (PSE) prescribing, the Board continues to receive inquiries about the electronic prescribing (e-prescribing) of PSE. Essentially, the question asked is, can a PSE prescription be transmitted to a pharmacy like other non-controlled legend drugs, or must it follow the laws related to e-prescribing of controlled substances (CS)? As you know, the rule that reclassified PSE as a CS in Oregon has promoted great strides in the deterrence of illegal methamphetamine manufacturing. However, the fact that PSE is not a federally scheduled CS has often created confusion with components of its legal use, specifically in the transmission of prescription data from prescriber to pharmacy. In the past, the Board had permitted a PSE prescription to be treated as a non-CS prescription with regard to how the pharmacy received the prescription. Now, a PSE prescription must be treated as any other CS prescription. Therefore, it is required that when a prescription for PSE is transmitted electronically to a pharmacy, it must be e-prescribed via a **Drug Enforcement Administration-authenticated system** (See Title 21 Code of Federal Regulations

§1311). If it is transmitted via fax, it must have the original, manual signature of the prescriber. And, as with all Schedule III drugs, it may certainly be phoned in or written on a prescription for a patient to hand deliver to a pharmacy.

Another common concern relates to a pharmacist's designation of a prescription as a **continuation of therapy (CT)**. In past policy discussions, the Board has made it clear that a pharmacist may utilize professional judgment to determine if a drug he or she is dispensing is a CT. It is important to reiterate, however, that it is a process that can only be used when there truly is no change whatsoever from the previous prescription that a patient has been taking and only if a pharmacist is making that determination. An example of the appropriate use of CT could be a patient who has taken the same blood pressure medication for the past few years with no change to the strength or prescriber. CT may not be used if a change in strength or directions has occurred or if it is a transferred prescription, nor is it to be used for an antibiotic a patient may have taken "X" number of months or years ago. Remember, pharmacists are the drug experts. You owe it to your patients to educate them and address their medication and health care concerns in a professional, thorough manner.

The Board continues to offer the Pharmacist-in-Charge (PIC) Training Program and welcomes you to register for the class. It is offered free of charge and is a great way to earn three continuing education hours! Participants receive helpful information regarding compliance, and gain firsthand insights regarding the expectations the Board has for PICs and licensees. Attendees are encouraged to ask questions throughout the program and are provided with valuable resources to take home for implementation into their own pharmacy practice. It is offered approximately once a month and is held at the Board office in Northeast Portland, OR. Additionally, it is occasionally offered in conjunction with local pharmacy association meetings, so keep an eye out for times the program may be offered in your area. Upcoming dates are November 18 and December 8, 2015, as well as January 21, February 17, March 15, April 14, and June 15, 2016. Registration is available at www.oregon.gov/pharmacy/pages/pic_training.aspx.

Page 4 – November 2015

The *Oregon State Board of Pharmacy News* is published by the Oregon State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation™ (NABPF™) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Marc Watt, RPh - State News Editor
Carmen A. Catizone, MS, RPh, DPh - National News Editor & Executive Editor
Deborah Zak - Communications Manager



Oregon State Board of Pharmacy

Published to promote compliance of pharmacy and drug law

800 NE Oregon St, Suite 150 • Portland, OR 97232

501

No. 568: Naloxone Prescribing by Oregon Pharmacists

By Sean Patel, 2017 PharmD Candidate

The abuse and dependence of opioids is a genuine public health issue. The number of opioid overdoses has drastically increased over the years. According to the Centers for Disease Control and Prevention, drug overdose is the main cause of accidental deaths, surpassing automobile collisions. Opioid overdose can also be incidental; individuals may misread their prescriptions or not realize that they have already taken their medication. Naloxone can reverse the effects of opioid overdose.

House Bill 4124, signed into Oregon law in April 2016, permits pharmacists to prescribe unit-of-use naloxone to a person who conducts training pursuant to protocols established by the Oregon Health Authority (OHA) or who has successfully completed approved training. This law was created as a way to increase access to naloxone, with an end goal to diminish the dangers related to opiate overdose. The law allows a pharmacist to prescribe to two types of authorized recipients. First, a pharmacist can prescribe to a trainer or an organization that shall possess and distribute naloxone to trainees. Second, a pharmacist can prescribe naloxone and the necessary supplies to administer it to trained individuals who may possess and administer naloxone to an individual experiencing an opiate overdose. Both of these options are permitted when the pharmacist is familiar with opiate overdose and naloxone rescue and works in a pharmacy that has policies and procedures developed to offer these services.

The OHA training is available online in both video and written format at <https://public.health.oregon.gov/ProviderPartnerResources/EMSTraumaSystems/Pages/epi-protocol-training.aspx#naloxone>. It covers signs and symptoms to look for during an opiate overdose and a general treatment overview. The training covers how to respond to an opiate overdose by checking responsiveness and calling 911 if there is no response, how to perform CPR, and how to properly administer naloxone and to continue CPR, if needed, until help arrives. Pharmacists must become familiar with this document, opiate overdose, and naloxone rescue to provide effective information and counseling to individuals seeking naloxone.

On September 2, 2016, the Oregon State Board of Pharmacy passed a temporary rule that outlines the requirements for an Oregon pharmacist to prescribe and dispense naloxone. Oregon Administrative Rule (OAR) 855-019-0460 states a pharmacist can prescribe naloxone and the necessary medical supplies for opiate overdose to an OHA-authorized person or organization and to an individual who has completed an OHA-approved training. The pharmacist shall determine that the individual seeking naloxone demonstrates understanding of educational materials related to opioid overdose prevention, recognition, response, and the

administration of naloxone. Naloxone may not be dispensed without providing oral counseling to the authorized recipient, to include dose, effectiveness, adverse effects, storage conditions, and safety. This means that the individual receiving the naloxone prescribed by a pharmacist cannot waive the consultation. The pharmacist must document the encounter and the prescription and maintain records for three years.

In school, pharmacists are trained and educated in pharmacology, pharmacokinetics, and drug-drug and drug-illness state interactions. A pharmacist is to use professional judgment in determining whether to complete additional education in opiate overdose prior to prescribing naloxone. A pharmacist can be an impactful member of the team by communicating with providers, giving instruction to patients, and increasing education throughout a community. Avoiding opioid overdose-related deaths should be one of many priorities to the pharmacy profession, since pharmacists are medication experts. Pharmacists are in an influential position to identify high-risk patients. A pharmacist can determine at-risk patients by obtaining a patient's medication history and identifying patients who are taking high doses of opioids for long-term management of chronic pain; have a confirmed history of substance abuse, dependence, or non-medical use of prescription or illicit opioids; or are completing a mandatory opioid detoxification or abstinence program. At-risk patients can complete the OHA training while waiting for their prescriptions to be filled.

Permitting Oregon pharmacists to prescribe naloxone and provide counseling to authorized individuals will broaden access to the medication, assist in preventing opioid overdose deaths, and give patients a chance to get suitable treatment. For related information, please visit the Board's website at www.oregon.gov/pharmacy/Pages/Naloxone.aspx.

No. 569: Oregon PDMP

The Board office receives regular updates from the Oregon Prescription Drug Monitoring Program (PDMP). It has come to the Board's attention that while hundreds of thousands of prescriptions are uploaded to the database annually with minimal errors, the program still does receive incorrect entries. Please take some time to review these opportunities with your staff to confirm that prescription data are being entered correctly into your systems, and in turn, being correctly uploaded to the PDMP.

- ◆ Be sure to enter the Drug Enforcement Administration (DEA) number provided on the prescription whenever available. There are many clinicians who practice in various locations with different DEA numbers (but who are the same practitioner). Entering the correct DEA number will ensure that the provider's associated information, such as practice address and phone number, will also be correct. This is important to ensure the most efficient communication with the correct office when calling for clarifications and renewing ongoing drug therapies.

continued on page 4



National Vaccine Safety Surveillance Program Available for Reporting Adverse Events

The Vaccine Adverse Event Reporting System (VAERS) eSubmitter program, a national vaccine safety surveillance program cosponsored by the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA), is available for the reporting of any clinically significant adverse event that occurs after the administration of any vaccine licensed in the United States. VAERS information is analyzed by CDC and FDA to identify new safety concerns. VAERS reports can be filed by anyone, including health care providers, manufacturers, state immunization programs, and vaccine recipients. Vaccine recipients are encouraged to seek help from their health care provider when filling out the VAERS form. Health care providers can find information about submitting a report on the VAERS website at <https://vaers.hhs.gov/professionals/index>.

Improper and Unsafe Vaccine Storage

 This column was prepared by the Institute for Safe Medication Practices (ISMP). ISMP is an independent nonprofit agency and federally certified patient safety organization that analyzes medication errors, near misses, and potentially hazardous conditions as reported by pharmacists and other practitioners. ISMP then makes appropriate contacts with companies and regulators, gathers expert opinion about prevention measures, and publishes its recommendations. To read about the risk reduction strategies that you can put into practice today, subscribe to ISMP Medication Safety Alert!® Community/Ambulatory Care Edition by visiting www.ismp.org. ISMP provides legal protection and confidentiality for submitted patient safety data and error reports. Help others by reporting actual and potential medication errors to the ISMP National Medication Errors Reporting Program Report online at www.ismp.org. Email: ismpinfo@ismp.org.

Few issues are more important than proper storage and handling of vaccines, because their ability to prevent disease is dependent on these factors. To maintain stability, most vaccines must be stored in a refrigerator or freezer, and many also require protection from light. Excessive heat or cold – even a single exposure in some instances – can reduce vaccine potency. These temperature excursions are often due to improper refrigeration or freezer units, inadequate thermostat controls, and refrigeration/freezer units with inadequate space to allow good air circulation and even temperatures.

Improper and unsafe storage can also result in serious errors caused by selecting the wrong vaccines, diluents, and other medications with look-alike names and/or labeling and packaging. Storing vaccines close to each other has led to dispensing and administering the wrong vaccine or wrong form of vaccine (eg, adult versus pediatric). Storing vaccines too close to non-biologic medications in a refrigerator or freezer has also led to serious adverse outcomes, particularly when the mix-up

involved a vaccine and a high-alert medication. For example, vials of insulin have frequently been mistaken as influenza vaccine, and various neuromuscular blocking agents have been used to reconstitute vaccines or were mistaken as influenza or hepatitis B vaccines.

Store vaccines in their own dedicated refrigeration and freezer units. Regular temperature monitoring is necessary, and technology is available to assist with alarmed, continuous monitoring devices that can alert staff via email and pager if a unit is out of specified range. Separate vaccine vials and syringes into bins or other containers according to vaccine type and formulation, keeping diluents with the appropriate vaccines. Never store different vaccines in the same containers. Do not store vaccines with similar labels, names, abbreviations, or overlapping components immediately next to each other or on the same shelf. Separate the storage areas of pediatric and adult formulations of vaccines. Label the specific locations where vaccines are stored to facilitate correct age-specific selection and to remind staff to combine the contents of vials. ISMP's March 26, 2015 newsletter¹ contains additional strategies, as does a Vaccine Storage & Handling Toolkit available from CDC.²

References

1. ISMP. Recommendations for practitioners to prevent vaccine errors. Part 2: analysis of ISMP vaccine errors reporting program (VERP). *ISMP Medication Safety Alert!* 2015;20(6):1-6.
2. CDC. Vaccine storage & handling toolkit. www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf. June 2016.

Coalition Reports Impact of Educational Efforts on Safe Acetaminophen Use

The Acetaminophen Awareness Coalition reports that progress has been made to increase consumer awareness about the safe use of acetaminophen. The coalition also notes a decline in unintentional overdoses. The National Poison Data System's 2015 report indicates unintentional acetaminophen exposures, including dosing errors and accidental misuse, have decreased through 2013 after a peak in 2009. In addition, a nationwide survey indicates the number of consumers who understand that exceeding the recommended daily dose of acetaminophen may lead to liver damage has increased to 87% in 2013 from 78% in 2010. The survey also reports the number of consumers who think it is important to check the medicine label for the maximum daily dose increased to 98% in 2013 from 93% in 2010.

Developed in 2011, the Know Your Dose campaign encourages pharmacists and other health care providers to talk to their patients about medicine safety and acetaminophen use. The Know Your Dose campaign offers a list of helpful health tips to share with patients, including the following:

- (1) Read and follow the label.
- (2) Know which medicines contain acetaminophen.

991

Compliance News

Compliance News to a particular state or jurisdiction should not be assumed as the law of such state or jurisdiction.)



National Association of
Boards of Pharmacy
FOUNDATION

- (3) Take only one medicine at a time that contains acetaminophen.
- (4) Ask a health care provider or pharmacist about dosing instructions or medicines that contain acetaminophen.

Pharmacists may download or order free educational materials, including posters, flyers, and talking points, to give their patients on the Know Your Dose website, www.knowyourdose.org.

FDA Offers Webinars on Online Drug Information Resources for Students and Clinicians

FDA's Division of Drug Information in the Center for Drug Evaluation and Research presents a series of CE webinars targeted toward students and health care providers who wish to learn more about FDA and drug regulation. The webinars are presented by FDA staff and allow participants to interact with staff. Previous webinar topics have included an overview of FDA's expanded access program and the pregnancy and lactation labeling rule. The webinars and presentation slides can be accessed on FDA's website at www.fda.gov/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/ucm228391.htm.

Fresenius Kabi Recalls Sensorcaine-MPF (Bupivacaine HCl) Injection, USP

In April 2016, Fresenius Kabi USA recalled a single lot of Sensorcaine®-MPF (bupivacaine HCl) injection, USP, 0.75%, 7.5 mg/mL, 30 mL fill in a 30 mL vial, because of visible particulate matter characterized as glass observed by the company during inspection of reserve samples. The recalled product was shipped in the US to wholesaler and distributor outlets between March 4, 2016, and March 21, 2016, and has an expiration date of September 2019. The recall affects lot number 6111504, product code 470237, and National Drug Code number 63323-472-37. The product is supplied as 0.75% strength in a 30 mL single-dose flint molded vial and is packaged in units of 25. To date, Fresenius Kabi has not received any reports of adverse events regarding this recall, indicates the press release posted to the FDA website.

Health care facilities that have the affected lot are instructed to immediately discontinue distributing, dispensing, or using the lot and return all units to Fresenius Kabi. Distributors are instructed to immediately notify their customers who have been shipped or may have been shipped the recalled product. Adverse reactions or quality problems may be reported to FDA's MedWatch Safety Information and Adverse Event Reporting program at www.fda.gov/MedWatch. Additional details are available on FDA's website at www.fda.gov/Safety/Recalls/ucm497812.htm.

Oral Liquid Docusate Sodium by PharmaTech Recalled Due to Contamination

In July 2016, FDA alerted health care providers that PharmaTech, LLC, of Davie, FL, voluntarily recalled all non-expired lots of Diocto Liquid, a docusate sodium solution

distributed by Rugby Laboratories of Livonia, MI. The affected product was distributed nationwide in one-pint (473 mL) bottles with a Rugby label. FDA confirmed the product has been contaminated with *Burkholderia cepacia*, a bacteria linked to an outbreak in five states. The safety alert indicates FDA has received several adverse event reports of *B. cepacia* infections in patients, and some of these reports identify liquid docusate sodium products manufactured by companies other than PharmaTech. FDA and CDC continue to investigate the extent of this issue in order to identify other potentially contaminated liquid docusate sodium products. FDA joins CDC in recommending that clinicians not use any liquid docusate sodium product as a stool softener or for any other medical purpose. Adverse events or side effects may be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch. More information may be found in the safety alert on FDA's website at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm511528.htm.

NABP Seeks Pharmacists From Districts 1, 5, and 7 to Serve as Volunteer Item Writers

The National Association of Boards of Pharmacy® (NABP®) is seeking pharmacists who reside in states in the following districts to serve as volunteer item writers:

- ♦ **District 1:** Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.
- ♦ **District 5:** Iowa, Minnesota, Nebraska, North Dakota, and South Dakota.
- ♦ **District 7:** Alaska, Idaho, Montana, Oregon, Washington, and Wyoming.

In an effort to secure more individuals representative of these areas of the country, NABP encourages pharmacists in all areas of practice as well as school and college of pharmacy faculty who reside in these states to apply.

NABP uses volunteer item writers to develop questions for the following examination programs: North American Pharmacist Licensure Examination® (NAPLEX®), Multistate Pharmacy Jurisprudence Examination® (MPJE®), Foreign Pharmacy Graduate Equivalency Examination® (FPGEE®), Pharmacy Curriculum Outcomes Assessment® (PCOA®), and Pharmacist Assessment for Remediation Evaluation® (PARE®).

Interested individuals should complete the online interest form available in the Meetings section of the NABP website. Individuals who are selected will receive further information on opportunities to attend and participate in NABP-hosted workshops.

For more information about NABP item writing, visit the Meetings section of the NABP website at www.nabp.pharmacy, or contact CompAssess@nabp.pharmacy.

107



801

continued from page 1

- ◆ Do not use “dummy” DEA numbers, eg, AR111119. The pharmacist has a corresponding responsibility to ensure that prescriptions are completed accurately.
- ◆ Input the correct original date for each prescription. The original date is not always the date that the pharmacy is processing the prescription.
- ◆ Use only a single profile for each patient. Unfortunately, having two active profiles for the same patient, sometimes with a “nickname” or other anomaly, creates confusion for providers’ effective use of the PDMP database. Pharmacists should follow company procedure to merge profiles when encountering this scenario at their pharmacy to ensure that the most accurate information is being documented and submitted to the database.

No. 570: Compliance Pearls

Return to Stock: Did you know that pharmacists must verify and document their verification of all “return to stock” (RTS) medications that are relabeled by a technician? Compliance staff has noticed that many pharmacists are not aware of this requirement for pharmacist verification. Regulations that address this requirement include:

- ◆ OAR 855-025-0025(4), which states that “Work performed by Pharmacy Technicians and Certified Oregon Pharmacy Technicians assisting the Pharmacist to prepare medications must be verified by a Pharmacist prior to release for patient use. Verification must be documented, available and consistent with the standard of practice.”
- ◆ OAR 855-019-0200(2), which states that “Only a pharmacist may practice pharmacy as defined in ORS 689.005, to include the provision of patient care services. Activities that require the professional judgment of a pharmacist include but are not limited to: . . . (i) Final verification of the work performed by those under their supervision.”

Please note that the Board does not require a pharmacy to relabel RTS medications.

Counseling: Did you know that solely asking a patient “Do you have any questions on your prescription?” does not constitute appropriate counseling for a new prescription? Please ensure that you provide all information necessary to promote the safe use of medication and to facilitate an appropriate outcome. Patients often do not know what questions to ask. Health care providers and patients are relying on the pharmacist’s expertise to educate patients about what to expect from medications and how to use them properly.

Allergies: Did you know that putting a note regarding a medication intolerance in the patient comment field of your computer system, rather than in the allergy field, is acceptable? Please note that this determination should be made by a pharmacist because it may affect a pharmacist’s decision when performing a drug use review (DUR) and which medications are flagged for a DUR by the computer software.

No. 571: Fifty-Year Pharmacists

The Board is pleased to acknowledge the pharmacists who have been licensed in Oregon for 50 years. The Board recognizes their many years of service and contributions to the profession and to the health and well-being of the citizens of Oregon. These distinguished individuals should be proud of their accomplishments, and they deserve the recognition and acknowledgement of their profession. The following is a list of pharmacists who reached this milestone in 2015 and 2016.

Gary Brew, Medford, OR	Lee Land, Eugene, OR
James Burch, Portland, OR	Robert Lovitt, Hayden, ID
David Bystrom, Westerville, OH	Richard Lundgren, Salem
William Carson, Lake Oswego, OR	Joe McCann, Lake Oswego
Daniel Cooke, Bend, OR	Robert McGill, Grand Coulee, WA
Michael Douglas, Newberg, OR	Raymond Michael, Boardman, OR
Daniel Ferry, Anderson, CA	William Milne, Wilsonville, OR
James Frahm, Vancouver, WA	Conrad Reinmiller, La Pine, OR
Harlen Hendrickson, Henderson, NV	Leroy Roberts, Springfield, OR
Mark Hyman, Portland	Gerald Rood, Warren, OR
Robert Ingram, Salem, OR	Bruce Sharrah, Baker City, OR
Richard Irwin, Newberg	Mary Lou Wacek, Portland
Lawrence Kralman, Milwaukie, OR	James Wells, Litchfield Park, AZ
William Labberton, Beaverton, OR	Willard Wilson, Black Butte Ranch, OR

Pharmacy, Board of

Summary Cross Reference Listing and Packages

2017-19 Biennium

Agency Number: 85500

BAM Analyst: Medina, Anthony

Budget Coordinator: UNASSIGNED

Cross Reference Number	Cross Reference Description	Package Number	Priority	Package Description	Package Group
001-00-00-00000	Board of Pharmacy	010	0	Non-PICS Psnl Svc / Vacancy Factor	Essential Packages
001-00-00-00000	Board of Pharmacy	021	0	Phase - In	Essential Packages
001-00-00-00000	Board of Pharmacy	022	0	Phase-out Pgm & One-time Costs	Essential Packages
001-00-00-00000	Board of Pharmacy	031	0	Standard Inflation	Essential Packages
001-00-00-00000	Board of Pharmacy	032	0	Above Standard Inflation	Essential Packages
001-00-00-00000	Board of Pharmacy	060	0	Technical Adjustments	Essential Packages
001-00-00-00000	Board of Pharmacy	080	0	May 2016 E-Board	Policy Packages
001-00-00-00000	Board of Pharmacy	090	0	Analyst Adjustments	Policy Packages
001-00-00-00000	Board of Pharmacy	091	0	Statewide Adjustment DAS Chgs	Policy Packages
001-00-00-00000	Board of Pharmacy	092	0	Statewide AG Adjustment	Policy Packages
001-00-00-00000	Board of Pharmacy	100	0	MyLicense Business Upgrade	Policy Packages
001-00-00-00000	Board of Pharmacy	101	0	Academic & Regulatory Fellowship	Policy Packages
001-00-00-00000	Board of Pharmacy	102	0	Board Member Per Diem	Policy Packages
999-00-00-00000	Suspense	010	0	Non-PICS Psnl Svc / Vacancy Factor	Essential Packages
999-00-00-00000	Suspense	021	0	Phase - In	Essential Packages
999-00-00-00000	Suspense	022	0	Phase-out Pgm & One-time Costs	Essential Packages
999-00-00-00000	Suspense	031	0	Standard Inflation	Essential Packages
999-00-00-00000	Suspense	080	0	May 2016 E-Board	Policy Packages

109

Pharmacy, Board of

**Policy Package List by Priority
2017-19 Biennium**

**Agency Number: 85500
BAM Analyst: Medina, Anthony
Budget Coordinator: UNASSIGNED**

<i>Priority</i>	<i>Policy Pkg Number</i>	<i>Policy Pkg Description</i>	<i>Summary Cross Reference Number</i>	<i>Cross Reference Description</i>
0	080	May 2016 E-Board	001-00-00-00000	Board of Pharmacy
			999-00-00-00000	Suspense
	090	Analyst Adjustments	001-00-00-00000	Board of Pharmacy
	091	Statewide Adjustment DAS Chgs	001-00-00-00000	Board of Pharmacy
	092	Statewide AG Adjustment	001-00-00-00000	Board of Pharmacy
	100	MyLicense Business Upgrade	001-00-00-00000	Board of Pharmacy
	101	Academic & Regulatory Fellowship	001-00-00-00000	Board of Pharmacy
	102	Board Member Per Diem	001-00-00-00000	Board of Pharmacy

Pharmacy, Board of

Agency Number: 85500

Budget Support - Detail Revenues and Expenditures

Cross Reference Number: 85500-000-00-00-00000

2017-19 Biennium

Pharmacy, Board Of

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
BEGINNING BALANCE						
0025 Beginning Balance						
3400 Other Funds Ltd	3,858,398	4,622,723	4,622,723	3,970,352	3,970,352	-
0030 Beginning Balance Adjustment						
3400 Other Funds Ltd	-	-	-	-	302,500	-
BEGINNING BALANCE						
3400 Other Funds Ltd	3,858,398	4,622,723	4,622,723	3,970,352	4,272,852	-
TOTAL BEGINNING BALANCE	\$3,858,398	\$4,622,723	\$4,622,723	\$3,970,352	\$4,272,852	-
REVENUE CATEGORIES						
LICENSES AND FEES						
0205 Business Lic and Fees						
3400 Other Funds Ltd	5,881,772	4,924,832	4,924,832	4,179,867	4,431,667	-
0210 Non-business Lic. and Fees						
3400 Other Funds Ltd	310,346	65,855	65,855	503,410	505,552	-
LICENSES AND FEES						
3400 Other Funds Ltd	6,192,118	4,990,687	4,990,687	4,683,277	4,937,219	-
TOTAL LICENSES AND FEES	\$6,192,118	\$4,990,687	\$4,990,687	\$4,683,277	\$4,937,219	-
FINES, RENTS AND ROYALTIES						
0505 Fines and Forfeitures						
3400 Other Funds Ltd	1,024,899	270,000	270,000	420,000	420,000	-
INTEREST EARNINGS						
0605 Interest Income						
3400 Other Funds Ltd	50,077	35,000	35,000	48,000	48,000	-

111

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Pharmacy, Board Of**

Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
OTHER						
0975 Other Revenues						
3400 Other Funds Ltd	56,851	29,700	29,700	39,700	39,700	-
REVENUE CATEGORIES						
3400 Other Funds Ltd	7,323,945	5,325,387	5,325,387	5,190,977	5,444,919	-
TOTAL REVENUE CATEGORIES	\$7,323,945	\$5,325,387	\$5,325,387	\$5,190,977	\$5,444,919	-
TRANSFERS OUT						
2443 Tsfr To Oregon Health Authority						
3400 Other Funds Ltd	(488,238)	(349,445)	(349,445)	(409,357)	(409,357)	-
AVAILABLE REVENUES						
3400 Other Funds Ltd	10,694,105	9,598,665	9,598,665	8,751,972	9,308,414	-
TOTAL AVAILABLE REVENUES	\$10,694,105	\$9,598,665	\$9,598,665	\$8,751,972	\$9,308,414	-
EXPENDITURES						
PERSONAL SERVICES						
SALARIES & WAGES						
3110 Class/Unclass Sal. and Per Diem						
3400 Other Funds Ltd	2,481,436	2,872,872	3,014,977	3,191,268	3,191,268	-
3160 Temporary Appointments						
3400 Other Funds Ltd	20,266	24,322	24,322	25,222	25,222	-
3170 Overtime Payments						
3400 Other Funds Ltd	2,107	-	-	-	-	-
3190 All Other Differential						
3400 Other Funds Ltd	122,824	176,911	176,911	183,457	183,457	-

112

Budget Support - Detail Revenues and Expenditures
 2017-19 Biennium
 Pharmacy, Board Of

Cross Reference Number: 85500-000-00-00-00000

Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
SALARIES & WAGES						
3400 Other Funds Ltd	2,626,633	3,074,105	3,216,210	3,399,947	3,399,947	-
TOTAL SALARIES & WAGES	\$2,626,633	\$3,074,105	\$3,216,210	\$3,399,947	\$3,399,947	-
OTHER PAYROLL EXPENSES						
3210 Empl. Rel. Bd. Assessments						
3400 Other Funds Ltd	741	880	880	1,083	1,083	-
3220 Public Employees' Retire Cont						
3400 Other Funds Ltd	352,474	478,038	500,476	504,012	504,012	-
3221 Pension Obligation Bond						
3400 Other Funds Ltd	157,887	176,574	179,452	195,224	195,224	-
3230 Social Security Taxes						
3400 Other Funds Ltd	193,719	235,168	246,039	256,020	256,020	-
3240 Unemployment Assessments						
3400 Other Funds Ltd	8,552	-	-	-	-	-
3250 Worker's Comp. Assess. (WCD)						
3400 Other Funds Ltd	1,178	1,380	1,380	1,380	1,380	-
3260 Mass Transit Tax						
3400 Other Funds Ltd	15,781	18,445	19,298	20,334	20,334	-
3270 Flexible Benefits						
3400 Other Funds Ltd	510,750	610,560	632,240	666,720	666,720	-
OTHER PAYROLL EXPENSES						
3400 Other Funds Ltd	1,241,082	1,521,045	1,579,765	1,644,773	1,644,773	-
TOTAL OTHER PAYROLL EXPENSES	\$1,241,082	\$1,521,045	\$1,579,765	\$1,644,773	\$1,644,773	-

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Pharmacy, Board Of**

Cross Reference Number: 85500-000-00-000000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
PERSONAL SERVICES						
3400 Other Funds Ltd	3,867,715	4,595,150	4,795,975	5,044,720	5,044,720	-
TOTAL PERSONAL SERVICES	\$3,867,715	\$4,595,150	\$4,795,975	\$5,044,720	\$5,044,720	-
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	82,116	106,639	106,639	110,585	110,585	-
4125 Out of State Travel						
3400 Other Funds Ltd	16,250	19,985	19,985	20,724	20,724	-
4150 Employee Training						
3400 Other Funds Ltd	18,219	48,559	48,559	52,335	52,335	-
4175 Office Expenses						
3400 Other Funds Ltd	113,411	119,463	119,463	123,883	122,959	-
4200 Telecommunications						
3400 Other Funds Ltd	31,873	36,349	36,349	44,794	38,109	-
4225 State Gov. Service Charges						
3400 Other Funds Ltd	181,486	72,769	72,769	134,288	125,499	-
4250 Data Processing						
3400 Other Funds Ltd	35,077	56,060	56,060	73,816	73,302	-
4275 Publicity and Publications						
3400 Other Funds Ltd	36,313	37,593	37,593	38,984	38,984	-
4300 Professional Services						
3400 Other Funds Ltd	275,219	116,711	116,711	402,408	402,408	-
4315 IT Professional Services						

114

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Pharmacy, Board Of**

Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
3400 Other Funds Ltd	58,900	78,096	78,096	353,340	353,340	-
4325 Attorney General						
3400 Other Funds Ltd	218,181	314,038	314,038	355,303	331,960	-
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	396	200	200	207	207	-
4400 Dues and Subscriptions						
3400 Other Funds Ltd	7,717	4,419	4,419	4,583	4,583	-
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	191,273	217,606	217,606	232,621	219,519	-
4475 Facilities Maintenance						
3400 Other Funds Ltd	1,455	49	49	51	51	-
4525 Medical Services and Supplies						
3400 Other Funds Ltd	2,061	1,070	1,070	1,110	1,110	-
4575 Agency Program Related S and S						
3400 Other Funds Ltd	199,093	221,248	221,248	229,434	229,434	-
4650 Other Services and Supplies						
3400 Other Funds Ltd	78,447	292,293	292,293	298,598	285,700	-
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	3,551	10,124	10,124	10,499	10,499	-
4715 IT Expendable Property						
3400 Other Funds Ltd	43,294	40,285	40,285	43,976	43,976	-
SERVICES & SUPPLIES						
3400 Other Funds Ltd	1,594,332	1,793,556	1,793,556	2,531,539	2,465,284	-

115

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Pharmacy, Board Of**

Cross Reference Number: 85500-00-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
TOTAL SERVICES & SUPPLIES	\$1,594,332	\$1,793,556	\$1,793,556	\$2,531,539	\$2,465,284	-
CAPITAL OUTLAY						
5550 Data Processing Software						
3400 Other Funds Ltd	-	271,077	271,077	-	-	-
5600 Data Processing Hardware						
3400 Other Funds Ltd	-	8,000	8,000	8,296	8,296	-
CAPITAL OUTLAY						
3400 Other Funds Ltd	-	279,077	279,077	8,296	8,296	-
TOTAL CAPITAL OUTLAY	-	\$279,077	\$279,077	\$8,296	\$8,296	-
SPECIAL PAYMENTS						
6085 Other Special Payments						
3400 Other Funds Ltd	-	11,563	11,563	11,991	11,991	-
6443 Spc Pmt to Oregon Health Authority						
3400 Other Funds Ltd	137,332	176,899	176,899	-	-	-
SPECIAL PAYMENTS						
3400 Other Funds Ltd	137,332	188,462	188,462	11,991	11,991	-
TOTAL SPECIAL PAYMENTS	\$137,332	\$188,462	\$188,462	\$11,991	\$11,991	-
EXPENDITURES						
3400 Other Funds Ltd	5,599,379	6,856,245	7,057,070	7,596,546	7,530,291	-
TOTAL EXPENDITURES	\$5,599,379	\$6,856,245	\$7,057,070	\$7,596,546	\$7,530,291	-
ENDING BALANCE						
3400 Other Funds Ltd	5,094,726	2,742,420	2,541,595	1,155,426	1,778,123	-
TOTAL ENDING BALANCE	\$5,094,726	\$2,742,420	\$2,541,595	\$1,155,426	\$1,778,123	-

116

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Pharmacy, Board Of**

Cross Reference Number: 85500-000-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
AUTHORIZED POSITIONS						
8150 Class/Unclass Positions	19	20	20	20	20	-
TOTAL AUTHORIZED POSITIONS	19	20	20	20	20	-
AUTHORIZED FTE						
8250 Class/Unclass FTE Positions	19.00	20.00	20.00	20.00	20.00	-
TOTAL AUTHORIZED FTE	19.00	20.00	20.00	20.00	20.00	-

Budget Support - Detail Revenues and Expenditures
 2017-19 Biennium
 Board of Pharmacy

Cross Reference Number: 85500-001-00-00-00000

Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
BEGINNING BALANCE						
0025 Beginning Balance						
3400 Other Funds Ltd	3,858,398	4,622,723	4,622,723	3,970,352	3,970,352	-
0030 Beginning Balance Adjustment						
3400 Other Funds Ltd	-	-	-	-	302,500	-
BEGINNING BALANCE						
3400 Other Funds Ltd	3,858,398	4,622,723	4,622,723	3,970,352	4,272,852	-
TOTAL BEGINNING BALANCE	\$3,858,398	\$4,622,723	\$4,622,723	\$3,970,352	\$4,272,852	-
REVENUE CATEGORIES						
LICENSES AND FEES						
0205 Business Lic and Fees						
3400 Other Funds Ltd	5,881,772	4,924,832	4,924,832	4,179,867	4,431,667	-
0210 Non-business Lic. and Fees						
3400 Other Funds Ltd	310,346	65,855	65,855	503,410	505,552	-
LICENSES AND FEES						
3400 Other Funds Ltd	6,192,118	4,990,687	4,990,687	4,683,277	4,937,219	-
TOTAL LICENSES AND FEES	\$6,192,118	\$4,990,687	\$4,990,687	\$4,683,277	\$4,937,219	-
FINES, RENTS AND ROYALTIES						
0505 Fines and Forfeitures						
3400 Other Funds Ltd	1,024,899	270,000	270,000	420,000	420,000	-
INTEREST EARNINGS						
0605 Interest Income						
3400 Other Funds Ltd	50,077	35,000	35,000	48,000	48,000	-

Budget Support - Detail Revenues and Expenditures
 2017-19 Biennium
 Board of Pharmacy

Cross Reference Number: 85500-001-00-00-00000

Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
OTHER						
0975 Other Revenues						
3400 Other Funds Ltd	56,851	29,700	29,700	39,700	39,700	-
REVENUE CATEGORIES						
3400 Other Funds Ltd	7,323,945	5,325,387	5,325,387	5,190,977	5,444,919	-
TOTAL REVENUE CATEGORIES	\$7,323,945	\$5,325,387	\$5,325,387	\$5,190,977	\$5,444,919	-
TRANSFERS OUT						
2443 Tsfr To Oregon Health Authority						
3400 Other Funds Ltd	(488,238)	(349,445)	(349,445)	(409,357)	(409,357)	-
AVAILABLE REVENUES						
3400 Other Funds Ltd	10,694,105	9,598,665	9,598,665	8,751,972	9,308,414	-
TOTAL AVAILABLE REVENUES	\$10,694,105	\$9,598,665	\$9,598,665	\$8,751,972	\$9,308,414	-
EXPENDITURES						
PERSONAL SERVICES						
SALARIES & WAGES						
3110 Class/Unclass Sal. and Per Diem						
3400 Other Funds Ltd	2,481,436	2,872,872	3,014,977	3,191,268	3,191,268	-
3160 Temporary Appointments						
3400 Other Funds Ltd	20,266	24,322	24,322	25,222	25,222	-
3170 Overtime Payments						
3400 Other Funds Ltd	2,107	-	-	-	-	-
3190 All Other Differential						
3400 Other Funds Ltd	122,824	176,911	176,911	183,457	183,457	-

Budget Support - Detail Revenues and Expenditures
 2017-19 Biennium
 Board of Pharmacy

Cross Reference Number: 85500-001-00-00-00000

Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
SALARIES & WAGES						
3400 Other Funds Ltd	2,626,633	3,074,105	3,216,210	3,399,947	3,399,947	-
TOTAL SALARIES & WAGES	\$2,626,633	\$3,074,105	\$3,216,210	\$3,399,947	\$3,399,947	-
OTHER PAYROLL EXPENSES						
3210 Empl. Rel. Bd. Assessments						
3400 Other Funds Ltd	741	880	880	1,083	1,083	-
3220 Public Employees' Retire Cont						
3400 Other Funds Ltd	352,474	478,038	500,476	504,012	504,012	-
3221 Pension Obligation Bond						
3400 Other Funds Ltd	157,887	176,574	179,452	195,224	195,224	-
3230 Social Security Taxes						
3400 Other Funds Ltd	193,719	235,168	246,039	256,020	256,020	-
3240 Unemployment Assessments						
3400 Other Funds Ltd	8,552	-	-	-	-	-
3250 Worker's Comp. Assess. (WCD)						
3400 Other Funds Ltd	1,178	1,380	1,380	1,380	1,380	-
3260 Mass Transit Tax						
3400 Other Funds Ltd	15,781	18,445	19,298	20,334	20,334	-
3270 Flexible Benefits						
3400 Other Funds Ltd	510,750	610,560	632,240	666,720	666,720	-
OTHER PAYROLL EXPENSES						
3400 Other Funds Ltd	1,241,082	1,521,045	1,579,765	1,644,773	1,644,773	-
TOTAL OTHER PAYROLL EXPENSES	\$1,241,082	\$1,521,045	\$1,579,765	\$1,644,773	\$1,644,773	-

120

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
PERSONAL SERVICES						
3400 Other Funds Ltd	3,867,715	4,595,150	4,795,975	5,044,720	5,044,720	-
TOTAL PERSONAL SERVICES	\$3,867,715	\$4,595,150	\$4,795,975	\$5,044,720	\$5,044,720	-
SERVICES & SUPPLIES						
4100 Instate Travel						
3400 Other Funds Ltd	82,116	106,639	106,639	110,585	110,585	-
4125 Out of State Travel						
3400 Other Funds Ltd	16,250	19,985	19,985	20,724	20,724	-
4150 Employee Training						
3400 Other Funds Ltd	18,219	48,559	48,559	52,335	52,335	-
4175 Office Expenses						
3400 Other Funds Ltd	113,411	119,463	119,463	123,883	122,959	-
4200 Telecommunications						
3400 Other Funds Ltd	31,873	36,349	36,349	44,794	38,109	-
4225 State Gov. Service Charges						
3400 Other Funds Ltd	181,486	72,769	72,769	134,288	125,499	-
4250 Data Processing						
3400 Other Funds Ltd	35,077	56,060	56,060	73,816	73,302	-
4275 Publicity and Publications						
3400 Other Funds Ltd	36,313	37,593	37,593	38,984	38,984	-
4300 Professional Services						
3400 Other Funds Ltd	275,219	116,711	116,711	402,408	402,408	-
4315 IT Professional Services						

Budget Support - Detail Revenues and Expenditures
 2017-19 Biennium
 Board of Pharmacy

Cross Reference Number: 85500-001-00-00-00000

Description	2013-15 Actuals	2015-17 Leg Adopted Budget	2015-17 Leg Approved Budget	2017-19 Agency Request Budget	2017-19 Governor's Budget	2017-19 Leg Adopted Budget
3400 Other Funds Ltd	58,900	78,096	78,096	353,340	353,340	-
4325 Attorney General						
3400 Other Funds Ltd	218,181	314,038	314,038	355,303	331,960	-
4375 Employee Recruitment and Develop						
3400 Other Funds Ltd	396	200	200	207	207	-
4400 Dues and Subscriptions						
3400 Other Funds Ltd	7,717	4,419	4,419	4,583	4,583	-
4425 Facilities Rental and Taxes						
3400 Other Funds Ltd	191,273	217,606	217,606	232,621	219,519	-
4475 Facilities Maintenance						
3400 Other Funds Ltd	1,455	49	49	51	51	-
4525 Medical Services and Supplies						
3400 Other Funds Ltd	2,061	1,070	1,070	1,110	1,110	-
4575 Agency Program Related S and S						
3400 Other Funds Ltd	199,093	221,248	221,248	229,434	229,434	-
4650 Other Services and Supplies						
3400 Other Funds Ltd	78,447	292,293	292,293	298,598	285,700	-
4700 Expendable Prop 250 - 5000						
3400 Other Funds Ltd	3,551	10,124	10,124	10,499	10,499	-
4715 IT Expendable Property						
3400 Other Funds Ltd	43,294	40,285	40,285	43,976	43,976	-
SERVICES & SUPPLIES						
3400 Other Funds Ltd	1,594,332	1,793,556	1,793,556	2,531,539	2,465,284	-

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
TOTAL SERVICES & SUPPLIES	\$1,594,332	\$1,793,556	\$1,793,556	\$2,531,539	\$2,465,284	-
CAPITAL OUTLAY						
5550 Data Processing Software						
3400 Other Funds Ltd	-	271,077	271,077	-	-	-
5600 Data Processing Hardware						
3400 Other Funds Ltd	-	8,000	8,000	8,296	8,296	-
CAPITAL OUTLAY						
3400 Other Funds Ltd	-	279,077	279,077	8,296	8,296	-
TOTAL CAPITAL OUTLAY	-	\$279,077	\$279,077	\$8,296	\$8,296	-
SPECIAL PAYMENTS						
6085 Other Special Payments						
3400 Other Funds Ltd	-	11,563	11,563	11,991	11,991	-
6443 Spc Pmt to Oregon Health Authority						
3400 Other Funds Ltd	137,332	176,899	176,899	-	-	-
SPECIAL PAYMENTS						
3400 Other Funds Ltd	137,332	188,462	188,462	11,991	11,991	-
TOTAL SPECIAL PAYMENTS	\$137,332	\$188,462	\$188,462	\$11,991	\$11,991	-
EXPENDITURES						
3400 Other Funds Ltd	5,599,379	6,856,245	7,057,070	7,596,546	7,530,291	-
TOTAL EXPENDITURES	\$5,599,379	\$6,856,245	\$7,057,070	\$7,596,546	\$7,530,291	-
ENDING BALANCE						
3400 Other Funds Ltd	5,094,726	2,742,420	2,541,595	1,155,426	1,778,123	-
TOTAL ENDING BALANCE	\$5,094,726	\$2,742,420	\$2,541,595	\$1,155,426	\$1,778,123	-

Pharmacy, Board of

Agency Number: 85500

**Budget Support - Detail Revenues and Expenditures
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

<i>Description</i>	<i>2013-15 Actuals</i>	<i>2015-17 Leg Adopted Budget</i>	<i>2015-17 Leg Approved Budget</i>	<i>2017-19 Agency Request Budget</i>	<i>2017-19 Governor's Budget</i>	<i>2017-19 Leg Adopted Budget</i>
AUTHORIZED POSITIONS						
8150 Class/Unclass Positions	19	20	20	20	20	-
TOTAL AUTHORIZED POSITIONS	19	20	20	20	20	-
AUTHORIZED FTE						
8250 Class/Unclass FTE Positions	19.00	20.00	20.00	20.00	20.00	-
TOTAL AUTHORIZED FTE	19.00	20.00	20.00	20.00	20.00	-

124

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
BEGINNING BALANCE				
0025 Beginning Balance				
3400 Other Funds Ltd	3,970,352	3,970,352	0	-
0030 Beginning Balance Adjustment				
3400 Other Funds Ltd	-	302,500	302,500	100.00%
TOTAL BEGINNING BALANCE				
3400 Other Funds Ltd	3,970,352	4,272,852	302,500	7.62%
REVENUE CATEGORIES				
LICENSES AND FEES				
0205 Business Lic and Fees				
3400 Other Funds Ltd	4,179,867	4,431,667	251,800	6.02%
0210 Non-business Lic. and Fees				
3400 Other Funds Ltd	503,410	505,552	2,142	0.43%
TOTAL LICENSES AND FEES				
3400 Other Funds Ltd	4,683,277	4,937,219	253,942	5.42%
FINES, RENTS AND ROYALTIES				
0505 Fines and Forfeitures				
3400 Other Funds Ltd	420,000	420,000	0	-
INTEREST EARNINGS				
0605 Interest Income				
3400 Other Funds Ltd	48,000	48,000	0	-
OTHER				
0975 Other Revenues				
3400 Other Funds Ltd	39,700	39,700	0	-

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
TOTAL REVENUES				
3400 Other Funds Ltd	5,190,977	5,444,919	253,942	4.89%
TRANSFERS OUT				
2443 Tsfr To Oregon Health Authority				
3400 Other Funds Ltd	(409,357)	(409,357)	0	-
AVAILABLE REVENUES				
3400 Other Funds Ltd	8,751,972	9,308,414	556,442	6.36%
EXPENDITURES				
PERSONAL SERVICES				
SALARIES & WAGES				
3110 Class/Unclass Sal. and Per Diem				
3400 Other Funds Ltd	3,180,288	3,180,288	0	-
3160 Temporary Appointments				
3400 Other Funds Ltd	24,322	24,322	0	-
3190 All Other Differential				
3400 Other Funds Ltd	176,911	176,911	0	-
TOTAL SALARIES & WAGES				
3400 Other Funds Ltd	3,381,521	3,381,521	0	-
OTHER PAYROLL EXPENSES				
3210 Empl. Rel. Bd. Assessments				
3400 Other Funds Ltd	1,083	1,083	0	-
3220 Public Employees' Retire Cont				
3400 Other Funds Ltd	502,762	502,762	0	-
3221 Pension Obligation Bond				

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
3400 Other Funds Ltd	179,452	179,452	0	-
3230 Social Security Taxes				
3400 Other Funds Ltd	254,611	254,611	0	-
3250 Worker's Comp. Assess. (WCD)				
3400 Other Funds Ltd	1,380	1,380	0	-
3260 Mass Transit Tax				
3400 Other Funds Ltd	19,298	19,298	0	-
3270 Flexible Benefits				
3400 Other Funds Ltd	666,720	666,720	0	-
TOTAL OTHER PAYROLL EXPENSES				
3400 Other Funds Ltd	1,625,306	1,625,306	0	-
TOTAL PERSONAL SERVICES				
3400 Other Funds Ltd	5,006,827	5,006,827	0	-
SERVICES & SUPPLIES				
4100 Instate Travel				
3400 Other Funds Ltd	106,639	106,639	0	-
4125 Out of State Travel				
3400 Other Funds Ltd	19,985	19,985	0	-
4150 Employee Training				
3400 Other Funds Ltd	48,559	48,559	0	-
4175 Office Expenses				
3400 Other Funds Ltd	119,463	119,463	0	-
4200 Telecommunications				
3400 Other Funds Ltd	36,349	36,349	0	-

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
4225 State Gov. Service Charges				
3400 Other Funds Ltd	77,118	77,118	0	-
4250 Data Processing				
3400 Other Funds Ltd	56,060	56,060	0	-
4275 Publicity and Publications				
3400 Other Funds Ltd	37,593	37,593	0	-
4300 Professional Services				
3400 Other Funds Ltd	116,711	116,711	0	-
4315 IT Professional Services				
3400 Other Funds Ltd	78,096	78,096	0	-
4325 Attorney General				
3400 Other Funds Ltd	314,038	314,038	0	-
4375 Employee Recruitment and Develop				
3400 Other Funds Ltd	200	200	0	-
4400 Dues and Subscriptions				
3400 Other Funds Ltd	4,419	4,419	0	-
4425 Facilities Rental and Taxes				
3400 Other Funds Ltd	217,606	217,606	0	-
4475 Facilities Maintenance				
3400 Other Funds Ltd	49	49	0	-
4525 Medical Services and Supplies				
3400 Other Funds Ltd	1,070	1,070	0	-
4575 Agency Program Related S and S				
3400 Other Funds Ltd	221,248	221,248	0	-

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
4650 Other Services and Supplies				
3400 Other Funds Ltd	287,944	287,944	0	-
4700 Expendable Prop 250 - 5000				
3400 Other Funds Ltd	10,124	10,124	0	-
4715 IT Expendable Property				
3400 Other Funds Ltd	40,285	40,285	0	-
TOTAL SERVICES & SUPPLIES				
3400 Other Funds Ltd	1,793,556	1,793,556	0	-
CAPITAL OUTLAY				
5550 Data Processing Software				
3400 Other Funds Ltd	271,077	271,077	0	-
5600 Data Processing Hardware				
3400 Other Funds Ltd	8,000	8,000	0	-
TOTAL CAPITAL OUTLAY				
3400 Other Funds Ltd	279,077	279,077	0	-
SPECIAL PAYMENTS				
6085 Other Special Payments				
3400 Other Funds Ltd	11,563	11,563	0	-
6443 Spc Pmt to Oregon Health Authority				
3400 Other Funds Ltd	176,899	176,899	0	-
TOTAL SPECIAL PAYMENTS				
3400 Other Funds Ltd	188,462	188,462	0	-
TOTAL EXPENDITURES				
3400 Other Funds Ltd	7,267,922	7,267,922	0	-

Description	Agency Request Budget (V-01) 2017-19 Base Budget	Governor's Budget (Y-01) 2017-19 Base Budget	Column 2 minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
ENDING BALANCE				
3400 Other Funds Ltd	1,484,050	2,040,492	556,442	37.49%
AUTHORIZED POSITIONS				
8150 Class/Unclass Positions	20	20	0	-
AUTHORIZED FTE				
8250 Class/Unclass FTE Positions	20.00	20.00	0	-

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Non-PICS Psnl Svc / Vacancy Factor
Pkg Group: ESS Pkg Type: 010 Pkg Number: 010**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
PERSONAL SERVICES				
SALARIES & WAGES				
3160 Temporary Appointments				
3400 Other Funds Ltd	900	900	0	0.00%
3190 All Other Differential				
3400 Other Funds Ltd	6,546	6,546	0	0.00%
SALARIES & WAGES				
3400 Other Funds Ltd	7,446	7,446	0	0.00%
TOTAL SALARIES & WAGES	\$7,446	\$7,446	\$0	0.00%
OTHER PAYROLL EXPENSES				
3220 Public Employees Retire Cont				
3400 Other Funds Ltd	1,250	1,250	0	0.00%
3221 Pension Obligation Bond				
3400 Other Funds Ltd	15,772	15,772	0	0.00%
3230 Social Security Taxes				
3400 Other Funds Ltd	570	570	0	0.00%
3260 Mass Transit Tax				
3400 Other Funds Ltd	1,036	1,036	0	0.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Non-PICS Psnl Svc / Vacancy Factor
Pkg Group: ESS Pkg Type: 010 Pkg Number: 010**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
OTHER PAYROLL EXPENSES				
3400 Other Funds Ltd	18,628	18,628	0	0.00%
TOTAL OTHER PAYROLL EXPENSES	\$18,628	\$18,628	\$0	0.00%
PERSONAL SERVICES				
3400 Other Funds Ltd	26,074	26,074	0	0.00%
TOTAL PERSONAL SERVICES	\$26,074	\$26,074	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	26,074	26,074	0	0.00%
TOTAL EXPENDITURES	\$26,074	\$26,074	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	(26,074)	(26,074)	0	0.00%
TOTAL ENDING BALANCE	(\$26,074)	(\$26,074)	\$0	0.00%

132

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Phase-out Pgm & One-time Costs
Pkg Group: ESS Pkg Type: 020 Pkg Number: 022**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4150 Employee Training				
3400 Other Funds Ltd	(31,423)	(31,423)	0	0.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	(31,423)	(31,423)	0	0.00%
TOTAL SERVICES & SUPPLIES	(\$31,423)	(\$31,423)	\$0	0.00%
CAPITAL OUTLAY				
5550 Data Processing Software				
3400 Other Funds Ltd	(271,077)	(271,077)	0	0.00%
CAPITAL OUTLAY				
3400 Other Funds Ltd	(271,077)	(271,077)	0	0.00%
TOTAL CAPITAL OUTLAY	(\$271,077)	(\$271,077)	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	(302,500)	(302,500)	0	0.00%
TOTAL EXPENDITURES	(\$302,500)	(\$302,500)	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	302,500	302,500	0	0.00%
TOTAL ENDING BALANCE	\$302,500	\$302,500	\$0	0.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

Package: Standard Inflation

Pkg Group: ESS Pkg Type: 030 Pkg Number: 031

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		

EXPENDITURES

SERVICES & SUPPLIES

4100 Instate Travel

3400 Other Funds Ltd 3,946 3,946 0 0.00%

4125 Out of State Travel

3400 Other Funds Ltd 739 739 0 0.00%

4150 Employee Training

3400 Other Funds Ltd 634 634 0 0.00%

4175 Office Expenses

3400 Other Funds Ltd 4,420 4,420 0 0.00%

4200 Telecommunications

3400 Other Funds Ltd 1,345 1,345 0 0.00%

4225 State Gov. Service Charges

3400 Other Funds Ltd 57,170 57,170 0 0.00%

4250 Data Processing

3400 Other Funds Ltd 2,074 2,074 0 0.00%

4275 Publicity and Publications

3400 Other Funds Ltd 1,391 1,391 0 0.00%

4300 Professional Services

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

Package: Standard Inflation

Pkg Group: ESS Pkg Type: 030 Pkg Number: 031

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
3400 Other Funds Ltd	4,785	4,785	0	0.00%
4315 IT Professional Services				
3400 Other Funds Ltd	3,202	3,202	0	0.00%
4325 Attorney General				
3400 Other Funds Ltd	41,265	41,265	0	0.00%
4375 Employee Recruitment and Develop				
3400 Other Funds Ltd	7	7	0	0.00%
4400 Dues and Subscriptions				
3400 Other Funds Ltd	164	164	0	0.00%
4425 Facilities Rental and Taxes				
3400 Other Funds Ltd	15,015	15,015	0	0.00%
4475 Facilities Maintenance				
3400 Other Funds Ltd	2	2	0	0.00%
4525 Medical Services and Supplies				
3400 Other Funds Ltd	40	40	0	0.00%
4575 Agency Program Related S and S				
3400 Other Funds Ltd	8,186	8,186	0	0.00%
4650 Other Services and Supplies				
3400 Other Funds Ltd	10,654	10,654	0	0.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

Package: Standard Inflation

Pkg Group: ESS Pkg Type: 030 Pkg Number: 031

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
4700 Expendable Prop 250 - 5000				
3400 Other Funds Ltd	375	375	0	0.00%
4715 IT Expendable Property				
3400 Other Funds Ltd	1,491	1,491	0	0.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	156,905	156,905	0	0.00%
TOTAL SERVICES & SUPPLIES	\$156,905	\$156,905	\$0	0.00%
CAPITAL OUTLAY				
5600 Data Processing Hardware				
3400 Other Funds Ltd	296	296	0	0.00%
CAPITAL OUTLAY				
3400 Other Funds Ltd	296	296	0	0.00%
TOTAL CAPITAL OUTLAY	\$296	\$296	\$0	0.00%
SPECIAL PAYMENTS				
6085 Other Special Payments				
3400 Other Funds Ltd	428	428	0	0.00%
6443 Spc Pmt to Oregon Health Authority				
3400 Other Funds Ltd	6,545	6,545	0	0.00%
SPECIAL PAYMENTS				

136

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

Package: Standard Inflation

Pkg Group: ESS Pkg Type: 030 Pkg Number: 031

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
3400 Other Funds Ltd	6,973	6,973	0	0.00%
TOTAL SPECIAL PAYMENTS	\$6,973	\$6,973	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	164,174	164,174	0	0.00%
TOTAL EXPENDITURES	\$164,174	\$164,174	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	(164,174)	(164,174)	0	0.00%
TOTAL ENDING BALANCE	(\$164,174)	(\$164,174)	\$0	0.00%

137

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Above Standard Inflation
Pkg Group: ESS Pkg Type: 030 Pkg Number: 032**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4200 Telecommunications				
3400 Other Funds Ltd	7,100	7,100	0	0.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	7,100	7,100	0	0.00%
TOTAL SERVICES & SUPPLIES	\$7,100	\$7,100	\$0	0.00%
SPECIAL PAYMENTS				
6443 Spc Pmt to Oregon Health Authority				
3400 Other Funds Ltd	708	708	0	0.00%
SPECIAL PAYMENTS				
3400 Other Funds Ltd	708	708	0	0.00%
TOTAL SPECIAL PAYMENTS	\$708	\$708	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	7,808	7,808	0	0.00%
TOTAL EXPENDITURES	\$7,808	\$7,808	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	(7,808)	(7,808)	0	0.00%
TOTAL ENDING BALANCE	(\$7,808)	(\$7,808)	\$0	0.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

Cross Reference Number: 85500-001-00-00-00000

Package: Technical Adjustments

Pkg Group: ESS Pkg Type: 060 Pkg Number: 060

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4300 Professional Services				
3400 Other Funds Ltd	184,152	184,152	0	0.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	184,152	184,152	0	0.00%
TOTAL SERVICES & SUPPLIES	\$184,152	\$184,152	\$0	0.00%
SPECIAL PAYMENTS				
6443 Spc Pmt to Oregon Health Authority				
3400 Other Funds Ltd	(184,152)	(184,152)	0	0.00%
SPECIAL PAYMENTS				
3400 Other Funds Ltd	(184,152)	(184,152)	0	0.00%
TOTAL SPECIAL PAYMENTS	(\$184,152)	(\$184,152)	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	-	-	0	0.00%
TOTAL EXPENDITURES	-	-	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	-	-	0	0.00%
TOTAL ENDING BALANCE	-	-	\$0	0.00%

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4175 Office Expenses				
3400 Other Funds Ltd	-	(924)	(924)	100.00%
4200 Telecommunications				
3400 Other Funds Ltd	-	(6,685)	(6,685)	100.00%
4225 State Gov. Service Charges				
3400 Other Funds Ltd	-	(8,789)	(8,789)	100.00%
4250 Data Processing				
3400 Other Funds Ltd	-	(514)	(514)	100.00%
4425 Facilities Rental and Taxes				
3400 Other Funds Ltd	-	(13,102)	(13,102)	100.00%
4650 Other Services and Supplies				
3400 Other Funds Ltd	-	(12,898)	(12,898)	100.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	-	(42,912)	(42,912)	100.00%
TOTAL SERVICES & SUPPLIES	-	(\$42,912)	(\$42,912)	100.00%

EXPENDITURES				
3400 Other Funds Ltd	-	(42,912)	(42,912)	100.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Statewide Adjustment DAS Chgs
Pkg Group: POL Pkg Type: 090 Pkg Number: 091**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
TOTAL EXPENDITURES	-	(\$42,912)	(\$42,912)	100.00%
ENDING BALANCE				
3400 Other Funds Ltd	-	42,912	42,912	100.00%
TOTAL ENDING BALANCE	-	\$42,912	\$42,912	100.00%

141

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Statewide AG Adjustment
Pkg Group: POL Pkg Type: 090 Pkg Number: 092**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4325 Attorney General				
3400 Other Funds Ltd	-	(23,343)	(23,343)	100.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	-	(23,343)	(23,343)	100.00%
TOTAL SERVICES & SUPPLIES	-	(\$23,343)	(\$23,343)	100.00%
EXPENDITURES				
3400 Other Funds Ltd	-	(23,343)	(23,343)	100.00%
TOTAL EXPENDITURES	-	(\$23,343)	(\$23,343)	100.00%
ENDING BALANCE				
3400 Other Funds Ltd	-	23,343	23,343	100.00%
TOTAL ENDING BALANCE	-	\$23,343	\$23,343	100.00%

142

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		

EXPENDITURES

SERVICES & SUPPLIES

4150 Employee Training

3400 Other Funds Ltd	34,565	34,565	0	0.00%
----------------------	--------	--------	---	-------

4250 Data Processing

3400 Other Funds Ltd	15,682	15,682	0	0.00%
----------------------	--------	--------	---	-------

4300 Professional Services

3400 Other Funds Ltd	27,500	27,500	0	0.00%
----------------------	--------	--------	---	-------

4315 IT Professional Services

3400 Other Funds Ltd	272,042	272,042	0	0.00%
----------------------	---------	---------	---	-------

4715 IT Expendable Property

3400 Other Funds Ltd	2,200	2,200	0	0.00%
----------------------	-------	-------	---	-------

SERVICES & SUPPLIES

3400 Other Funds Ltd	351,989	351,989	0	0.00%
----------------------	---------	---------	---	-------

TOTAL SERVICES & SUPPLIES	\$351,989	\$351,989	\$0	0.00%
--------------------------------------	------------------	------------------	------------	--------------

EXPENDITURES

3400 Other Funds Ltd	351,989	351,989	0	0.00%
----------------------	---------	---------	---	-------

TOTAL EXPENDITURES	\$351,989	\$351,989	\$0	0.00%
---------------------------	------------------	------------------	------------	--------------

ENDING BALANCE

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: MyLicense Business Upgrade
Pkg Group: POL Pkg Type: POL Pkg Number: 100**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
3400 Other Funds Ltd	(351,989)	(351,989)	0	0.00%
TOTAL ENDING BALANCE	(\$351,989)	(\$351,989)	\$0	0.00%

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Academic & Regulatory Fellowship
Pkg Group: POL Pkg Type: POL Pkg Number: 101**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
EXPENDITURES				
SERVICES & SUPPLIES				
4300 Professional Services				
3400 Other Funds Ltd	69,260	69,260	0	0.00%
SERVICES & SUPPLIES				
3400 Other Funds Ltd	69,260	69,260	0	0.00%
TOTAL SERVICES & SUPPLIES	\$69,260	\$69,260	\$0	0.00%
EXPENDITURES				
3400 Other Funds Ltd	69,260	69,260	0	0.00%
TOTAL EXPENDITURES	\$69,260	\$69,260	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	(69,260)	(69,260)	0	0.00%
TOTAL ENDING BALANCE	(\$69,260)	(\$69,260)	\$0	0.00%

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		

EXPENDITURES

PERSONAL SERVICES

SALARIES & WAGES

3110 Class/Unclass Sal. and Per Diem

3400 Other Funds Ltd	10,980	10,980	0	0.00%
----------------------	--------	--------	---	-------

SALARIES & WAGES

3400 Other Funds Ltd	10,980	10,980	0	0.00%
----------------------	--------	--------	---	-------

TOTAL SALARIES & WAGES	\$10,980	\$10,980	\$0	0.00%
-----------------------------------	-----------------	-----------------	------------	--------------

OTHER PAYROLL EXPENSES

3230 Social Security Taxes

3400 Other Funds Ltd	839	839	0	0.00%
----------------------	-----	-----	---	-------

OTHER PAYROLL EXPENSES

3400 Other Funds Ltd	839	839	0	0.00%
----------------------	-----	-----	---	-------

TOTAL OTHER PAYROLL EXPENSES	\$839	\$839	\$0	0.00%
-------------------------------------	--------------	--------------	------------	--------------

PERSONAL SERVICES

3400 Other Funds Ltd	11,819	11,819	0	0.00%
----------------------	--------	--------	---	-------

TOTAL PERSONAL SERVICES	\$11,819	\$11,819	\$0	0.00%
--------------------------------	-----------------	-----------------	------------	--------------

EXPENDITURES

3400 Other Funds Ltd	11,819	11,819	0	0.00%
----------------------	--------	--------	---	-------

146

Pharmacy, Board of

Agency Number: 85500

**Package Comparison Report - Detail
2017-19 Biennium
Board of Pharmacy**

**Cross Reference Number: 85500-001-00-00-00000
Package: Board Member Per Diem
Pkg Group: POL Pkg Type: POL Pkg Number: 102**

Description	Agency Request Budget (V-01)	Governor's Budget (Y-01)	Column 2 Minus Column 1	% Change from Column 1 to Column 2
	Column 1	Column 2		
TOTAL EXPENDITURES	\$11,819	\$11,819	\$0	0.00%
ENDING BALANCE				
3400 Other Funds Ltd	(11,819)	(11,819)	0	0.00%
TOTAL ENDING BALANCE	(\$11,819)	(\$11,819)	\$0	0.00%

147

12/22/16 REPORT NO.: PPDELBUDCL
 REPORT: SUMMARY LIST BY PKG BY SUMMARY XREF
 AGENCY: 85500 PHARMACY, OREGON BOARD OF
 SUMMARY XREF: 001-00-00 000 Board of Pharmacy

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PKG	CLASS	COMP	DESCRIPTION	POS CNT	FTE	MOS	AVERAGE RATE	GF SAL	OF SAL	FF SAL	LF SAL	AF SAL
000	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	0.00		22,320			22,320
000	MEAHZ7008	HA	PRINCIPAL EXECUTIVE/MANAGER E	1	1.00	24.00	9,055.00		217,320			217,320
000	MMN X0871	AA	OPERATIONS & POLICY ANALYST 2	1	1.00	24.00	5,770.00		138,480			138,480
000	MMS X0806	AA	OFFICE MANAGER 2	1	1.00	24.00	3,386.00		81,264			81,264
000	MMS X0860	AA	PROGRAM ANALYST 1	1	1.00	24.00	4,982.00		119,568			119,568
000	MMS X7006	AA	PRINCIPAL EXECUTIVE/MANAGER D	2	2.00	48.00	7,714.00		370,272			370,272
000	OAS C0104	AP	OFFICE SPECIALIST 2	4	4.00	96.00	3,472.50		333,360			333,360
000	OAS C0107	AP	ADMINISTRATIVE SPECIALIST 1	1	1.00	24.00	4,022.00		96,528			96,528
000	OAS C0323	AP	PUBLIC SERVICE REP 3	3	3.00	72.00	3,561.66		256,440			256,440
000	OAS C5911	EP	HEALTH CARE INVESTIGTR/ADVISR	6	6.00	144.00	10,727.33		1,544,736			1,544,736
000				20	20.00	480.00	4,537.31		3,180,288			3,180,288

148

12/22/16 REPORT NO.: PPDPLBUDCL
 REPORT: SUMMARY LIST BY PKG BY SUMMARY XREF
 AGENCY: 85500 PHARMACY, OREGON BOARD OF
 SUMMARY XREF: 001-00-00 102 Board of Pharmacy

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PKG	CLASS	COMP	DESCRIPTION	POS CNT	FTE	MOS	AVERAGE RATE	GF SAL	OF SAL	FF SAL	LF SAL	AF SAL
102	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	0.00		10,980			10,980
102					.00	.00	0.00		10,980			10,980
				20	20.00	480.00	2,799.61		3,191,268			3,191,268
				20	20.00	480.00	2,799.61		3,191,268			3,191,268

12/22/16 REPORT NO.: PPDPLBUDCL
REPORT: SUMMARY LIST BY PKG BY SUMMARY XREF
AGENCY: 85500 PHARMACY, OREGON BOARD OF
SUMMARY XREF: 001-00-00 102 Board of Pharmacy

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PKG	CLASS	COMP	DESCRIPTION	POS CNT	FTE	MOS	AVERAGE RATE	GF SAL	OF SAL	FF SAL	LF SAL	AF SAL
				20	20.00	480.00	2,799.61		3,191,268			3,191,268

12/22/16 REPORT NO.: PPDPLAGYCL
 REPORT: SUMMARY LIST BY PKG BY AGENCY
 AGENCY: 85500 PHARMACY, OREGON BOARD OF

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PAGE 1
 2017-19 PROD FILE
 PICS SYSTEM: BUDGET PREPARATION

PKG	CLASS	COMP	DESCRIPTION	POS CNT	FTE	MOS	AVERAGE RATE	GF SAL	OF SAL	FF SAL	LF SAL	AF SAL
102	B	Y7500	AE BOARD AND COMMISSION MEMBER		.00	.00	0.00		33,300			33,300
000	MEAHZ7008	HA	PRINCIPAL EXECUTIVE/MANAGER E	1	1.00	24.00	9,055.00		217,320			217,320
000	MMN X0871	AA	OPERATIONS & POLICY ANALYST 2	1	1.00	24.00	5,770.00		138,480			138,480
000	MMS X0806	AA	OFFICE MANAGER 2	1	1.00	24.00	3,386.00		81,264			81,264
000	MMS X0860	AA	PROGRAM ANALYST 1	1	1.00	24.00	4,982.00		119,568			119,568
000	MMS X7006	AA	PRINCIPAL EXECUTIVE/MANAGER D	2	2.00	48.00	7,714.00		370,272			370,272
000	OAS C0104	AP	OFFICE SPECIALIST 2	4	4.00	96.00	3,472.50		333,360			333,360
000	OAS C0107	AP	ADMINISTRATIVE SPECIALIST 1	1	1.00	24.00	4,022.00		96,528			96,528
000	OAS C0323	AP	PUBLIC SERVICE REP 3	3	3.00	72.00	3,561.66		256,440			256,440
000	OAS C5911	EP	HEALTH CARE INVESTIGTR/ADVISR	6	6.00	144.00	10,727.33		1,544,736			1,544,736
				20	20.00	480.00	2,799.61		3,191,268			3,191,268

12/22/16 REPORT NO.: PPDPLAGYCL
REPORT: SUMMARY LIST BY PKG BY AGENCY
AGENCY: 85500 PHARMACY, OREGON BOARD OF

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PICS SYSTEM: BUDGET PREPARATION

PKG	CLASS	COMP	DESCRIPTION	POS CNT	FTE	MOS	AVERAGE RATE	GF SAL	OF SAL	FF SAL	LF SAL	AF SAL
				20	20.00	480.00	2,799.61		3,191,268			3,191,268

12/22/16 REPORT NO.: PPDPLWSBUD
 REPORT: DETAIL LISTING BY SUMMARY XREF AGENCY
 AGENCY: 85500 PHARMACY, OREGON BOARD OF
 SUMMARY XREF: 001-00-00 102 Board of Pharmacy

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PAGE 1
 2017-19 PROD FILE
 PICS SYSTEM: BUDGET PREPARATION

POSITION NUMBER	AUTH NO	ORG STRUC	F POS	PKG Y TYP	CLASS COMP	RNG P	S T POS CNT	FTE	BUDGET RATE	MOS	GF SAL	OF SAL	FF SAL	LF SAL	T R K
0004401	001001850	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,240-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004401	001001850	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004402	001001860	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,240-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004402	001001860	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004403	001001870	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,240-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004403	001001870	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004404	001001880	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,240-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004404	001001880	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004405	001001890	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,240-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004405	001001890	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004406	001001900	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,060-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004406	001001900	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004407	001001910	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,060-			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004407	001001910	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004408	001116310	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00					B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004408	001116310	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															

153

12/22/16 REPORT NO.: PPDPLWSBUD
 REPORT: DETAIL LISTING BY SUMMARY XREF AGENCY
 AGENCY: 85500 PHARMACY, OREGON BOARD OF
 SUMMARY XREF: 001-00-00 102 Board of Pharmacy

DEPT. OF ADMIN. SVCS. -- PPDB PICS SYSTEM

PAGE 2
 2017-19 PROD FILE
 PICS SYSTEM: BUDGET PREPARATION

POSITION NUMBER	AUTH NO	ORG STRUC	F POS	PKG Y TYP	CLASS COMP	RNG P	POS CNT	FTE	BUDGET RATE	MOS	GF SAL	OF SAL	FF SAL	LF SAL	T R K
0004413	001001920	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00					B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
0004413	001001920	001-01-00-00000	102 0 PP B	Y7500 AE	00 00			.00	0.00	.00		3,700			B
EST DATE: 2017/07/01 EXP DATE: 9999/01/01															
								102	.00	.00		10,980			
									.00	.00		10,980			
									.00	.00		10,980			

154

REPORT: DETAIL LISTING BY SUMMARY XREF AGENCY

2017-19

PROD FILE

AGENCY: 85500 PHARMACY, OREGON BOARD OF

PICS SYSTEM: BUDGET PREPARATION

SUMMARY XREF: 001-00-00 102 Board of Pharmacy

POSITION NUMBER	AUTH NO	ORG STRUC	F POS	CLASS	COMP	S T POS RNG P CNT	FTE	BUDGET RATE	MOS	GF SAL	OF SAL	FF SAL	LF SAL	T R K
							.00		.00		10,980			

PACKAGE: 102 - Board Member Per Diem

POSITION NUMBER	CLASS COMP	CLASS NAME	POS CNT	FTE	MOS	STEP	RATE	GF SAL/OPE	OF SAL/OPE	FF SAL/OPE	LF SAL/OPE	AF SAL/OPE
0004401	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004401	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004402	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004402	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004403	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004403	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004404	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004404	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004405	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,240-248-			3,240-248-
0004405	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004406	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,060-234-			3,060-234-
0004406	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004407	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,060-234-			3,060-234-
0004407	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004408	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
0004413	B	Y7500 AE BOARD AND COMMISSION MEMBER		.00	.00	00	0.00		3,700-283			3,700-283
TOTAL PICS SALARY									10,980			10,980

156

